

## Complete List of Publications

### Univ.Prof.Dr. Michael TRAUNER

Medical University of Vienna, Division of Gastroenterology and Hepatology, Department Medicine III, Währinger Gürtel 18-20, 1090 Vienna, Austria, Tel: +43 1 40 400 47410, Fax: +43 1 40 400 47350, E-Mail: michael.trauner@meduniwien.ac.at, Homepage: www.meduniwien.ac.at/gastro, **ORCID ID:** orcid.org/0000-0002-1275-6425

### Overview:

H-index: 81 (Web of Science accessed May 18<sup>th</sup>, 2021)  
Citations 26.479 (24.115 without self citations)

Total number of publications: 577 (Pubmed-listed)

First or Senior author publications: 195

Co-author publications: 382

Original papers: 431

Reviews: 101

Letters, Comments and Editorials: 37

Consensus Reports: 8

Book Chapters: 47

Books as Editor: 8

### Pubmed listed papers

1. Trauner M, Stepan KM, Resch M, Ebner F, Pristautz H, Klimpfinger M. Diagnostic problems in nodular regenerative hyperplasia (nodular transformation) of the liver. Review of the literature and report of two cases. **Z Gastroenterol**. 1992 Mar;30(3):187-94.
2. Stauber RE, Mischinger HJ, Trauner M, Pristautz H. Indications for liver transplantation in neoplasms of the liver. **Acta Med Austriaca**. 1993;20(3):57-60. Review
3. Stauber RE, Horina JH, Trauner M, Krejs GJ, Ratschek M, Klimpfinger M. Glomerulonephritis as late manifestation of severe alpha 1-antitrypsin deficiency. **Clin Investig**. 1994 May;72(5):404-8. doi: 10.1007/BF00252839. Case Report
4. Schreiber F, Gurakuqi GC, Trauner M, Krejs GJ. Ultrasound controlled extracorporeal shockwave lithotripsy of pancreatic calculi in patients with chronic recurrent pancreatitis. **Bildgebung**. 1994 Sep;61(3):182-6.

5. Trauner M, Grygar S, Stauber RE, Brodatsch-Häusler E, Klimpfinger M. Carcinoembryonic antigen, cytokeratin expression and mucin composition in hyperplastic and neoplastic polyps of the colorectum. **Z Gastroenterol**. 1994 Nov;32(11):626-31.
6. Stauber RE, Stepan V, Trauner M, Wilders-Truschnig M, Leb G, Krejs GJ. Evaluation of carbohydrate-deficient transferrin for detection of alcohol abuse in patients with liver dysfunction. **Alcohol Alcohol**. 1995 Mar;30(2):171-6.
7. Schmidt F, Penka B, Trauner M, Reinsperger L, Ranner G, Ebner F, Waldhauser F. Lack of pineal growth during childhood. **J Clin Endocrinol Metab**. 1995 Apr;80(4):1221-5. doi: 10.1210/jcem.80.4.7536203.
8. Trauner M, Klimpfinger M, Stauber RE, Schreiber F, Stöger H, Krejs GJ. Laparoscopic diagnosis of peritoneal serous papillary carcinoma. **Endoscopy**. 1995 May;27(4):337-41. doi: 10.1055/s-2007-1005704. Case Report
9. Trauner M, Grasmug E, Stauber RE, Hammer HF, Hoefler G, Reisinger EC. Recurrent Salmonella enteritidis sepsis and hepatic tuberculosis. **Gut**. 1995 Jul;37(1):136-9. doi: 10.1136/gut.37.1.136. Case Report
10. Abrams GA, Trauner M, Nathanson MH. Nitric oxide and liver disease. **Gastroenterologist**. 1995 Sep;3(3):220-33. Review
11. Groell R, Kugler C, Aschauer M, Rienmueller R, Stauber R, Trauner M, Mischinger HJ. Quantitative perfusion parameters of focal nodular hyperplasia and normal liver parenchyma as determined by electron beam tomography. **Br J Radiol**. 1995 Nov;68(815):1185-9. doi: 10.1259/0007-1285-68-815-1185.
12. Schreiber F, Gurakuqi GC, Trauner M. Endoscopic intracorporeal laser lithotripsy of difficult common bile duct stones with a stone-recognition pulsed dye laser system. **Gastrointest Endosc**. 1995 Nov;42(5):416-9. doi: 10.1016/s0016-5107(95)70042-0.
13. Schreiber F, Gurakuqi GC, Pristautz H, Trauner M, Schnedl W. Sonographically-guided extracorporeal shockwave lithotripsy for pancreatic stones in patients with chronic pancreatitis. **J Gastroenterol Hepatol**. 1996 Mar;11(3):247-51. doi: 10.1111/j.1440-1746.1996.tb00070.x.
14. Stauber RE, Heinemann A, Trauner M, Krejs GJ. Divergent effects of propranolol and nadolol in isolated mesenteric arteries from normal and portal hypertensive rats. **Eur J Clin Invest**. 1996 Aug;26(8):676-80. doi: 10.1111/j.1365-2362.1996.tb02152.x.
15. Schreiber F, Steindorfer P, Pristautz H, Gurakuqi GC, Schnedl W, Trauner M. Complications and surgical interventions during 4 years of biliary extracorporeal shockwave lithotripsy. **Hepatogastroenterology**. 1996 Sep-Oct;43(11):1124-8.
16. Schreiber F, Gurakuqi GC, Schnedl W, Trauner M. ERCP and balloon dilation is a valuable alternative to surgical biliodigestive anastomosis in the long common channel syndrome in childhood. **Endoscopy**. 1996 Oct;28(8):724-5. doi: 10.1055/s-2007-1005585. Comment
17. Trauner M, Nathanson MH, Mennone A, Rydberg SA, Boyer JL. Nitric oxide donors stimulate bile flow and glutathione disulfide excretion independent of guanosine 3',5'-

- cyclic [corrected] monophosphate in the isolated perfused rat liver. *Hepatology*. 1997 Feb;25(2):263-9. doi: 10.1002/hep.510250202.
18. Trauner M, Nathanson MH, Rydberg SA, Koeppl TA, Gartung C, Sessa WC, Boyer JL. Endotoxin impairs biliary glutathione and HCO<sub>3</sub><sup>-</sup> excretion and blocks the choleric effect of nitric oxide in rat liver. *Hepatology*. 1997 May;25(5):1184-91. doi: 10.1002/hep.510250522.
  19. Trauner M, Arrese M, Soroka CJ, Ananthanarayanan M, Koeppl TA, Schlosser SF, Suchy FJ, Keppler D, Boyer JL. The rat canalicular conjugate export pump (Mrp2) is down-regulated in intrahepatic and obstructive cholestasis. *Gastroenterology*. 1997 Jul;113(1):255-64. doi: 10.1016/s0016-5085(97)70103-3.
  20. Koeppl TA, Thies JC, Schemmer P, Trauner M, Gebhard MM, Otto G, Post S. Inhibition of nitric oxide synthesis in ischemia/reperfusion of the rat liver is followed by impairment of hepatic microvascular blood flow. *J Hepatol*. 1997 Jul;27(1):163-9. doi: 10.1016/s0168-8278(97)80297-8.
  21. Trauner M. Molecular alterations of canalicular transport systems in experimental models of cholestasis: possible functional correlations. *Yale J Biol Med*. 1997 Jul-Aug;70(4):365-78. Review
  22. Koeppl TA, Trauner M, Baas JC, Thies JC, Schlosser SF, Post S, Gebhard MM, Herfarth C, Boyer JL, Otto G. Extrahepatic biliary obstruction impairs microvascular perfusion and increases leukocyte adhesion in rat liver. *Hepatology*. 1997 Nov;26(5):1085-91. doi: 10.1002/hep.510260501.
  23. Trauner M, Arrese M, Lee H, Boyer JL, Karpen SJ. Endotoxin downregulates rat hepatic ntcp gene expression via decreased activity of critical transcription factors. *J Clin Invest*. 1998 May 15;101(10):2092-100. doi: 10.1172/JCI1680.
  24. Koeppl TA, Trauner M, Mennone A, Arrese M, Rios-Velez L, Boyer JL. Role of glutathione in hepatic bile formation during reperfusion after cold ischemia of the rat liver. *J Hepatol*. 1998 May;28(5):812-9. doi: 10.1016/s0168-8278(98)80231-6.
  25. Heinemann A, Wachter CH, Fickert P, Trauner M, Stauber RE. Vasopressin reverses mesenteric hyperemia and vasoconstrictor hyporesponsiveness in anesthetized portal hypertensive rats. *Hepatology*. 1998 Sep;28(3):646-54. doi: 10.1002/hep.510280307.
  26. Arrese M, Trauner M, Ananthanarayanan M, Boyer JL, Suchy FJ. Maternal cholestasis does not affect the ontogenic pattern of expression of the Na<sup>+</sup>/taurocholate cotransporting polypeptide (ntcp) in the fetal and neonatal rat liver. *Hepatology*. 1998 Sep;28(3):789-95. doi: 10.1002/hep.510280328.
  27. Arrese M, Trauner M, Sacchiero RJ, Crossman MW, Shneider BL. Neither intestinal sequestration of bile acids nor common bile duct ligation modulate the expression and function of the rat ileal bile acid transporter. *Hepatology*. 1998 Oct;28(4):1081-7. doi: 10.1002/hep.510280424.
  28. Fickert P, Trauner M, Sill H, Hinterleitner TA, Stauber RE. Successful steroid treatment of idiopathic thrombocytopenic purpura after orthotopic liver transplantation for primary biliary cirrhosis. *Am J Gastroenterol*. 1998 Oct;93(10):1985-6. doi: 10.1111/j.1572-0241.1998.00561.x. Case Report

29. Trauner M, Meier PJ, Boyer JL. Molecular pathogenesis of cholestasis. *N Engl J Med*. 1998 Oct 22;339(17):1217-27. doi: 10.1056/NEJM199810223391707. Review
30. Trauner M, Mennone A, Gigliozzi A, Fraioli F, Boyer JL. Nitric oxide and guanosine 3',5'-cyclic monophosphate stimulate bile secretion in isolated rat hepatocyte couplets, but not in isolated bile duct units. *Hepatology*. 1998 Dec;28(6):1621-8. doi: 10.1002/hep.510280623.
31. Trauner M, Meier PJ, Boyer JL. Molecular regulation of hepatocellular transport systems in cholestasis. *J Hepatol*. 1999 Jul;31(1):165-78. doi: 10.1016/s0168-8278(99)80179-2. Review
32. Trauner M, Fickert P, Stauber RE. New molecular aspects of cholestatic liver diseases. *Z Gastroenterol*. 1999 Jul;37(7):639-47. Review.
33. Trauner M, Graziadei IW. Review article: mechanisms of action and therapeutic applications of ursodeoxycholic acid in chronic liver diseases. *Aliment Pharmacol Ther*. 1999 Aug;13(8):979-96. doi: 10.1046/j.1365-2036.1999.00596.x. Review
34. Trauner M, Boyer JL. Cholestatic syndromes. *Curr Opin Gastroenterol*. 1999 May;15(3):217-28. doi: 10.1097/00001574-199905000-00006. Review
35. Trauner M, Fickert P, Stauber RE. Inflammation-induced cholestasis. *J Gastroenterol Hepatol*. 1999 Oct;14(10):946-59. doi: 10.1046/j.1440-1746.1999.01982.x. Review
36. Lee JM, Trauner M, Soroka CJ, Stieger B, Meier PJ, Boyer JL. Expression of the bile salt export pump is maintained after chronic cholestasis in the rat. *Gastroenterology*. 2000 Jan;118(1):163-72. doi: 10.1016/s0016-5085(00)70425-2.
37. Trauner M, Boyer JL. Cholestatic syndromes. *Curr Opin Gastroenterol*. 2000 May;16(3):239-50. doi: 10.1097/00001574-200005000-00006. Review
38. Fickert P, Trauner M, Hausegger K, Tauss J, Lackner H, Krejs GJ, Stauber RE. Intra-hepatic haematoma complicating transjugular intra-hepatic portosystemic shunt for Budd-Chiari syndrome associated with anti-phospholipid antibodies, aplastic anaemia and chronic hepatitis C. *Eur J Gastroenterol Hepatol*. 2000 Jul;12(7):813-6. doi: 10.1097/00042737-200012070-00017. Case Report
39. Trauner M, Fickert P, Stauber RE. Hepatocellular bile salt transport: lessons from cholestasis. *Can J Gastroenterol*. 2000 Nov;14 Suppl D:99D-104D. doi: 10.1155/2000/870929. Review
40. Zollner G, Fickert P, Zenz R, Fuchsbichler A, Stumptner C, Kenner L, Ferenci P, Stauber RE, Krejs GJ, Denk H, Zatloukal K, Trauner M. Hepatobiliary transporter expression in percutaneous liver biopsies of patients with cholestatic liver diseases. *Hepatology*. 2001 Mar;33(3):633-46. doi: 10.1053/jhep.2001.22646.
41. Trauner M, Fickert P, Zollner G. Abnormal hepatic sinusoidal bile acid transport: new insights into the pathogenesis of cholestasis? *Gastroenterology*. 2001 Jan;120(1):321-3. doi: 10.1053/gast.2001.21380. Comment

42. Trauner M, Fickert P, Zollner G. Genetic disorders and molecular mechanisms in cholestatic liver disease--a clinical approach. **Semin Gastrointest Dis**. 2001 Apr;12(2):66-88. Review
43. Fickert P, Zollner G, Fuchsbichler A, Stumptner C, Pojer C, Zenz R, Lammert F, Stieger B, Meier PJ, Zatloukal K, Denk H, Trauner M. Effects of ursodeoxycholic and cholic acid feeding on hepatocellular transporter expression in mouse liver. **Gastroenterology**. 2001 Jul;121(1):170-83. doi: 10.1053/gast.2001.25542.
44. Hegenbarth K, Maurer U, Kroisel PM, Fickert P, Trauner M, Stauber RE. No evidence for mutagenic effects of ribavirin: report of two normal pregnancies. **Am J Gastroenterol**. 2001 Jul;96(7):2286-7. doi: 10.1111/j.1572-0241.2001.03997.x. Case Report
45. Trauner M, Boyer JL. Cholestatic syndromes. **Curr Opin Gastroenterol**. 2001 May;17(3):242-56. doi: 10.1097/00001574-200105000-00007. Review
46. Langner C, Thonhofer R, Hegenbarth K, Trauner M. Diffuse hemangiomatosis of the liver and spleen in an adult. **Pathologe**. 2001 Nov;22(6):424-8. doi: 10.1007/s002920100491. Case Report
47. Zollner G, Fickert P, Silbert D, Fuchsbichler A, Stumptner C, Zatloukal K, Denk H, Trauner M. Induction of short heterodimer partner 1 precedes downregulation of Ntcp in bile duct-ligated mice. **Am J Physiol Gastrointest Liver Physiol**. 2002 Jan;282(1):G184-91. doi: 10.1152/ajpgi.00215.2001.
48. Fickert P, Trauner M, Fuchsbichler A, Stumptner C, Zatloukal K, Denk H. Cytokeratins as targets for bile acid-induced toxicity. **Am J Pathol**. 2002 Feb;160(2):491-9. doi: 10.1016/S0002-9440(10)64868-7.
49. Ferenci P, Zollner G, Trauner M. Hepatic transport systems. **J Gastroenterol Hepatol**. 2002 Feb;17 Suppl:S105-12. doi: 10.1046/j.1440-1746.17.s1.15.x. Review
50. Trauner M, Boyer JL. Cholestatic syndromes. **Curr Opin Gastroenterol**. 2002 May;18(3):314-29. doi: 10.1097/00001574-200205000-00005. Review
51. Hegenbarth K, Fickert P, Aschauer M, Horina JH, Stauber RE, Trauner M. Successful management of acute portal vein thrombosis by low molecular weight heparin and oral anticoagulation. **Am J Gastroenterol**. 2002 Jun;97(6):1567-8. doi: 10.1111/j.1572-0241.2002.05750.x. Case Report
52. Fickert P, Zollner G, Fuchsbichler A, Stumptner C, Weiglein AH, Lammert F, Marschall HU, Tsybrovskyy O, Zatloukal K, Denk H, Trauner M. Ursodeoxycholic acid aggravates bile infarcts in bile duct-ligated and Mdr2 knockout mice via disruption of cholangioles. **Gastroenterology**. 2002 Oct;123(4):1238-51. doi: 10.1053/gast.2002.35948.
53. Fickert P, Trauner M, Fuchsbichler A, Stumptner C, Zatloukal K, Denk H. Bile acid-induced Mallory body formation in drug-primed mouse liver. **Am J Pathol**. 2002 Dec;161(6):2019-26. doi: 10.1016/S0002-9440(10)64480-X.
54. Arrese M, Trauner M, Ananthanarayanan M, Pizarro M, Solís N, Accatino L, Soroka C, Boyer JL, Karpen SJ, Miquel JF, Suchy FJ. Down-regulation of the Na<sup>+</sup>/taurocholate cotransporting polypeptide during pregnancy in the rat. **J Hepatol**. 2003 Feb;38(2):148-55. doi: 10.1016/s0168-8278(02)00379-3.

55. Trauner M. When bile ducts say NO: the good, the bad, and the ugly. **Gastroenterology**. 2003 Mar;124(3):847-51. doi: 10.1053/gast.2003.50122. Review
56. Marschall HU, Trauner M, Lammert F. Jaundice. **Scand J Gastroenterol**. 2003 Mar;38(3):233-4. doi: 10.1080/00365520310000573a. Editorial
57. Fickert P, Trauner M, Fuchsbichler A, Stumtner C, Zatloukal K, Denk H. Mallory body formation in primary biliary cirrhosis is associated with increased amounts and abnormal phosphorylation and ubiquitination of cytokeratins. **J Hepatol**. 2003 Apr;38(4):387-94. doi: 10.1016/s0168-8278(02)00439-7.
58. Tilg H, Jalan R, Kaser A, Davies NA, Offner FA, Hodges SJ, Ludwiczek O, Shawcross D, Zoller H, Alisa A, Mookerjee RP, Graziadei I, Datz C, Trauner M, Schuppan D, Obrist P, Vogel W, Williams R. Anti-tumor necrosis factor-alpha monoclonal antibody therapy in severe alcoholic hepatitis. **J Hepatol**. 2003 Apr;38(4):419-25. doi: 10.1016/s0168-8278(02)00442-7.
59. Trauner M, Boyer JL. Bile salt transporters: molecular characterization, function, and regulation. **Physiol Rev**. 2003 Apr;83(2):633-71. doi: 10.1152/physrev.00027.2002. Review
60. Trauner M, Boyer JL. Cholestatic syndromes. **Curr Opin Gastroenterol**. 2003 May;19(3):216-31. doi: 10.1097/00001574-200305000-00005. Review
61. Zollner G, Fickert P, Silbert D, Fuchsbichler A, Marschall HU, Zatloukal K, Denk H, Trauner M. Role of nuclear bile acid receptor, FXR, in adaptive ABC transporter regulation by cholic and ursodeoxycholic acid in mouse liver, kidney and intestine. **J Hepatol**. 2003 Jun;38(6):717-27. doi: 10.1016/s0168-8278(03)00096-5.
62. Zollner G, Fickert P, Silbert D, Fuchsbichler A, Marschall HU, Zatloukal K, Denk H, Trauner M. Adaptive changes in hepatobiliary transporter expression in primary biliary cirrhosis. **J Hepatol** 2003 Jun;38(6):717-27. doi: 10.1016/s0168-8278(03)00096-5.
63. Wagner M, Fickert P, Zollner G, Fuchsbichler A, Silbert D, Tsybrovskyy O, Zatloukal K, Guo GL, Schuetz JD, Gonzalez FJ, Marschall HU, Denk H, Trauner M. Role of farnesoid X receptor in determining hepatic ABC transporter expression and liver injury in bile duct-ligated mice. **Gastroenterology**. 2003 Sep;125(3):825-38. doi: 10.1016/s0016-5085(03)01068-0.
64. Zollner G, Fickert P, Fuchsbichler A, Silbert D, Wagner M, Arbeiter S, Gonzalez FJ, Marschall HU, Zatloukal K, Denk H, Trauner M. Role of nuclear bile acid receptor, FXR, in adaptive ABC transporter regulation by cholic and ursodeoxycholic acid in mouse liver, kidney and intestine. **J Hepatol**. 2003 Oct;39(4):480-8. doi: 10.1016/s0168-8278(03)00228-9.
65. Wagner M, Kaufmann P, Fickert P, Trauner M, Lackner C, Stauber RE. Successful conservative management of acute hepatic failure following exertional heatstroke. **Eur J Gastroenterol Hepatol**. 2003 Oct;15(10):1135-9. doi: 10.1097/00042737-200310000-00013. Case Report
66. Arrese M, Trauner M. Molecular aspects of bile formation and cholestasis. **Trends Mol Med**. 2003 Dec;9(12):558-64. doi: 10.1016/j.molmed.2003.10.002. Review

67. Lammert F, Wang DQ, Hillebrandt S, Geier A, Fickert P, Trauner M, Matern S, Paigen B, Carey MC. Spontaneous cholecysto- and hepatolithiasis in Mdr2<sup>-/-</sup> mice: a model for low phospholipid-associated cholelithiasis. *Hepatology*. 2004 Jan;39(1):117-28. doi: 10.1002/hep.20022.
68. Stauber RE, Krisper P, Zollner G, Iberer F, Beuers U, Trauner M. Extracorporeal albumin dialysis in a patient with primary sclerosing cholangitis: effect on pruritus and bile acid profile. *Int J Artif Organs*. 2004 Apr;27(4):342-4. doi: 10.1177/039139880402700411. Case Report
69. Trauner M, Boyer JL. Cholestatic syndromes. *Curr Opin Gastroenterol*. 2004 May;20(3):220-30. doi: 10.1097/00001574-200405000-00006. Review
70. Fickert P, Fuchsbichler A, Wagner M, Zollner G, Kaser A, Tilg H, Krause R, Lammert F, Langner C, Zatloukal K, Marschall HU, Denk H, Trauner M. Regurgitation of bile acids from leaky bile ducts causes sclerosing cholangitis in Mdr2 (Abcb4) knockout mice. *Gastroenterology*. 2004 Jul;127(1):261-74. doi: 10.1053/j.gastro.2004.04.009.
71. Trauner M. The nuclear bile acid receptor FXR as a novel therapeutic target in cholestatic liver diseases: hype or hope? *Hepatology*. 2004 Jul;40(1):260-3. doi: 10.1002/hep.20294. Editorial
72. Zatloukal K, Stumptner C, Fuchsbichler A, Fickert P, Lackner C, Trauner M, Denk H. The keratin cytoskeleton in liver diseases. *J Pathol*. 2004 Nov;204(4):367-76. doi: 10.1002/path.1649. Review.
73. Pizarro M, Balasubramaniyan N, Solís N, Solar A, Duarte I, Miquel JF, Suchy FJ, Trauner M, Accatino L, Ananthanarayanan M, Arrese M. Bile secretory function in the obese Zucker rat: evidence of cholestasis and altered canalicular transport function. *Gut*. 2004 Dec;53(12):1837-43. doi: 10.1136/gut.2003.037689.
74. Cover C, Fickert P, Knight TR, Fuchsbichler A, Farhood A, Trauner M, Jaeschke H. Pathophysiological role of poly(ADP-ribose) polymerase (PARP) activation during acetaminophen-induced liver cell necrosis in mice. *Toxicol Sci*. 2005 Mar;84(1):201-8. doi: 10.1093/toxsci/kfi065. Epub 2004 Dec 15.
75. Fickert P, Trauner M, Fuchsbichler A, Zollner G, Wagner M, Marschall HU, Zatloukal K, Denk H. Oncosis represents the main type of cell death in mouse models of cholestasis. *J Hepatol*. 2005 Mar;42(3):378-85. doi: 10.1016/j.jhep.2004.10.016.
76. Geier A, Zollner G, Dietrich CG, Wagner M, Fickert P, Denk H, van Rooijen N, Matern S, Gartung C, Trauner M. Cytokine-independent repression of rodent Ntcp in obstructive cholestasis. *Hepatology*. 2005 Mar;41(3):470-7. doi: 10.1002/hep.20594.
77. Trauner M, Wagner M, Fickert P, Zollner G. Molecular regulation of hepatobiliary transport systems: clinical implications for understanding and treating cholestasis. *J Clin Gastroenterol*. 2005 Apr;39(4 Suppl 2):S111-24. doi: 10.1097/01.mcg.0000155551.37266.26. Review
78. Zollner G, Wagner M, Fickert P, Silbert D, Fuchsbichler A, Zatloukal K, Denk H, Trauner M. Hepatobiliary transporter expression in human hepatocellular carcinoma. *Liver Int*. 2005 Apr;25(2):367-79. doi: 10.1111/j.1478-3231.2005.01033.x.

79. Wagner M, Trauner M. Transcriptional regulation of hepatobiliary transport systems in health and disease: implications for a rationale approach to the treatment of intrahepatic cholestasis. *Ann Hepatol*. 2005 Apr-Jun;4(2):77-99. Review
80. Geier A, Dietrich CG, Voigt S, Ananthanarayanan M, Lammert F, Schmitz A, Trauner M, Wasmuth HE, Boraschi D, Balasubramanian N, Suchy FJ, Matern S, Gartung C. Cytokine-dependent regulation of hepatic organic anion transporter gene transactivators in mouse liver. *Am J Physiol Gastrointest Liver Physiol*. 2005 Nov;289(5):G831-41. doi: 10.1152/ajpgi.00307.2004.
81. Peck-Radosavljevic M, Trauner M, Schreiber F; Austrian Society of Gastroenterology and Hepatology. Austrian consensus on the definition and treatment of portal hypertension and its complications. *Endoscopy*. 2005 Jul;37(7):667-73. doi: 10.1055/s-2005-861464. Review
82. Zollner G, Wagner M, Fickert P, Geier A, Fuchsbichler A, Silbert D, Gumhold J, Zatloukal K, Kaser A, Tilg H, Denk H, Trauner M. Role of nuclear receptors and hepatocyte-enriched transcription factors for Ntcp repression in biliary obstruction in mouse liver. *Am J Physiol Gastrointest Liver Physiol*. 2005 Nov;289(5):G798-805. doi: 10.1152/ajpgi.00319.2004. Epub 2005 Jul 7.
83. Wagner M, Halilbasic E, Marschall HU, Zollner G, Fickert P, Langner C, Zatloukal K, Denk H, Trauner M. CAR and PXR agonists stimulate hepatic bile acid and bilirubin detoxification and elimination pathways in mice. *Hepatology*. 2005 Aug;42(2):420-30. doi: 10.1002/hep.20784.
84. Marschall HU, Wagner M, Zollner G, Fickert P, Diczfalusy U, Gumhold J, Silbert D, Fuchsbichler A, Benthin L, Grundström R, Gustafsson U, Sahlin S, Einarsson C, Trauner M. Complementary stimulation of hepatobiliary transport and detoxification systems by rifampicin and ursodeoxycholic acid in humans. *Gastroenterology*. 2005 Aug;129(2):476-85. doi: 10.1016/j.gastro.2005.05.009.
85. Stadlbauer V, Fickert P, Lackner C, Schmerlaib J, Krisper P, Trauner M, Stauber RE. Hepatotoxicity of NONI juice: report of two cases. *World J Gastroenterol*. 2005 Aug 14;11(30):4758-60. doi: 10.3748/wjg.v11.i30.4758.
86. Popov Y, Patsenker E, Fickert P, Trauner M, Schuppan D. Mdr2 (Abcb4)-/- mice spontaneously develop severe biliary fibrosis via massive dysregulation of pro- and antifibrogenic genes. *J Hepatol*. 2005 Dec;43(6):1045-54. doi: 10.1016/j.jhep.2005.06.025. Epub 2005 Aug 15.
87. Krisper P, Haditsch B, Stauber R, Jung A, Stadlbauer V, Trauner M, Holzer H, Schneditz D. In vivo quantification of liver dialysis: comparison of albumin dialysis and fractionated plasma separation. *J Hepatol*. 2005 Sep;43(3):451-7. doi: 10.1016/j.jhep.2005.02.038.
88. Ellis E, Wagner M, Lammert F, Nemeth A, Gumhold J, Strassburg CP, Kylander C, Katsika D, Trauner M, Einarsson C, Marschall HU. Successful treatment of severe unconjugated hyperbilirubinemia via induction of UGT1A1 by rifampicin. *J Hepatol*. 2006 Jan;44(1):243-5. doi: 10.1016/j.jhep.2005.09.011. Case Report
89. Marschall HU, Wagner M, Bodin K, Zollner G, Fickert P, Gumhold J, Silbert D, Fuchsbichler A, Sjövall J, Trauner M. Fxr(-/-) mice adapt to biliary obstruction by



enhanced phase I detoxification and renal elimination of bile acids. *J Lipid Res.* 2006 Mar;47(3):582-92. doi: 10.1194/jlr.M500427-JLR200.

90. Zollner G, Wagner M, Moustafa T, Fickert P, Silbert D, Gumhold J, Fuchsbichler A, Halilbasic E, Denk H, Marschall HU, Trauner M. Coordinated induction of bile acid detoxification and alternative elimination in mice: role of FXR-regulated organic solute transporter-alpha/beta in the adaptive response to bile acids. *Am J Physiol Gastrointest Liver Physiol.* 2006 May;290(5):G923-32. doi: 10.1152/ajpgi.00490.2005.
91. Jung A, Krisper P, Haditsch B, Stauber RE, Trauner M, Holzer H, Schneditz D. Bilirubin kinetic modeling for quantification of extracorporeal liver support. *Blood Purif.* 2006;24(4):413-22. doi: 10.1159/000094575.
92. Boyer JL, Trauner M, Mennone A, Soroka CJ, Cai SY, Moustafa T, Zollner G, Lee JY, Ballatori N. Upregulation of a basolateral FXR-dependent bile acid efflux transporter OSTalpha-OSTbeta in cholestasis in humans and rodents. *Am J Physiol Gastrointest Liver Physiol.* 2006 Jun;290(6):G1124-30. doi: 10.1152/ajpgi.00539.2005.
93. Fickert P, Fuchsbichler A, Marschall HU, Wagner M, Zollner G, Krause R, Zatloukal K, Jaeschke H, Denk H, Trauner M. Lithocholic acid feeding induces segmental bile duct obstruction and destructive cholangitis in mice. *Am J Pathol.* 2006 Feb;168(2):410-22. doi: 10.2353/ajpath.2006.050404.
94. Gurakuqi GC, Stadlbauer V, Stepan V, Warnkross H, Trauner M. Addison's disease as a rare cause of chronically elevated liver enzymes. *Z Gastroenterol.* 2006 Feb;44(2):179-83. doi: 10.1055/s-2005-858976. Case Report
95. Fickert P, Wagner M, Marschall HU, Fuchsbichler A, Zollner G, Tsybrovskyy O, Zatloukal K, Liu J, Waalkes MP, Cover C, Denk H, Hofmann AF, Jaeschke H, Trauner M. 24-norUrsodeoxycholic acid is superior to ursodeoxycholic acid in the treatment of sclerosing cholangitis in Mdr2 (Abcb4) knockout mice. *Gastroenterology.* 2006 Feb;130(2):465-81. doi: 10.1053/j.gastro.2005.10.018.
96. Zollner G, Marschall HU, Wagner M, Trauner M. Role of nuclear receptors in the adaptive response to bile acids and cholestasis: pathogenetic and therapeutic considerations. *Mol Pharm.* 2006 May-Jun;3(3):231-51. doi: 10.1021/mp060010s. Review
97. Geier A, Wagner M, Dietrich CG, Trauner M. Principles of hepatic organic anion transporter regulation during cholestasis, inflammation and liver regeneration. *Biochim Biophys Acta.* 2007 Mar;1773(3):283-308. doi: 10.1016/j.bbamcr.2006.04.014. Review
98. Zollner G, Trauner M. Molecular mechanisms of cholestasis. *Wien Med Wochenschr.* 2006 Jul;156(13-14):380-5. doi: 10.1007/s10354-006-0312-7. Review
99. Panzitt K, Tschernatsch MM, Guelly C, Moustafa T, Stradner M, Strohmaier HM, Buck CR, Denk H, Schroeder R, Trauner M, Zatloukal K. Characterization of HULC, a novel gene with striking up-regulation in hepatocellular carcinoma, as noncoding RNA. *Gastroenterology.* 2007 Jan;132(1):330-42. doi: 10.1053/j.gastro.2006.08.026.

100. Geier A, Fickert P, Trauner M. Mechanisms of disease: mechanisms and clinical implications of cholestasis in sepsis. *Nat Clin Pract Gastroenterol Hepatol*. 2006 Oct;3(10):574-85. doi: 10.1038/ncpgasthep0602. Review
101. Putz-Bankuti C, Datz C, März W, Lackner C, Stauber RE, Trauner M, Toplak H, Stojakovic T, Krejs GJ. Clinical-pathological conference series from the Medical University of Graz : case no. 131: elevated transaminases in a 30-year-old male. *Wien Klin Wochenschr*. 2006 Dec;118(23-24):769-75. doi: 10.1007/s00508-006-0718-7. Case Report
102. Asslaber M, Abuja PM, Stark K, Eder J, Gottweis H, Trauner M, Samonigg H, Mischinger HJ, Schippinger W, Berghold A, Denk H, Zatloukal K. The Genome Austria Tissue Bank (GATiB). *Pathobiology*. 2007;74(4):251-8. doi: 10.1159/000104453.
103. Fickert P, Moustafa T, Trauner M. Primary sclerosing cholangitis--the arteriosclerosis of the bile duct? *Lipids Health Dis*. 2007 Jan 25;6:3. doi: 10.1186/1476-511X-6-3. Review
104. Trauner M, Fickert P, Wagner M. MDR3 (ABCB4) defects: a paradigm for the genetics of adult cholestatic syndromes. *Semin Liver Dis*. 2007 Feb;27(1):77-98. doi: 10.1055/s-2006-960172. Review
105. Stadlbauer V, Krisper P, Beuers U, Haditsch B, Schneditz D, Jung A, Putz-Bankuti C, Holzer H, Trauner M, Stauber RE. Removal of bile acids by two different extracorporeal liver support systems in acute-on-chronic liver failure. *ASAIO J*. 2007 Mar-Apr;53(2):187-93. doi: 10.1097/01.mat.0000249852.71634.6c.
106. Ambros-Rudolph CM, Glatz M, Trauner M, Kerl H, Müllegger RR. The importance of serum bile acid level analysis and treatment with ursodeoxycholic acid in intrahepatic cholestasis of pregnancy: a case series from central Europe. *Arch Dermatol*. 2007 Jun;143(6):757-62. doi: 10.1001/archderm.143.6.757. Case Report
107. Wagner M, Zollner G, Fickert P, Gumhold J, Silbert D, Fuchsbichler A, Gujral JS, Zatloukal K, Denk H, Jaeschke H, Trauner M. Hepatobiliary transporter expression in intercellular adhesion molecule 1 knockout and Fas receptor-deficient mice after common bile duct ligation is independent of the degree of inflammation and oxidative stress. *Drug Metab Dispos*. 2007 Sep;35(9):1694-9. doi: 10.1124/dmd.107.015610.
108. Fickert P, Stöger U, Fuchsbichler A, Moustafa T, Marschall HU, Weiglein AH, Tsybrovskyy O, Jaeschke H, Zatloukal K, Denk H, Trauner M. A new xenobiotic-induced mouse model of sclerosing cholangitis and biliary fibrosis. *Am J Pathol*. 2007 Aug;171(2):525-36. doi: 10.2353/ajpath.2007.061133.
109. Trauner M. A little orphan runs to fat: the orphan receptor small heterodimer partner as a key player in the regulation of hepatic lipid metabolism. *Hepatology*. 2007 Jul;46(1):1-5. doi: 10.1002/hep.21801. Editorial
110. Stojakovic T, Putz-Bankuti C, Fauler G, Scharnagl H, Wagner M, Stadlbauer V, Gurakuqi G, Stauber RE, März W, Trauner M. Atorvastatin in patients with primary biliary cirrhosis and incomplete biochemical response to ursodeoxycholic acid. *Hepatology*. 2007 Sep;46(3):776-84. doi: 10.1002/hep.21741.
111. Zollner G, Wagner M, Fickert P, Silbert D, Gumhold J, Zatloukal K, Denk H, Trauner M. Expression of bile acid synthesis and detoxification enzymes and the alternative bile

- acid efflux pump MRP4 in patients with primary biliary cirrhosis. *Liver Int.* 2007 Sep;27(7):920-9. doi: 10.1111/j.1478-3231.2007.01506.x.
112. Geier A, Dietrich CG, Trauner M, Gartung C. Extrahepatic cholestasis downregulates Oatp1 by TNF-alpha signalling without affecting Oatp2 and Oatp4 expression and sodium-independent bile salt uptake in rat liver. *Liver Int.* 2007 Oct;27(8):1056-65. doi: 10.1111/j.1478-3231.2007.01523.x.
113. Marschall HU, Wagner M, Zollner G, Trauner M. Clinical hepatotoxicity. Regulation and treatment with inducers of transport and cofactors. *Mol Pharm.* 2007 Nov-Dec;4(6):895-910. doi: 10.1021/mp060133c. Review
114. Gurakuqi GC, Stadlbauer V, Portugaller HR, Högenauer C, Trauner M, Stauber RE. Fatal hemobilia resulting from an iatrogenic arteriobiliary fistula as a rare complication of transjugular liver biopsy. *Eur J Gastroenterol Hepatol.* 2008 Jan;20(1):83-6. doi: 10.1097/MEG.0b013e3282748f32. Case Report
115. Trauner M, Fickert P, Halilbasic E, Moustafa T. Lessons from the toxic bile concept for the pathogenesis and treatment of cholestatic liver diseases. *Wien Med Wochenschr.* 2008;158(19-20):542-8. doi: 10.1007/s10354-008-0592-1. Review
116. Zollner G, Trauner M. Mechanisms of cholestasis. *Clin Liver Dis.* 2008 Feb;12(1):1-26, vii. doi: 10.1016/j.cld.2007.11.010. Review
117. Baghdasaryan A, Fickert P, Fuchsbichler A, Silbert D, Gumhold J, Hörl G, Langner C, Moustafa T, Halilbasic E, Claudel T, Trauner M. Role of hepatic phospholipids in development of liver injury in Mdr2 (Abcb4) knockout mice. *Liver Int.* 2008 Aug;28(7):948-58. doi: 10.1111/j.1478-3231.2008.01758.x.
118. Wagner M, Zollner G, Trauner M. Ischemia and cholestasis: more than (just) the bile ducts! *Transplantation.* 2008 Apr 27;85(8):1083-5. doi: 10.1097/TP.0b013e31816b2393. Comment
119. Magnes C, Suppan M, Pieber TR, Moustafa T, Trauner M, Haemmerle G, Sinner FM. Validated comprehensive analytical method for quantification of coenzyme A activated compounds in biological tissues by online solid-phase extraction LC/MS/MS. *Anal Chem.* 2008 Aug 1;80(15):5736-42. doi: 10.1021/ac800031u.
120. Kratzer A, Buchebner M, Pfeifer T, Becker TM, Uray G, Miyazaki M, Miyazaki-Anzai S, Ebner B, Chandak PG, Kadam RS, Calayir E, Rathke N, Ahammer H, Radovic B, Trauner M, Hoefler G, Kompella UB, Fauler G, Levi M, Levak-Frank S, Kostner GM, Kratky D. Synthetic LXR agonist attenuates plaque formation in apoE-/- mice without inducing liver steatosis and hypertriglyceridemia. *J Lipid Res.* 2009 Feb;50(2):312-26. doi: 10.1194/jlr.M800376-JLR200.
121. Wagner M, Zollner G, Trauner M. Nuclear bile acid receptor farnesoid X receptor meets nuclear factor-kappaB: new insights into hepatic inflammation. *Hepatology.* 2008 Nov;48(5):1383-6. doi: 10.1002/hep.22668. Editorial
122. Fickert P, Trauner M. When lightning strikes twice: the plot thickens for a dual role of the anion exchanger 2 (AE2/SLC4A2) in the pathogenesis and treatment of primary biliary cirrhosis. *J Hepatol.* 2009 Mar;50(3):633-5. doi: 10.1016/j.jhep.2008.12.006. Editorial

123. Zollner G, Trauner M. Nuclear receptors as therapeutic targets in cholestatic liver diseases. *Br J Pharmacol*. 2009 Jan;156(1):7-27. doi: 10.1111/j.1476-5381.2008.00030.x. Review
124. Sturm E, Wagner M, Trauner M. Nuclear receptor ligands in therapy of cholestatic liver disease. *Front Biosci* (Landmark Ed). 2009 Jan 1;14:4299-325. doi: 10.2741/3529. Review
125. Klein K, Kullak-Ublick GA, Wagner M, Trauner M, Eloranta JJ. Hepatocyte nuclear factor-4alpha and bile acids regulate human concentrative nucleoside transporter-1 gene expression. *Am J Physiol Gastrointest Liver Physiol*. 2009 Apr;296(4):G936-47. doi: 10.1152/ajpgi.90678.2008.
126. Wagner M, Zollner G, Trauner M. New molecular insights into the mechanisms of cholestasis. *J Hepatol*. 2009 Sep;51(3):565-80. doi: 10.1016/j.jhep.2009.05.012. Review
127. Halilbasic E, Fiorotto R, Fickert P, Marschall HU, Moustafa T, Spirli C, Fuchsbichler A, Gumhold J, Silbert D, Zatloukal K, Langner C, Maitra U, Denk H, Hofmann AF, Strazzabosco M, Trauner M. Side chain structure determines unique physiologic and therapeutic properties of norursodeoxycholic acid in Mdr2<sup>-/-</sup> mice. *Hepatology*. 2009 Jun;49(6):1972-81. doi: 10.1002/hep.22891.
128. European Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of cholestatic liver diseases. *J Hepatol*. 2009 Aug;51(2):237-67. doi: 10.1016/j.jhep.2009.04.009. Consensus Report (all authors listed in acknowledgement)
129. Jahnle J, Fickert P, Langner C, Högenauer C, Silbert D, Gumhold J, Fuchsbichler A, Trauner M. Impact of experimental colitis on hepatobiliary transporter expression and bile duct injury in mice. *Liver Int*. 2009 Oct;29(9):1316-25. doi: 10.1111/j.1478-3231.2009.02044.x.
130. Stojakovic T, Scharnagl H, Trauner M, Pieske B, Wellnitz B, Seelhorst U, Schilling D, Winkelmann BR, Boehm BO, März W. Serum gamma-glutamyl transferase and mortality in persons undergoing coronary angiography-The Ludwigshafen Risk and Cardiovascular Health Study. *Atherosclerosis*. 2010 Feb;208(2):564-71. doi: 10.1016/j.atherosclerosis.2009.07.026.
131. Fickert P, Fuchsbichler A, Wagner M, Silbert D, Zatloukal K, Denk H, Trauner M. The role of the hepatocyte cytokekeratin network in bile formation and resistance to bile acid challenge and cholestasis in mice. *Hepatology*. 2009 Sep;50(3):893-9. doi: 10.1002/hep.23068.
132. Stauber RE, Wagner D, Stadlbauer V, Palma S, Gurakuqi G, Kniepeiss D, Iberer F, Smolle KH, Haas J, Trauner M. Evaluation of indocyanine green clearance and model for end-stage liver disease for estimation of short-term prognosis in decompensated cirrhosis. *Liver Int*. 2009 Nov;29(10):1516-20. doi: 10.1111/j.1478-3231.2009.02104.x.
133. Stojakovic T, Claudel T, Putz-Bankuti C, Fauler G, Scharnagl H, Wagner M, Sourij H, Stauber RE, Winkler K, März W, Wascher TC, Trauner M. Low-dose atorvastatin improves dyslipidemia and vascular function in patients with primary biliary cirrhosis after one year of treatment. *Atherosclerosis*. 2010 Mar;209(1):178-83. doi: 10.1016/j.atherosclerosis.2009.08.052.

134. Loebermann M, Sombetzki M, Langner C, Fuchsbichler A, Gumhold J, Silbert D, Riebold D, Holtfreter M, Fickert P, Nizze H, Trauner M, Reisinger EC. Imbalance of pro- and antifibrogenic genes and bile duct injury in murine *Schistosoma mansoni* infection-induced liver fibrosis. *Trop Med Int Health*. 2009 Nov;14(11):1418-25. doi: 10.1111/j.1365-3156.2009.02387.x.
135. Trauner M, Arrese M, Wagner M. Fatty liver and lipotoxicity. *Biochim Biophys Acta*. 2010 Mar;1801(3):299-310. doi: 10.1016/j.bbali.2009.10.007. Review
136. Trottier J, El Hussein D, Perreault M, Pâquet S, Caron P, Bourassa S, Verreault M, Inaba TT, Poirier GG, Bélanger A, Guillemette C, Trauner M, Barbier O. The human UGT1A3 enzyme conjugates norursodeoxycholic acid into a C23-ester glucuronide in the liver. *J Biol Chem*. 2010 Jan 8;285(2):1113-21. doi: 10.1074/jbc.M109.073908.
137. Fickert P, Fuchsbichler A, Moustafa T, Wagner M, Zollner G, Halilbasic E, Stöger U, Arrese M, Pizarro M, Solís N, Carrasco G, Caligiuri A, Sombetzki M, Reisinger E, Tsybrovskyy O, Zatloukal K, Denk H, Jaeschke H, Pinzani M, Trauner M. Farnesoid X receptor critically determines the fibrotic response in mice but is expressed to a low extent in human hepatic stellate cells and periductal myofibroblasts. *Am J Pathol*. 2009 Dec;175(6):2392-405. doi: 10.2353/ajpath.2009.090114.
138. Karpen SJ, Trauner M. The new therapeutic frontier--nuclear receptors and the liver. *J Hepatol*. 2010 Mar;52(3):455-62. doi: 10.1016/j.jhep.2009.12.002. Review
139. Trauner M, Fickert P, Baghdasaryan A, Claudel T, Halilbasic E, Moustafa T, Wagner M, Zollner G. New insights into autoimmune cholangitis through animal models. *Dig Dis*. 2010;28(1):99-104. doi: 10.1159/000282072. Review
140. Trauner M, Claudel T, Fickert P, Moustafa T, Wagner M. Bile acids as regulators of hepatic lipid and glucose metabolism. *Dig Dis*. 2010;28(1):220-4. doi: 10.1159/000282091. Review
141. Mair M, Zollner G, Schneller D, Musteanu M, Fickert P, Gumhold J, Schuster C, Fuchsbichler A, Bilban M, Tauber S, Esterbauer H, Kenner L, Poli V, Blaas L, Kornfeld JW, Casanova E, Mikulits W, Trauner M, Eferl R. Signal transducer and activator of transcription 3 protects from liver injury and fibrosis in a mouse model of sclerosing cholangitis. *Gastroenterology*. 2010 Jun;138(7):2499-508. doi: 10.1053/j.gastro.2010.02.049.
142. Tannapfel A, Denk H, Dienes HP, Langner C, Schirmacher P, Trauner M, Flott-Rahmel B. Histopathological diagnose of non-alcoholic and alcoholic fatty liver disease. *Z Gastroenterol*. 2010 Apr;48(4):486-98. doi: 10.1055/s-0029-1245278.
143. Blaas L, Kornfeld JW, Schramek D, Musteanu M, Zollner G, Gumhold J, van Zijl F, Schneller D, Esterbauer H, Egger G, Mair M, Kenner L, Mikulits W, Eferl R, Moriggl R, Penninger J, Trauner M, Casanova E. Disruption of the growth hormone--signal transducer and activator of transcription 5--insulinlike growth factor 1 axis severely aggravates liver fibrosis in a mouse model of cholestasis. *Hepatology*. 2010 Apr;51(4):1319-26. doi: 10.1002/hep.23469.
144. Baghdasaryan A, Claudel T, Kosters A, Gumhold J, Silbert D, Thüringer A, Leski K, Fickert P, Karpen SJ, Trauner M. Curcumin improves sclerosing cholangitis in *Mdr2*<sup>-/-</sup>

- mice by inhibition of cholangiocyte inflammatory response and portal myofibroblast proliferation. **Gut**. 2010 Apr;59(4):521-30. doi: 10.1136/gut.2009.186528.
145. Fickert P, Thueringer A, Moustafa T, Silbert D, Gumhold J, Tsybrovskyy O, Lebofsky M, Jaeschke H, Denk H, Trauner M. The role of osteopontin and tumor necrosis factor alpha receptor-1 in xenobiotic-induced cholangitis and biliary fibrosis in mice. **Lab Invest**. 2010 Jun;90(6):844-52. doi: 10.1038/labinvest.2010.61.
  146. Zollner G, Wagner M, Trauner M. Nuclear receptors as drug targets in cholestasis and drug-induced hepatotoxicity. **Pharmacol Ther**. 2010 Jun;126(3):228-43. doi: 10.1016/j.pharmthera.2010.03.005. Review
  147. Wagner M, Zollner G, Trauner M. Nuclear receptor regulation of the adaptive response of bile acid transporters in cholestasis. **Semin Liver Dis**. 2010 May;30(2):160-77. doi: 10.1055/s-0030-1253225. Review
  148. Tannapfel A, Denk H, Dienes HP, Langner C, Schirmacher P, Trauner M, Flott-Rahmel B. Histopathological diagnosis of non-alcoholic and alcoholic fatty liver disease. Grade 2 consensus-based guidelines. **Pathologe**. 2010 May;31(3):225-37. doi: 10.1007/s00292-010-1274-5. Review
  149. Morgan RE, Trauner M, van Staden CJ, Lee PH, Ramachandran B, Eschenberg M, Afshari CA, Qualls CW Jr, Lightfoot-Dunn R, Hamadeh HK. Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development. **Toxicol Sci**. 2010 Dec;118(2):485-500. doi: 10.1093/toxsci/kfq269.
  150. Denk GU, Maitz S, Wimmer R, Rust C, Invernizzi P, Ferdinandusse S, Kulik W, Fuchsichler A, Fickert P, Trauner M, Hofmann AF, Beuers U. Conjugation is essential for the anticholestatic effect of NorUrsodeoxycholic acid in tauro lithocholic acid-induced cholestasis in rat liver. **Hepatology**. 2010 Nov;52(5):1758-68. doi: 10.1002/hep.23911.
  151. Beraza N, Ofner-Ziegenfuss L, Ehedego H, Boekschoten M, Bischoff SC, Mueller M, Trauner M, Trautwein C. Nor-ursodeoxycholic acid reverses hepatocyte-specific nemo-dependent steatohepatitis. **Gut**. 2011 Mar;60(3):387-96. doi: 10.1136/gut.2010.223834.
  152. Claudel T, Zollner G, Wagner M, Trauner M. Role of nuclear receptors for bile acid metabolism, bile secretion, cholestasis, and gallstone disease. **Biochim Biophys Acta**. 2011 Aug;1812(8):867-78. doi: 10.1016/j.bbadis.2010.12.021. Review
  153. Trauner M, Baghdasaryan A, Claudel T, Fickert P, Halilbasic E, Moustafa T, Zollner G. Targeting nuclear bile acid receptors for liver disease. **Dig Dis**. 2011;29(1):98-102. doi: 10.1159/000324141. Review
  154. Marschall HU, Wagner M, Zollner G, Fickert P, Lackner C, Thorell A, Trauner M. Ursodeoxycholic acid for treatment of fatty liver disease and dyslipidemia in morbidly obese patients. **Dig Dis**. 2011;29(1):117-8. doi: 10.1159/000324146.
  155. Kniepeiss D, Wagner D, Krause R, Aigelsreiter A, Iberer F, Fickert P, Tscheliessnigg KH, Trauner M. Mycosis as a cause of secondary sclerosing cholangitis requiring liver retransplantation. **Transplantation**. 2011 Jan 27;91(2):e14-6. doi: 10.1097/TP.0b013e318200ba57. Case Report

156. Wagner M, Zollner G, Trauner M. Nuclear receptors in liver disease. *Hepatology*. 2011 Mar;53(3):1023-34. doi: 10.1002/hep.24148. Review
157. Trauner M, Halilbasic E. Nuclear receptors as new perspective for the management of liver diseases. *Gastroenterology*. 2011 Apr;140(4):1120-1125.e1-12. doi: 10.1053/j.gastro.2011.02.044. Review
158. Zhang G, Chen M, Graham D, Subsin B, McDougall C, Gilady S, Kneteman M, Law L, Swain M, Trauner M, Wrzesinski S, Flavell R, Wasilenko S, Mason A. Mouse mammary tumor virus in anti-mitochondrial antibody producing mouse models. *J Hepatol*. 2011 Oct;55(4):876-84. doi: 10.1016/j.jhep.2011.01.037.
159. Reiberger T, Rutter K, Ferlitsch A, Payer BA, Hofer H, Beinhardt S, Kundi M, Ferenci P, Gangl A, Trauner M, Peck-Radosavljevic M. Portal pressure predicts outcome and safety of antiviral therapy in cirrhotic patients with hepatitis C virus infection. *Clin Gastroenterol Hepatol*. 2011 Jul;9(7):602-8.e1. doi: 10.1016/j.cgh.2011.03.002.
160. Tannapfel A, Denk H, Dienes HP, Langner C, Schirmacher P, Trauner M, Flott-Rahmel B. Histopathological diagnosis of non-alcoholic and alcoholic fatty liver disease. *Virchows Arch*. 2011 May;458(5):511-23. doi: 10.1007/s00428-011-1066-1. Review
161. Penz-Österreicher M, Österreicher CH, Trauner M. Fibrosis in autoimmune and cholestatic liver disease. *Best Pract Res Clin Gastroenterol*. 2011 Apr;25(2):245-58. doi: 10.1016/j.bpg.2011.02.001. Review
162. Das SK, Eder S, Schauer S, Diwoky C, Temmel H, Guertl B, Gorkiewicz G, Tamilarasan KP, Kumari P, Trauner M, Zimmermann R, Vesely P, Haemmerle G, Zechner R, Hoefler G. Adipose triglyceride lipase contributes to cancer-associated cachexia. *Science*. 2011 Jul 8;333(6039):233-8. doi: 10.1126/science.1198973.
163. Pollheimer MJ, Trauner M, Fickert P. Will we ever model PSC? - "it's hard to be a PSC model!". *Clin Res Hepatol Gastroenterol*. 2011 Dec;35(12):792-804. doi: 10.1016/j.clinre.2011.04.014. Review
164. Fiorotto R, Scirpo R, Trauner M, Fabris L, Hoque R, Spirli C, Strazzabosco M. Loss of CFTR affects biliary epithelium innate immunity and causes TLR4-NF- $\kappa$ B-mediated inflammatory response in mice. *Gastroenterology*. 2011 Oct;141(4):1498-508, 1508.e1-5. doi: 10.1053/j.gastro.2011.06.052.
165. Chennamsetty I, Claudel T, Kostner KM, Baghdasaryan A, Kratky D, Levak-Frank S, Frank S, Gonzalez FJ, Trauner M, Kostner GM. Farnesoid X receptor represses hepatic human APOA gene expression. *J Clin Invest*. 2011 Sep;121(9):3724-34. doi: 10.1172/JCI45277.
166. Krones E, Graziadei I, Trauner M, Fickert P. Evolving concepts in primary sclerosing cholangitis. *Liver Int*. 2012 Mar;32(3):352-69. doi: 10.1111/j.1478-3231.2011.02607.x. Review
167. Haemmerle G, Moustafa T, Woelkart G, Büttner S, Schmidt A, van de Weijer T, Hesselink M, Jaeger D, Kienesberger PC, Zierler K, Schreiber R, Eichmann T, Kolb D, Kotzbeck P, Schweiger M, Kumari M, Eder S, Schoiswohl G, Wongsiriroj N, Pollak NM, Radner FP, Preiss-Landl K, Kolbe T, Rüllicke T, Pieske B, Trauner M, Lass A, Zimmermann R, Hoefler G, Cinti S, Kershaw EE, Schrauven P, Madeo F, Mayer B,

- Zechner R. ATGL-mediated fat catabolism regulates cardiac mitochondrial function via PPAR- $\alpha$  and PGC-1. *Nat Med*. 2011 Aug 21;17(9):1076-85. doi: 10.1038/nm.2439.
168. Bernhardt GA, Zollner G, Cerwenka H, Kornprat P, Fickert P, Bacher H, Werkgartner G, Müller G, Zatloukal K, Mischinger HJ, Trauner M. Hepatobiliary transporter expression and post-operative jaundice in patients undergoing partial hepatectomy. *Liver Int*. 2012 Jan;32(1):119-27. doi: 10.1111/j.1478-3231.2011.02625.x.
169. Fuhrmann V, Derfler K, Trauner M. Extracorporeal artificial liver support in hepatic failure: pathfinder, bridge to recovery or dead end street? *Liver Int*. 2011 Sep;31 Suppl 3:iv. doi: 10.1111/j.1478-3231.2011.02581.x.
170. Fuhrmann V, Drolz A, Trauner M. Extracorporeal artificial liver support systems in the management of intractable cholestatic pruritus. *Liver Int*. 2011 Sep;31 Suppl 3:31-3. doi: 10.1111/j.1478-3231.2011.02584.x. Review
171. Ferlitsch M, Reinhart K, Pramhas S, Wiener C, Gal O, Bannert C, Hassler M, Kozbial K, Dunkler D, Trauner M, Weiss W. Sex-specific prevalence of adenomas, advanced adenomas, and colorectal cancer in individuals undergoing screening colonoscopy. *JAMA*. 2011 Sep 28;306(12):1352-8. doi: 10.1001/jama.2011.1362.
172. Baghdasaryan A, Claudel T, Gumhold J, Silbert D, Adorini L, Roda A, Vecchiotti S, Gonzalez FJ, Schoonjans K, Strazzabosco M, Fickert P, Trauner M. Dual farnesoid X receptor/TGR5 agonist INT-767 reduces liver injury in the Mdr2-/- (Abcb4-/-) mouse cholangiopathy model by promoting biliary HCO<sub>3</sub><sup>-</sup> output. *Hepatology*. 2011 Oct;54(4):1303-12. doi: 10.1002/hep.24537.
173. Moustafa T, Fickert P, Magnes C, Guelly C, Thueringer A, Frank S, Kratky D, Sattler W, Reicher H, Sinner F, Gumhold J, Silbert D, Fauler G, Höfler G, Lass A, Zechner R, Trauner M. Alterations in lipid metabolism mediate inflammation, fibrosis, and proliferation in a mouse model of chronic cholestatic liver injury. *Gastroenterology*. 2012 Jan;142(1):140-151.e12. doi: 10.1053/j.gastro.2011.09.051.
174. Lax S, Schauer G, Prein K, Kapitan M, Silbert D, Berghold A, Berger A, Trauner M. Expression of the nuclear bile acid receptor/farnesoid X receptor is reduced in human colon carcinoma compared to nonneoplastic mucosa independent from site and may be associated with adverse prognosis. *Int J Cancer*. 2012 May 15;130(10):2232-9. doi: 10.1002/ijc.26293.
175. Modica S, Petruzzelli M, Bellafante E, Murzilli S, Salvatore L, Celli N, Di Tullio G, Palasciano G, Moustafa T, Halilbasic E, Trauner M, Moschetta A. Selective activation of nuclear bile acid receptor FXR in the intestine protects mice against cholestasis. *Gastroenterology*. 2012 Feb;142(2):355-65.e1-4. doi: 10.1053/j.gastro.2011.10.028.
176. Pollheimer MJ, Halilbasic E, Fickert P, Trauner M. Pathogenesis of primary sclerosing cholangitis. *Best Pract Res Clin Gastroenterol*. 2011 Dec;25(6):727-39. doi: 10.1016/j.bpg.2011.10.009. Review
177. Bechmann LP, Hannivoort RA, Gerken G, Hotamisligil GS, Trauner M, Canbay A. The interaction of hepatic lipid and glucose metabolism in liver diseases. *J Hepatol*. 2012 Apr;56(4):952-64. doi: 10.1016/j.jhep.2011.08.025. Review
178. Reiberger T, Payer BA, Ferlitsch A, Sieghart W, Breitenecker F, Aichelburg MC, Schmied B, Rieger A, Trauner M, Peck-Radosavljevic M; Vienna Hepatic



- Hemodynamic Lab and Vienna HIV & Liver Study Group. A prospective evaluation of pulmonary, systemic and hepatic haemodynamics in HIV-HCV-coinfected patients before and after antiviral therapy with pegylated interferon and ribavirin. *Antivir Ther.* 2012;17(7):1327-34. doi: 10.3851/IMP2349.
179. Marschall HU, Wagner M, Zollner G, Fickert P, Silbert D, Gustafsson U, Sahlin S, Trauner M. Combined rifampicin and ursodeoxycholic acid treatment does not amplify rifampicin effects on hepatic detoxification and transport systems in humans. *Digestion.* 2012;86(3):244-9. doi: 10.1159/000341420.
  180. Starmann J, Fälth M, Spindelböck W, Lanz KL, Lackner C, Zatloukal K, Trauner M, Sültmann H. Gene expression profiling unravels cancer-related hepatic molecular signatures in steatohepatitis but not in steatosis. *PLoS One.* 2012;7(10):e46584. doi: 10.1371/journal.pone.0046584.
  181. Trauner M, Halilbasic E, Baghdasaryan A, Moustafa T, Krones E, Fickert P, Hofer H, Penner E. Primary sclerosing cholangitis: new approaches to diagnosis, surveillance and treatment. *Dig Dis.* 2012;30 Suppl 1:39-47. doi: 10.1159/000341123. Review
  182. Recknagel P, Gonnert FA, Westermann M, Lambeck S, Lupp A, Rudiger A, Dyson A, Carré JE, Kortgen A, Krafft C, Popp J, Sponholz C, Fuhrmann V, Hilger I, Claus RA, Riedemann NC, Wetzker R, Singer M, Trauner M, Bauer M. Liver dysfunction and phosphatidylinositol-3-kinase signalling in early sepsis: experimental studies in rodent models of peritonitis. *PLoS Med.* 2012;9(11):e1001338. doi: 10.1371/journal.pmed.1001338.
  183. Stauffer K, Trauner M, Fuhrmann V. Akutes Leberversagen. *Wien Klin Wochenschr Educ.* 2012;7(2):59-76. doi: 10.1007/s11812-012-0051-1. Review
  184. Putz-Bankuti C, Pilz S, Stojakovic T, Scharnagl H, Pieber TR, Trauner M, Obermayer-Pietsch B, Stauber RE. Association of 25-hydroxyvitamin D levels with liver dysfunction and mortality in chronic liver disease. *Liver Int.* 2012 May;32(5):845-51. doi: 10.1111/j.1478-3231.2011.02735.x.
  185. Chennamsetty I, Claudel T, Kostner KM, Trauner M, Kostner GM. FGF19 signaling cascade suppresses APOA gene expression. *Arterioscler Thromb Vasc Biol.* 2012 May;32(5):1220-7. doi: 10.1161/ATVBAHA.111.243055.
  186. von Haehling S, Schefold JC, Jankowska EA, Springer J, Vazir A, Kalra PR, Sandek A, Fauler G, Stojakovic T, Trauner M, Ponikowski P, Volk HD, Doehner W, Coats AJ, Poole-Wilson PA, Anker SD. Ursodeoxycholic acid in patients with chronic heart failure: a double-blind, randomized, placebo-controlled, crossover trial. *J Am Coll Cardiol.* 2012 Feb 7;59(6):585-92. doi: 10.1016/j.jacc.2011.10.880.
  187. Haybaeck J, Stumptner C, Thueringer A, Kolbe T, Magin TM, Hesse M, Fickert P, Tsybrovskyy O, Müller H, Trauner M, Zatloukal K, Denk H. Genetic background effects of keratin 8 and 18 in a DDC-induced hepatotoxicity and Mallory-Denk body formation mouse model. *Lab Invest.* 2012 Jun;92(6):857-67. doi: 10.1038/labinvest.2012.49.
  188. Österreicher CH, Trauner M. Xenobiotic-induced liver injury and fibrosis. *Expert Opin Drug Metab Toxicol.* 2012 May;8(5):571-80. doi: 10.1517/17425255.2012.674511. Review

189. Österreicher CH, Trauner M. Animal models of biliary tract injury. *Curr Opin Gastroenterol*. 2012 May;28(3):239-43. doi: 10.1097/MOG.0b013e32835264d9. Review
190. Stättermayer AF, Rutter K, Beinhardt S, Scherzer TM, Stadlmayr A, Hofer H, Wrba F, Steindl-Munda P, Krebs M, Datz C, Trauner M, Ferenci P. Association of the IL28B genotype with insulin resistance in patients with chronic hepatitis C. *J Hepatol*. 2012 Sep;57(3):492-8. doi: 10.1016/j.jhep.2012.04.036.
191. Fuchs CD, Claudel T, Kumari P, Haemmerle G, Pollheimer MJ, Stojakovic T, Scharnagl H, Halilbasic E, Gumhold J, Silbert D, Koefeler H, Trauner M. Absence of adipose triglyceride lipase protects from hepatic endoplasmic reticulum stress in mice. *Hepatology*. 2012 Jul;56(1):270-80. doi: 10.1002/hep.25601.
192. Wibmer A, Aliya Q, Steininger R, Trauner M, Maresch J, Mühlbacher F, Ba-Ssalamah A. Liver transplantation: impaired biliary excretion of gadoxate is associated with an inferior 1-year retransplantation-free survival. *Invest Radiol*. 2012 Jun;47(6):353-8. doi: 10.1097/RLI.0b013e318245f7be.
193. Reiberger T, Ferlitsch A, Payer BA, Pinter M, Schwabl P, Stift J, Trauner M, Peck-Radosavljevic M. Noninvasive screening for liver fibrosis and portal hypertension by transient elastography--a large single center experience. *Wien Klin Wochenschr*. 2012 Jun;124(11-12):395-402. doi: 10.1007/s00508-012-0190-5.
194. Trauner M. EASL recognition awardee 2012: Professor Peter L.M. Jansen. *J Hepatol*. 2012 Aug;57(2):241-3. doi: 10.1016/j.jhep.2012.05.002. Editorial
195. Hofer H, Willheim-Polli C, Knoflach P, Gabriel C, Vogel W, Trauner M, Müller T, Ferenci P. Identification of a novel Wilson disease gene mutation frequent in Upper Austria: a genetic and clinical study. *J Hum Genet*. 2012 Sep;57(9):564-7. doi: 10.1038/jhg.2012.65.
196. Pinto M, Trauner M, Ecker GF. An In Silico Classification Model for Putative ABCC2 Substrates. *Mol Inform*. 2012 Aug;31(8):547-553. doi: 10.1002/minf.201200049.
197. Halilbasic E, Claudel T, Trauner M. Bile acid transporters and regulatory nuclear receptors in the liver and beyond. *J Hepatol*. 2013 Jan;58(1):155-68. doi: 10.1016/j.jhep.2012.08.002. Review
198. Ferlitsch M, Reiberger T, Hoke M, Salzl P, Schwengerer B, Ulbrich G, Payer BA, Trauner M, Peck-Radosavljevic M, Ferlitsch A. von Willebrand factor as new noninvasive predictor of portal hypertension, decompensation and mortality in patients with liver cirrhosis. *Hepatology*. 2012 Oct;56(4):1439-47. doi: 10.1002/hep.25806.
199. Dolak W, Kulnigg-Dabsch S, Evstatiev R, Gasche C, Trauner M, Püspök A. A randomized head-to-head study of small-bowel imaging comparing MiroCam and EndoCapsule. *Endoscopy*. 2012 Nov;44(11):1012-20. doi: 10.1055/s-0032-1310158.
200. Chennamsetty I, Kostner KM, Claudel T, Vinod M, Frank S, Weiss TS, Trauner M, Kostner GM. Nicotinic acid inhibits hepatic APOA gene expression: studies in humans and in transgenic mice. *J Lipid Res*. 2012 Nov;53(11):2405-12. doi: 10.1194/jlr.M029769.

201. Jäger B, Drolz A, Michl B, Schellongowski P, Bojic A, Nikfardjam M, Zauner C, Heinz G, Trauner M, Fuhrmann V. Jaundice increases the rate of complications and one-year mortality in patients with hypoxic hepatitis. *Hepatology*. 2012 Dec;56(6):2297-304. doi: 10.1002/hep.25896.
202. Grünhage F, Hochrath K, Krawczyk M, Höblinger A, Obermayer-Pietsch B, Geisel J, Trauner M, Sauerbruch T, Lammert F. Common genetic variation in vitamin D metabolism is associated with liver stiffness. *Hepatology*. 2012 Nov;56(5):1883-91. doi: 10.1002/hep.25830.
203. Recknagel P, Gonnert FA, Halilbasic E, Gajda M, Jbeily N, Lupp A, Rubio I, Claus RA, Kortgen A, Trauner M, Singer M, Bauer M. Mechanisms and functional consequences of liver failure substantially differ between endotoxaemia and faecal peritonitis in rats. *Liver Int*. 2013 Feb;33(2):283-93. doi: 10.1111/liv.12012.
204. Bannert C, Reinhart K, Dunkler D, Trauner M, Renner F, Knoflach P, Ferlitsch A, Weiss W, Ferlitsch M. Sedation in screening colonoscopy: impact on quality indicators and complications. *Am J Gastroenterol*. 2012 Dec;107(12):1837-48. doi: 10.1038/ajg.2012.347.
205. Smolen JS, Schoels MM, Nishimoto N, Breedveld FC, Burmester GR, Dougados M, Emery P, Ferraccioli G, Gabay C, Gibofsky A, Gomez-Reino JJ, Jones G, Kvien TK, Murakami M, Betteridge N, Bingham CO 3rd, Bykerk V, Choy EH, Combe B, Cutolo M, Graninger W, Lanas A, Martin-Mola E, Montecucco C, Ostergaard M, Pavelka K, Rubbert-Roth A, Sattar N, Scholte-Voshaar M, Tanaka Y, Trauner M, Valentini G, Winthrop KL, de Wit M, van der Heijde D. Consensus statement on blocking the effects of interleukin-6 and in particular by interleukin-6 receptor inhibition in rheumatoid arthritis and other inflammatory conditions. *Ann Rheum Dis*. 2013 Apr;72(4):482-92. doi: 10.1136/annrheumdis-2012-202469. Consensus Report
206. Marzioni M, Saccomanno S, Agostinelli L, Rychlicki C, De Minicis S, Pierantonelli I, Trauner M, Fickert P, Müller T, Shanmukhappa K, Trozzi L, Candelaresi C, Baroni GS, Benedetti A. PDX-1/Hes-1 interactions determine cholangiocyte proliferative response to injury in rodents: possible implications for sclerosing cholangitis. *J Hepatol*. 2013 Apr;58(4):750-6. doi: 10.1016/j.jhep.2012.11.033.
207. Reiberger T, Ulbrich G, Ferlitsch A, Payer BA, Schwabl P, Pinter M, Heinisch BB, Trauner M, Kramer L, Peck-Radosavljevic M; Vienna Hepatic Hemodynamic Lab. Carvedilol for primary prophylaxis of variceal bleeding in cirrhotic patients with haemodynamic non-response to propranolol. *Gut*. 2013 Nov;62(11):1634-41. doi: 10.1136/gutjnl-2012-304038.
208. Reiberger T, Ferlitsch A, Payer BA, Mandorfer M, Heinisch BB, Hayden H, Lammert F, Trauner M, Peck-Radosavljevic M, Vogelsang H; Vienna Hepatic Hemodynamic Lab. Non-selective betablocker therapy decreases intestinal permeability and serum levels of LBP and IL-6 in patients with cirrhosis. *J Hepatol*. 2013 May;58(5):911-21. doi: 10.1016/j.jhep.2012.12.011.
209. Reinhart K, Bannert C, Dunkler D, Salzl P, Trauner M, Renner F, Knoflach P, Ferlitsch A, Weiss W, Ferlitsch M. Prevalence of flat lesions in a large screening population and their role in colonoscopy quality improvement. *Endoscopy*. 2013;45(5):350-6. doi: 10.1055/s-0032-1326348.

210. Acimovic J, Lövgren-Sandblom A, Olin M, Ali Z, Heverin M, Schüle R, Schöls L, Fischler B, Fickert P, Trauner M, Björkhem I. Sulphatation does not appear to be a protective mechanism to prevent oxysterol accumulation in humans and mice. *PLoS One*. 2013 Jul 3;8(7):e68031. doi: 10.1371/journal.pone.0068031.
211. Mandorfer M, Reiberger T, Payer BA, Ferlitsch A, Breitenecker F, Aichelburg MC, Obermayer-Pietsch B, Rieger A, Trauner M, Peck-Radosavljevic M; Vienna HIV & Liver Study Group. Low vitamin D levels are associated with impaired virologic response to PEGIFN+RBV therapy in HIV-hepatitis C virus coinfecting patients. *AIDS*. 2013 Jan 14;27(2):227-32. doi: 10.1097/QAD.0b013e32835aa161.
212. Sieghart W, Pinter M, Hucke F, Graziadei I, Schöniger-Hekele M, Müller C, Vogel W, Trauner M, Peck-Radosavljevic M. Single determination of C-reactive protein at the time of diagnosis predicts long-term outcome of patients with hepatocellular carcinoma. *Hepatology*. 2013 Jun;57(6):2224-34. doi: 10.1002/hep.26057.
213. Reiberger T, Payer BA, Schwabl P, Hayden H, Horvatits T, Jäger B, Hummel T, Mitterhauser M, Trauner M, Fuhrmann V, Angermayr B, Peck-Radosavljevic M; Vienna Hepatic Hemodynamic Lab. Nebivolol treatment increases splanchnic blood flow and portal pressure in cirrhotic rats via modulation of nitric oxide signalling. *Liver Int*. 2013 Apr;33(4):561-8. doi: 10.1111/liv.12101.
214. Fickert P, Pollheimer MJ, Silbert D, Moustafa T, Halilbasic E, Krones E, Durchschein F, Thüringer A, Zollner G, Denk H, Trauner M. Differential effects of norUDCA and UDCA in obstructive cholestasis in mice. *J Hepatol*. 2013 Jun;58(6):1201-8. doi: 10.1016/j.jhep.2013.01.026.
215. Trauner M, Fickert P, Tilg H. Bile acids as modulators of gut microbiota linking dietary habits and inflammatory bowel disease: a potentially dangerous liaison. *Gastroenterology*. 2013 Apr;144(4):844-6. doi: 10.1053/j.gastro.2013.02.029. Editorial
216. Horvatits T, Trauner M, Fuhrmann V. Hypoxic liver injury and cholestasis in critically ill patients. *Curr Opin Crit Care*. 2013 Apr;19(2):128-32. doi: 10.1097/MCC.0b013e32835ec9e6. Review
217. Bauer M, Press AT, Trauner M. The liver in sepsis: patterns of response and injury. *Curr Opin Crit Care*. 2013 Apr;19(2):123-7. doi: 10.1097/MCC.0b013e32835eba6d. Review
218. Peck-Radosavljevic M, Angermayr B, Datz C, Ferlitsch A, Ferlitsch M, Fuhrmann V, Häfner M, Kramer L, Maieron A, Payer B, Reiberger T, Stauber R, Steininger R, Trauner M, Thurnher S, Ulbrich G, Vogel W, Zoller H, Graziadei I; Austrian Society of Gastroenterology and Hepatology. Austrian consensus on the definition and treatment of portal hypertension and its complications (Billroth II). *Wien Klin Wochenschr*. 2013 Apr;125(7-8):200-19. doi: 10.1007/s00508-013-0337-z. Consensus Report
219. Huang J, Das SK, Jha P, Al Zoughbi W, Schauer S, Claudel T, Sexl V, Vesely P, Birner-Gruenberger R, Kratky D, Trauner M, Hoefler G. The PPAR $\alpha$  agonist fenofibrate suppresses B-cell lymphoma in mice by modulating lipid metabolism. *Biochim Biophys Acta*. 2013 Oct;1831(10):1555-65. doi: 10.1016/j.bbali.2013.04.012.

220. Halilbasic E, Baghdasaryan A, Trauner M. Nuclear receptors as drug targets in cholestatic liver diseases. *Clin Liver Dis*. 2013 May;17(2):161-89. doi: 10.1016/j.cld.2012.12.001. Review
221. Sieghart W, Huckle F, Pinter M, Graziadei I, Vogel W, Müller C, Heinzl H, Trauner M, Peck-Radosavljevic M. The ART of decision making: retreatment with transarterial chemoembolization in patients with hepatocellular carcinoma. *Hepatology*. 2013 Jun;57(6):2261-73. doi: 10.1002/hep.26256.
222. Claudel T, Trauner M. Adiponectin, bile acids, and burnt-out nonalcoholic steatohepatitis: new light on an old paradox. *Hepatology*. 2013 Jun;57(6):2106-9. doi: 10.1002/hep.26340. Editorial
223. Stättermayer AF, Rutter K, Beinhardt S, Wrba F, Scherzer TM, Strasser M, Hofer H, Steindl-Munda P, Trauner M, Ferenci P. Role of FDFT1 polymorphism for fibrosis progression in patients with chronic hepatitis C. *Liver Int*. 2014 Mar;34(3):388-95. doi: 10.1111/liv.12269.
224. Rainer PP, Primessnig U, Harenkamp S, Doleschal B, Wallner M, Fauler G, Stojakovic T, Wachter R, Yates A, Groschner K, Trauner M, Pieske BM, von Lewinski D. Bile acids induce arrhythmias in human atrial myocardium--implications for altered serum bile acid composition in patients with atrial fibrillation. *Heart*. 2013 Nov;99(22):1685-92. doi: 10.1136/heartjnl-2013-304163.
225. Mandorfer M, Payer BA, Scheiner B, Breitenecker F, Aichelburg MC, Grabmeier-Pfistershammer K, Rieger A, Trauner M, Peck-Radosavljevic M, Reiberger T. Health-related quality of life and severity of fatigue in HIV/HCV co-infected patients before, during, and after antiviral therapy with pegylated interferon plus ribavirin. *Liver Int*. 2014 Jan;34(1):69-77. doi: 10.1111/liv.12253.
226. Mandorfer M, Reiberger T, Payer BA, Breitenecker F, Aichelburg MC, Obermayer-Pietsch B, Rieger A, Puoti M, Zangerle R, Trauner M, Peck-Radosavljevic M. Revisiting predictors of virologic response to PEGIFN + RBV therapy in HIV-/HCV-coinfected patients: the role of metabolic factors and elevated GGT levels. *J Viral Hepat*. 2014 Jan;21(1):33-41. doi: 10.1111/jvh.12118.
227. Pinter M, Sieghart W, Schmid M, Dauser B, Prager G, Dienes HP, Trauner M, Peck-Radosavljevic M. Hedgehog inhibition reduces angiogenesis by downregulation of tumoral VEGF-A expression in hepatocellular carcinoma. *United European Gastroenterol J*. 2013 Aug;1(4):265-75. doi: 10.1177/2050640613496605.
228. Schaap FG, Trauner M, Jansen PL. Bile acid receptors as targets for drug development. *Nat Rev Gastroenterol Hepatol*. 2014 Jan;11(1):55-67. doi: 10.1038/nrgastro.2013.151. Review
229. Huckle F, Sieghart W, Pinter M, Graziadei I, Vogel W, Müller C, Heinzl H, Waneck F, Trauner M, Peck-Radosavljevic M. The ART-strategy: sequential assessment of the ART score predicts outcome of patients with hepatocellular carcinoma re-treated with TACE. *J Hepatol*. 2014 Jan;60(1):118-26. doi: 10.1016/j.jhep.2013.08.022.
230. Angelberger S, Reinisch W, Makristathis A, Lichtenberger C, Dejaco C, Papay P, Novacek G, Trauner M, Loy A, Berry D. Temporal bacterial community dynamics vary among ulcerative colitis patients after fecal microbiota transplantation. *Am J Gastroenterol*. 2013 Oct;108(10):1620-30. doi: 10.1038/ajg.2013.257.

231. Beinhardt S, Leiss W, Stättermayer AF, Graziadei I, Zoller H, Stauber R, Maieron A, Datz C, Steindl-Munda P, Hofer H, Vogel W, Trauner M, Ferenci P. Long-term outcomes of patients with Wilson disease in a large Austrian cohort. ***Clin Gastroenterol Hepatol***. 2014 Apr;12(4):683-9. doi: 10.1016/j.cgh.2013.09.025.
232. Pinter M, Hucke F, Zielonke N, Waldhör T, Trauner M, Peck-Radosavljevic M, Sieghart W. Incidence and mortality trends for biliary tract cancers in Austria. ***Liver Int***. 2014 Aug;34(7):1102-8. doi: 10.1111/liv.12325.
233. Dolak W, Schreiber F, Schwaighofer H, Gschwantler M, Plieschnegger W, Ziachehabi A, Mayer A, Kramer L, Kopecky A, Schrutka-Kölbl C, Wolkersdörfer G, Madl C, Berr F, Trauner M, Püspök A; Austrian Biliary RFA Study Group. Endoscopic radiofrequency ablation for malignant biliary obstruction: a nationwide retrospective study of 84 consecutive applications. ***Surg Endosc***. 2014 Mar;28(3):854-60. doi: 10.1007/s00464-013-3232-9.
234. Fickert P, Krones E, Pollheimer MJ, Thueringer A, Moustafa T, Silbert D, Halilbasic E, Yang M, Jaeschke H, Stokman G, Wells RG, Eller K, Rosenkranz AR, Eggertsen G, Wagner CA, Langner C, Denk H, Trauner M. Bile acids trigger cholemic nephropathy in common bile-duct-ligated mice. ***Hepatology***. 2013 Dec;58(6):2056-69. doi: 10.1002/hep.26599.
235. Fuchs C, Claudel T, Trauner M. Bile acid-mediated control of liver triglycerides. ***Semin Liver Dis***. 2013 Nov;33(4):330-42. doi: 10.1055/s-0033-1358520. Review
236. Yang M, Ramachandran A, Yan HM, Woolbright BL, Copple BL, Fickert P, Trauner M, Jaeschke H. Osteopontin is an initial mediator of inflammation and liver injury during obstructive cholestasis after bile duct ligation in mice. ***Toxicol Lett***. 2014 Jan 13;224(2):186-95. doi: 10.1016/j.toxlet.2013.10.030.
237. Stättermayer AF, Strassl R, Maieron A, Rutter K, Stauber R, Strasser M, Beinhardt S, Datz C, Scherzer TM, Steindl-Munda P, Gschwantler M, Trauner M, Hofer H, Ferenci P. Polymorphisms of interferon- $\lambda$ 4 and IL28B - effects on treatment response to interferon/ribavirin in patients with chronic hepatitis C. ***Aliment Pharmacol Ther***. 2014 Jan;39(1):104-11. doi: 10.1111/apt.12547.
238. Mandorfer M, Neukam K, Reiberger T, Payer BA, Rivero A, Puoti M, Boesecke C, Baumgarten A, Grzeszczuk A, Zangerle R, Meyer-Olson D, Rockstroh JK, Trauner M, Pineda JA, Peck-Radosavljevic M. The impact of interleukin 28B rs12979860 single nucleotide polymorphism and liver fibrosis stage on response-guided therapy in HIV/HCV-coinfected patients. ***AIDS***. 2013 Nov 13;27(17):2707-14. doi: 10.1097/01.aids.0000432460.44593.ef.
239. Maieron A, Salzl P, Peck-Radosavljevic M, Trauner M, Hametner S, Schöfl R, Ferenci P, Ferlitsch M. Von Willebrand Factor as a new marker for non-invasive assessment of liver fibrosis and cirrhosis in patients with chronic hepatitis C. ***Aliment Pharmacol Ther***. 2014 Feb;39(3):331-8. doi: 10.1111/apt.12564.
240. Baghdasaryan A, Chiba P, Trauner M. Clinical application of transcriptional activators of bile salt transporters. ***Mol Aspects Med***. 2014 Jun;37(100):57-76. doi: 10.1016/j.mam.2013.12.001. Review

241. Mandorfer M, Neukam K, Rivero A, Puoti M, Boesecke C, Baumgarten A, Grzeszczuk A, Zangerle R, Ernst D, Rockstroh JK, Trauner M, Pineda JA, Peck-Radosavljevic M, Reiberger T. Strategies for assignment of HIV-HCV genotype-1-coinfected patients to either dual-therapy or direct-acting antiviral agent-based triple-therapy. *Antivir Ther*. 2014;19(4):407-14. doi: 10.3851/IMP2717.
242. Trauner M, Halilbasic E, Kazemi-Shirazi L, Kienbacher C, Stauffer K, Traussnigg S, Hofer H. Therapeutic role of bile acids and nuclear receptor agonists in fibrosing cholangiopathies. *Dig Dis*. 2014;32(5):631-6. doi: 10.1159/000360517. Review
243. Zollner G, Thueringer A, Lackner C, Fickert P, Trauner M. Alterations of canalicular ATP-binding cassette transporter expression in drug-induced liver injury. *Digestion*. 2014;90(2):81-8. doi: 10.1159/000365003.
244. Pinter M, Hucke F, Zielonke N, Trauner M, Sieghart W, Peck-Radosavljevic M. Epidemiological trends of hepatocellular carcinoma in Austria. *Dig Dis*. 2014;32(6):664-9. doi: 10.1159/000367983.
245. Drolz A, Wewalka M, Horvatits T, Fuhrmann V, Schneeweiss B, Trauner M, Zauner C. Gender-specific differences in energy metabolism during the initial phase of critical illness. *Eur J Clin Nutr*. 2014 Jun;68(6):707-11. doi: 10.1038/ejcn.2013.287.
246. Jha P, Claudel T, Baghdasaryan A, Mueller M, Halilbasic E, Das SK, Lass A, Zimmermann R, Zechner R, Hoefler G, Trauner M. Role of adipose triglyceride lipase (PNPLA2) in protection from hepatic inflammation in mouse models of steatohepatitis and endotoxemia. *Hepatology*. 2014 Mar;59(3):858-69. doi: 10.1002/hep.26732.
247. Cuperus FJ, Claudel T, Gautherot J, Halilbasic E, Trauner M. The role of canalicular ABC transporters in cholestasis. *Drug Metab Dispos*. 2014 Apr;42(4):546-60. doi: 10.1124/dmd.113.056358. Review
248. Drolz A, Horvatits T, Michl B, Roedl K, Schellongowski P, Holzinger U, Zauner C, Heinz G, Madl C, Trauner M, Fuhrmann V. Statin therapy is associated with reduced incidence of hypoxic hepatitis in critically ill patients. *J Hepatol*. 2014 Jun;60(6):1187-93. doi: 10.1016/j.jhep.2014.01.019.
249. Schwabl P, Payer BA, Grahovac J, Klein S, Horvatits T, Mitterhauser M, Stift J, Boucher Y, Trebicka J, Trauner M, Angermayr B, Fuhrmann V, Reiberger T, Peck-Radosavljevic M. Pioglitazone decreases portosystemic shunting by modulating inflammation and angiogenesis in cirrhotic and non-cirrhotic portal hypertensive rats. *J Hepatol*. 2014 Jun;60(6):1135-42. doi: 10.1016/j.jhep.2014.01.025.
250. Fickert P, Pollheimer MJ, Beuers U, Lackner C, Hirschfield G, Housset C, Keitel V, Schramm C, Marschall HU, Karlsen TH, Melum E, Kaser A, Eksteen B, Strazzabosco M, Manns M, Trauner M; International PSC Study Group (IPSCSG). Characterization of animal models for primary sclerosing cholangitis (PSC). *J Hepatol*. 2014 Jun;60(6):1290-303. doi: 10.1016/j.jhep.2014.02.006. Review
251. Bastati N, Feier D, Wibmer A, Traussnigg S, Balassy C, Tamandl D, Einspieler H, Wrba F, Trauner M, Herold C, Ba-Ssalamah A. Noninvasive differentiation of simple steatosis and steatohepatitis by using gadoxetic acid-enhanced MR imaging in patients with nonalcoholic fatty liver disease: a proof-of-concept study. *Radiology*. 2014 Jun;271(3):739-47. doi: 10.1148/radiol.14131890.

252. Stojakovic T, Claudel T, Trauner M. Editorial for 'randomized controlled trial assessing the effect of simvastatin in primary biliary cirrhosis'. *Liver Int*. 2014 Mar;34(3):328-9. doi: 10.1111/liv.12359. Editorial
253. Jha P, Knopf A, Koefeler H, Mueller M, Lackner C, Hoefler G, Claudel T, Trauner M. Role of adipose tissue in methionine-choline-deficient model of non-alcoholic steatohepatitis (NASH). *Biochim Biophys Acta*. 2014 Jul;1842(7):959-70. doi: 10.1016/j.bbadis.2014.02.012.
254. Mandorfer M, Bota S, Schwabl P, Bucsics T, Pfisterer N, Kruzik M, Hagmann M, Blacky A, Ferlitsch A, Sieghart W, Trauner M, Peck-Radosavljevic M, Reiberger T. Nonselective  $\beta$  blockers increase risk for hepatorenal syndrome and death in patients with cirrhosis and spontaneous bacterial peritonitis. *Gastroenterology*. 2014 Jun;146(7):1680-90.e1. doi: 10.1053/j.gastro.2014.03.005.
255. Valkovič L, Gajdošík M, Traussnigg S, Wolf P, Chmelík M, Kienbacher C, Bogner W, Krebs M, Trauner M, Trattinig S, Krššák M. Application of localized  $^{31}\text{P}$  MRS saturation transfer at 7 T for measurement of ATP metabolism in the liver: reproducibility and initial clinical application in patients with non-alcoholic fatty liver disease. *Eur Radiol*. 2014 Jul;24(7):1602-9. doi: 10.1007/s00330-014-3141-x.
256. García-Rodríguez JL, Barbier-Torres L, Fernández-Álvarez S, Gutiérrez-de Juan V, Monte MJ, Halilbasic E, Herranz D, Álvarez L, Aspichueta P, Marín JJ, Trauner M, Mato JM, Serrano M, Beraza N, Martínez-Chantar ML. SIRT1 controls liver regeneration by regulating bile acid metabolism through farnesoid X receptor and mammalian target of rapamycin signaling. *Hepatology*. 2014 May;59(5):1972-83. doi: 10.1002/hep.26971.
257. Woolbright BL, Li F, Xie Y, Farhood A, Fickert P, Trauner M, Jaeschke H. Lithocholic acid feeding results in direct hepato-toxicity independent of neutrophil function in mice. *Toxicol Lett*. 2014 Jul 3;228(1):56-66. doi: 10.1016/j.toxlet.2014.04.001.
258. Cuperus FJ, Halilbasic E, Trauner M. Fibrate treatment for primary biliary cirrhosis. *Curr Opin Gastroenterol*. 2014 May;30(3):279-86. doi: 10.1097/MOG.0000000000000056. Review
259. Mandorfer M, Payer BA, Niederecker A, Lang G, Aichelburg MC, Strassl R, Boesecke C, Rieger A, Trauner M, Peck-Radosavljevic M, Reiberger T. Therapeutic potential of and treatment with boceprevir/telaprevir-based triple-therapy in HIV/chronic hepatitis C co-infected patients in a real-world setting. *AIDS Patient Care STDS*. 2014 May;28(5):221-7. doi: 10.1089/apc.2013.0359.
260. Horvatits T, Drolz A, Roedl K, Herkner H, Ferlitsch A, Perkmann T, Müller C, Trauner M, Schenk P, Fuhrmann V. Von Willebrand factor antigen for detection of hepatopulmonary syndrome in patients with cirrhosis. *J Hepatol*. 2014 Sep;61(3):544-9. doi: 10.1016/j.jhep.2014.04.025.
261. Salzl P, Reiberger T, Ferlitsch M, Payer BA, Schwengerer B, Trauner M, Peck-Radosavljevic M, Ferlitsch A. Evaluation of portal hypertension and varices by acoustic radiation force impulse imaging of the liver compared to transient elastography and AST to platelet ratio index. *Ultraschall Med*. 2014 Dec;35(6):528-33. doi: 10.1055/s-0034-1366506.



262. Rudashevskaya EL, Stockner T, Trauner M, Freissmuth M, Chiba P. Pharmacological correction of misfolding of ABC proteins. *Drug Discov Today Technol*. 2014 Jun;12(100):e87-94. doi: 10.1016/j.ddtec.2014.03.009. Review
263. Janel J, Fickert P, Hauer AC, Högenauer C, Avian A, Trauner M. Inflammatory bowel disease alters intestinal bile acid transporter expression. *Drug Metab Dispos*. 2014 Sep;42(9):1423-31. doi: 10.1124/dmd.114.058065.
264. Mandorfer M, Payer BA, Schwabl P, Steiner S, Ferlitsch A, Aichelburg MC, Stättermayer AF, Ferenci P, Obermayer-Pietsch B, Grabmeier-Pfistershammer K, Trauner M, Peck-Radosavljevic M, Reiberger T. Revisiting liver disease progression in HIV/HCV-coinfected patients: the influence of vitamin D, insulin resistance, immune status, IL28B and PNPLA3. *Liver Int*. 2015 Mar;35(3):876-85. doi: 10.1111/liv.12615.
265. Schwabl P, Bota S, Salzl P, Mandorfer M, Payer BA, Ferlitsch A, Stift J, Wrba F, Trauner M, Peck-Radosavljevic M, Reiberger T. New reliability criteria for transient elastography increase the number of accurate measurements for screening of cirrhosis and portal hypertension. *Liver Int*. 2015 Feb;35(2):381-90. doi: 10.1111/liv.12623.
266. Waldmann E, Britto-Arias M, Gessl I, Heinze G, Salzl P, Sallinger D, Trauner M, Weiss W, Ferlitsch A, Ferlitsch M. Endoscopists with low adenoma detection rates benefit from high-definition endoscopy. *Surg Endosc*. 2015 Feb;29(2):466-73. doi: 10.1007/s00464-014-3688-2.
267. Hucke F, Pinter M, Graziadei I, Bota S, Vogel W, Müller C, Heinzl H, Waneck F, Trauner M, Peck-Radosavljevic M, Sieghart W. How to STATE suitability and START transarterial chemoembolization in patients with intermediate stage hepatocellular carcinoma. *J Hepatol*. 2014 Dec;61(6):1287-96. doi: 10.1016/j.jhep.2014.07.002.
268. Stauer K, Halilbasic E, Trauner M, Kazemi-Shirazi L. Cystic fibrosis related liver disease--another black box in hepatology. *Int J Mol Sci*. 2014 Aug 4;15(8):13529-49. doi: 10.3390/ijms150813529. Review
269. Ferlitsch M, Heinze G, Salzl P, Britto-Arias M, Waldmann E, Reinhart K, Bannert C, Fasching E, Knoflach P, Weiss W, Trauner M, Ferlitsch A. Sex is a stronger predictor of colorectal adenoma and advanced adenoma than fecal occult blood test. *Med Oncol*. 2014 Sep;31(9):151. doi: 10.1007/s12032-014-0151-0.
270. Jeschek P, Ferlitsch A, Salzl P, Heinze G, Györi G, Reinhart K, Waldmann E, Britto-Arias M, Trauner M, Ferlitsch M. A greater proportion of liver transplant candidates have colorectal neoplasia than in the healthy screening population. *Clin Gastroenterol Hepatol*. 2015 May;13(5):956-62. doi: 10.1016/j.cgh.2014.08.018.
271. Fuchs CD, Claudel T, Trauner M. Role of metabolic lipases and lipolytic metabolites in the pathogenesis of NAFLD. *Trends Endocrinol Metab*. 2014 Nov;25(11):576-85. doi: 10.1016/j.tem.2014.08.001. Review
272. Lanaya H, Natarajan A, Komposch K, Li L, Amberg N, Chen L, Wculek SK, Hammer M, Zenz R, Peck-Radosavljevic M, Sieghart W, Trauner M, Wang H, Sibilia M. EGFR has a tumour-promoting role in liver macrophages during hepatocellular carcinoma formation. *Nat Cell Biol*. 2014 Oct;16(10):972-7. doi: 10.1038/ncb3031.
273. Bitter A, Rümmele P, Klein K, Kandel BA, Rieger JK, Nüssler AK, Zanger UM, Trauner M, Schwab M, Burk O. Pregnane X receptor activation and silencing promote steatosis

of human hepatic cells by distinct lipogenic mechanisms. *Arch Toxicol*. 2015 Nov;89(11):2089-103. doi: 10.1007/s00204-014-1348-x.

274. Wree A, Schlattjan M, Bechmann LP, Claudel T, Sowa JP, Stojakovic T, Scharnagl H, Köfeler H, Baba HA, Gerken G, Feldstein AE, Trauner M, Canbay A. Adipocyte cell size, free fatty acids and apolipoproteins are associated with non-alcoholic liver injury progression in severely obese patients. *Metabolism*. 2014 Dec;63(12):1542-52. doi: 10.1016/j.metabol.2014.09.001.
275. Mandorfer M, Steiner S, Schwabl P, Payer BA, Aichelburg MC, Lang G, Grabmeier-Pfistershammer K, Trauner M, Peck-Radosavljevic M, Reiberger T. Response-guided boceprevir-based triple therapy in HIV/HCV-coinfected patients: the HIVCOBOC-RGT study. *J Infect Dis*. 2015 Mar 1;211(5):729-35. doi: 10.1093/infdis/jiu516.
276. Aigner E, Stadlmayr A, Huber-Schönauer U, Zwerina J, Husar-Memmer E, Niederseer D, Trauner M, Heuberger A, Hohla F, Schett G, Patsch W, Datz C. Gender- and site-specific differences of colorectal neoplasia relate to vitamin D. *Aliment Pharmacol Ther*. 2014 Dec;40(11-12):1341-8. doi: 10.1111/apt.12981.
277. Rupp C, Rössler A, Halibasic E, Sauer P, Weiss KH, Friedrich K, Wannhoff A, Stiehl A, Stremmel W, Trauner M, Gotthardt DN. Reduction in alkaline phosphatase is associated with longer survival in primary sclerosing cholangitis, independent of dominant stenosis. *Aliment Pharmacol Ther*. 2014 Dec;40(11-12):1292-301. doi: 10.1111/apt.12979.
278. Dolak W, Mesteri I, Asari R, Preusser M, Tribl B, Wrba F, Schoppmann SF, Hejna M, Trauner M, Häfner M, Püspök A. A pilot study of the endomicroscopic assessment of tumor extension in Barrett's esophagus-associated neoplasia before endoscopic resection. *Endosc Int Open*. 2015 Feb;3(1):E19-28. doi: 10.1055/s-0034-1377935.
279. Pandey V, Sultan M, Kashofer K, Ralser M, Amstislavskiy V, Starmann J, Osprian I, Grimm C, Hache H, Yaspo ML, Sültmann H, Trauner M, Denk H, Zatloukal K, Lehrach H, Wierling C. Comparative analysis and modeling of the severity of steatohepatitis in DDC-treated mouse strains. *PLoS One*. 2014 Oct 27;9(10):e111006. doi: 10.1371/journal.pone.0111006.
280. Mandorfer M, Bota S, Schwabl P, Bucsics T, Pfisterer N, Summereder C, Hagmann M, Blacky A, Ferlitsch A, Sieghart W, Trauner M, Peck-Radosavljevic M, Reiberger T. Proton pump inhibitor intake neither predisposes to spontaneous bacterial peritonitis or other infections nor increases mortality in patients with cirrhosis and ascites. *PLoS One*. 2014 Nov 4;9(11):e110503. doi: 10.1371/journal.pone.0110503.
281. Demetz E, Schroll A, Auer K, Heim C, Patsch JR, Eller P, Theurl M, Theurl I, Theurl M, Seifert M, Lener D, Stanzl U, Haschka D, Asshoff M, Dichtl S, Nairz M, Huber E, Stadlinger M, Moschen AR, Li X, Pallweber P, Scharnagl H, Stojakovic T, März W, Kleber ME, Garlaschelli K, Uboldi P, Catapano AL, Stellaard F, Rudling M, Kuba K, Imai Y, Arita M, Schuetz JD, Pramstaller PP, Tietge UJF, Trauner M, Norata GD, Claudel T, Hicks AA, Weiss G, Tancevski I. The arachidonic acid metabolome serves as a conserved regulator of cholesterol metabolism. *Cell Metab*. 2014 Nov 4;20(5):787-798. doi: 10.1016/j.cmet.2014.09.004.
282. Kozbial K, Reinhart K, Heinze G, Zwatz C, Bannert C, Salzl P, Waldmann E, Britto-Arias M, Ferlitsch A, Trauner M, Weiss W, Ferlitsch M. High quality of screening

colonoscopy in Austria is not dependent on endoscopist specialty or setting. **Endoscopy**. 2015 Mar;47(3):207-16. doi: 10.1055/s-0034-1390910.

283. Sombetzki M, Fuchs CD, Fickert P, Österreicher CH, Mueller M, Claudel T, Loebermann M, Engelmann R, Langner C, Sahin E, Schwinge D, Guenther ND, Schramm C, Mueller-Hilke B, Reisinger EC, Trauner M. 24-nor-ursodeoxycholic acid ameliorates inflammatory response and liver fibrosis in a murine model of hepatic schistosomiasis. **J Hepatol**. 2015 Apr;62(4):871-8. doi: 10.1016/j.jhep.2014.11.020.
284. Hirschfield GM, Mason A, Luketic V, Lindor K, Gordon SC, Mayo M, Kowdley KV, Vincent C, Bodhenheimer HC Jr, Parés A, Trauner M, Marschall HU, Adorini L, Sciacca C, Beecher-Jones T, Castelloe E, Böhm O, Shapiro D. Efficacy of obeticholic acid in patients with primary biliary cirrhosis and inadequate response to ursodeoxycholic acid. **Gastroenterology**. 2015 Apr;148(4):751-61.e8. doi: 10.1053/j.gastro.2014.12.005.
285. Rupp C, Stiehl A, Trauner M, Gotthardt DN. Editorial: further evidence for the role of serum alkaline phosphatase as a useful surrogate marker of prognosis in PSC - authors' reply. **Aliment Pharmacol Ther**. 2015 Jan;41(1):151-2. doi: 10.1111/apt.13020. Editorial
286. Waldmann E, Ferlitsch M, Binder N, Sellner F, Karner J, Heinisch B, Klimpfinger M, Trauner M. Tumor and Patient Characteristics of Individuals with Mismatch Repair Deficient Colorectal Cancer. **Digestion**. 2015;91(4):286-93. doi: 10.1159/000381284.
287. Krones E, Wagner M, Eller K, Rosenkranz AR, Trauner M, Fickert P. Bile acid-induced cholemic nephropathy. **Dig Dis**. 2015;33(3):367-75. doi: 10.1159/000371689. Review
288. Trauner M, Halilbasic E, Claudel T, Steinacher D, Fuchs C, Moustafa T, Pollheimer M, Krones E, Kienbacher C, Traussnigg S, Kazemi-Shirazi L, Munda P, Hofer H, Fickert P, Paumgartner G. Potential of nor-Ursodeoxycholic Acid in Cholestatic and Metabolic Disorders. **Dig Dis**. 2015;33(3):433-9. doi: 10.1159/000371904. Review
289. Traussnigg S, Kienbacher C, Halilbasic E, Rechling C, Kazemi-Shirazi L, Hofer H, Munda P, Trauner M. Challenges and Management of Liver Cirrhosis: Practical Issues in the Therapy of Patients with Cirrhosis due to NAFLD and NASH. **Dig Dis**. 2015;33(4):598-607. doi: 10.1159/000375353. Review
290. Halilbasic E, Fuchs C, Hofer H, Paumgartner G, Trauner M. Therapy of Primary Sclerosing Cholangitis--Today and Tomorrow. **Dig Dis**. 2015;33 Suppl 2:149-63. doi: 10.1159/000440827. Review
291. Chmelík M, Valkovič L, Wolf P, Bogner W, Gajdošík M, Halilbasic E, Gruber S, Trauner M, Krebs M, Trattinig S, Krššák M. Phosphatidylcholine contributes to in vivo (31)P MRS signal from the human liver. **Eur Radiol**. 2015 Jul;25(7):2059-66. doi: 10.1007/s00330-014-3578-y.
292. Reichl P, Fang M, Starlinger P, Staufer K, Nenutil R, Muller P, Greplova K, Valik D, Dooley S, Brostjan C, Gruenberger T, Shen J, Man K, Trauner M, Yu J, Gao CF, Mikulits W. Multicenter analysis of soluble Axl reveals diagnostic value for very early stage hepatocellular carcinoma. **Int J Cancer**. 2015 Jul 15;137(2):385-394. doi: 10.1002/ijc.29394.
293. Mueller M, Thorell A, Claudel T, Jha P, Koefeler H, Lackner C, Hoesel B, Fauler G, Stojakovic T, Einarsson C, Marschall HU, Trauner M. Ursodeoxycholic acid exerts

farnesoid X receptor-antagonistic effects on bile acid and lipid metabolism in morbid obesity. *J Hepatol*. 2015 Jun;62(6):1398-404. doi: 10.1016/j.jhep.2014.12.034.

294. Rutter K, Stättermayer AF, Beinhardt S, Scherzer TM, Steindl-Munda P, Trauner M, Ferenci P, Hofer H. Successful anti-viral treatment improves survival of patients with advanced liver disease due to chronic hepatitis C. *Aliment Pharmacol Ther*. 2015 Mar;41(6):521-31. doi: 10.1111/apt.13085.
295. Stiedl P, McMahon R, Blaas L, Stanek V, Svinka J, Grabner B, Zollner G, Kessler SM, Claudel T, Müller M, Mikulits W, Bilban M, Esterbauer H, Eferl R, Haybaeck J, Trauner M, Casanova E. Growth hormone resistance exacerbates cholestasis-induced murine liver fibrosis. *Hepatology*. 2015 Feb;61(2):613-26. doi: 10.1002/hep.27408.
296. Stättermayer AF, Traussnigg S, Dienes HP, Aigner E, Stauber R, Lackner K, Hofer H, Stift J, Wrba F, Stadlmayr A, Datz C, Strasser M, Maieron A, Trauner M, Ferenci P. Hepatic steatosis in Wilson disease--Role of copper and PNPLA3 mutations. *J Hepatol*. 2015 Jul;63(1):156-63. doi: 10.1016/j.jhep.2015.01.034.
297. Schwabl P, Bucsics T, Soucek K, Mandorfer M, Bota S, Blacky A, Hirschl AM, Ferlitsch A, Trauner M, Peck-Radosavljevic M, Reiberger T. Risk factors for development of spontaneous bacterial peritonitis and subsequent mortality in cirrhotic patients with ascites. *Liver Int*. 2015 Sep;35(9):2121-8. doi: 10.1111/liv.12795.
298. Reiter FP, Hohenester S, Nagel JM, Wimmer R, Artmann R, Wottke L, Makeschin MC, Mayr D, Rust C, Trauner M, Denk GU. 1,25-(OH)<sub>2</sub>-vitamin D<sub>3</sub> prevents activation of hepatic stellate cells in vitro and ameliorates inflammatory liver damage but not fibrosis in the Abcb4(-/-) model. *Biochem Biophys Res Commun*. 2015 Apr 3;459(2):227-233. doi: 10.1016/j.bbrc.2015.02.074.
299. Ockenga J, Pirlich M, Plauth M, Schmidt H, Tilg H, Trauner M. Obituary for Prof. Dr. Herbert Lochs (1946-2015). *Z Gastroenterol*. 2015 Mar;53(3):246-7. doi: 10.1055/s-0034-1397611. Editorial
300. Beuers U, Trauner M, Jansen P, Poupon R. New paradigms in the treatment of hepatic cholestasis: from UDCA to FXR, PXR and beyond. *J Hepatol*. 2015 Apr;62(1 Suppl):S25-37. doi: 10.1016/j.jhep.2015.02.023. Review
301. Eigner W, Mesteri I, Tribl B, Ba-Ssalamah A, Friedl J, Trauner M, Kazemi-Shirazi L. Intraductal papillary mucinous neoplasm of the pancreas in an adult patient with cystic fibrosis after double-lung transplantation. *J Cyst Fibros*. 2015 Jul;14(4):523-5. doi: 10.1016/j.jcf.2015.03.011.
302. Ba-Ssalamah A, Antunes C, Feier D, Bastati N, Hodge JC, Stift J, Cipriano MA, Wrba F, Trauner M, Herold CJ, Caseiro-Alves F. Morphologic and Molecular Features of Hepatocellular Adenoma with Gadoteric Acid-enhanced MR Imaging. *Radiology*. 2015 Oct;277(1):104-13. doi: 10.1148/radiol.2015142366.
303. Bota S, Paternostro R, Etschmaier A, Schwarzer R, Salzl P, Mandorfer M, Kienbacher C, Ferlitsch M, Reiberger T, Trauner M, Peck-Radosavljevic M, Ferlitsch A. Performance of 2-D shear wave elastography in liver fibrosis assessment compared with serologic tests and transient elastography in clinical routine. *Ultrasound Med Biol*. 2015 Sep;41(9):2340-9. doi: 10.1016/j.ultrasmedbio.2015.04.013.

304. Krones E, Erwa W, Trauner M, Fickert P. Serum alkaline phosphatase levels accurately reflect cholestasis in mice. *Hepatology*. 2015 Sep;62(3):981-3. doi: 10.1002/hep.27622. Letter
305. Krones E, Erwa W, Trauner M, Fickert P. Reply. *Hepatology*. 2016 Jan;63(1):346-7. doi: 10.1002/hep.27873. Letter
306. Britto-Arias M, Waldmann E, Jeschek P, Gessl I, Sallinger D, Bannert C, Weber M, Trauner M, Weiss W, Ferlitsch A, Ferlitsch M. Forceps versus snare polypectomies in colorectal cancer screening: are we adhering to the guidelines? *Endoscopy*. 2015 Oct;47(10):898-902. doi: 10.1055/s-0034-1392328.
307. Jahnel J, Zöhrer E, Alisi A, Ferrari F, Ceccarelli S, De Vito R, Scharnagl H, Stojakovic T, Fauler G, Trauner M, Nobili V. Serum Bile Acid Levels in Children With Nonalcoholic Fatty Liver Disease. *J Pediatr Gastroenterol Nutr*. 2015 Jul;61(1):85-90. doi: 10.1097/MPG.0000000000000774.
308. Mandorfer M, Kozbial K, Freissmuth C, Schwabl P, Stättermayer AF, Reiberger T, Beinhardt S, Schwarzer R, Trauner M, Ferlitsch A, Hofer H, Peck-Radosavljevic M, Ferenci P. Interferon-free regimens for chronic hepatitis C overcome the effects of portal hypertension on virological responses. *Aliment Pharmacol Ther*. 2015 Sep;42(6):707-18. doi: 10.1111/apt.13315.
309. Hartig SM, Bader DA, Abadie KV, Motamed M, Hamilton MP, Long W, York B, Mueller M, Wagner M, Trauner M, Chan L, Bajaj M, Moore DD, Mancini MA, McGuire SE. Ubc9 Impairs Activation of the Brown Fat Energy Metabolism Program in Human White Adipocytes. *Mol Endocrinol*. 2015 Sep;29(9):1320-33. doi: 10.1210/me.2015-1084.
310. Luger M, Kruschitz R, Marculescu R, Haslacher H, Hoppichler F, Kallay E, Kienbacher C, Klammer C, Kral M, Langer F, Luger E, Prager G, Trauner M, Traussnigg S, Würger T, Schindler K, Ludvik B. The link between obesity and vitamin D in bariatric patients with omega-loop gastric bypass surgery - a vitamin D supplementation trial to compare the efficacy of postoperative cholecalciferol loading (LOAD): study protocol for a randomized controlled trial. *Trials*. 2015 Aug 5;16:328. doi: 10.1186/s13063-015-0877-9.
311. Dolak W, Kiesewetter B, Müllauer L, Mayerhoefer M, Troch M, Trauner M, Häfner M, Raderer M, Püspök A. A pilot study of confocal laser endomicroscopy for diagnosing gastrointestinal mucosa-associated lymphoid tissue (MALT) lymphoma. *Surg Endosc*. 2016 Jul;30(7):2879-85. doi: 10.1007/s00464-015-4572-4.
312. Baghdasaryan A, Fuchs CD, Österreicher CH, Lemberger UJ, Halilbasic E, Pählman I, Graffner H, Krones E, Fickert P, Wahlström A, Ståhlman M, Paumgartner G, Marschall HU, Trauner M. Inhibition of intestinal bile acid absorption improves cholestatic liver and bile duct injury in a mouse model of sclerosing cholangitis. *J Hepatol*. 2016 Mar;64(3):674-81. doi: 10.1016/j.jhep.2015.10.024.
313. Bucsics T, Mandorfer M, Schwabl P, Bota S, Sieghart W, Ferlitsch A, Trauner M, Peck-Radosavljevic M, Reiberger T. Impact of acute kidney injury on prognosis of patients with liver cirrhosis and ascites: A retrospective cohort study. *J Gastroenterol Hepatol*. 2015 Nov;30(11):1657-65. doi: 10.1111/jgh.13002.
314. Ferlitsch A, Puspok A, Bota S, Wewalka F, Schoefl R, Brownstone E, Madl C, Lenzen H, Lankisch TO, Dolak W, Trauner MH, Ferlitsch M. Efficacy and safety of bovine

activated factors IIa/VIIa/IXa/Xa in patients with active gastrointestinal bleeding: a proof of concept study. **Endoscopy**. 2016 Apr;48(4):380-4. doi: 10.1055/s-0034-1393312.

315. Scheiner B, Mandorfer M, Schwabl P, Payer BA, Bucsecs T, Bota S, Aichelburg MC, Grabmeier-Pfistershammer K, Stättermayer A, Ferenci P, Trauner M, Peck-Radosavljevic M, Reiberger T. The Impact of PNPLA3 rs738409 SNP on Liver Fibrosis Progression, Portal Hypertension and Hepatic Steatosis in HIV/HCV Coinfection. **PLoS One**. 2015 Nov 23;10(11):e0143429. doi: 10.1371/journal.pone.0143429.
316. Wibmer A, Nolz R, Trauner M, Ba-Ssalamah A. Functional MR imaging of the liver. **Radiologe**. 2015 Dec;55(12):1057-66. doi: 10.1007/s00117-015-0032-3. Review
317. Horvatits T, Kneidinger N, Drolz A, Roedl K, Rutter K, Kluge S, Trauner M, Fuhrmann V. Prognostic impact of ICG-PDR in patients with hypoxic hepatitis. **Ann Intensive Care**. 2015 Dec;5(1):47. doi: 10.1186/s13613-015-0092-6.
318. Mandorfer M, Steiner S, Schwabl P, Payer BA, Aichelburg MC, Grabmeier-Pfistershammer K, Trauner M, Reiberger T, Peck-Radosavljevic M. Treatment intensification with boceprevir in HIV-positive patients with acute HCV-genotype 1 infection at high risk for treatment failure. **Wien Klin Wochenschr**. 2016 Jun;128(11-12):414-20. doi: 10.1007/s00508-015-0912-6.
319. Ponsioen CY, Chapman RW, Chazouillères O, Hirschfield GM, Karlsen TH, Lohse AW, Pinzani M, Schrupf E, Trauner M, Gores GJ. Surrogate endpoints for clinical trials in primary sclerosing cholangitis: Review and results from an International PSC Study Group consensus process. **Hepatology**. 2016 Apr;63(4):1357-67. doi: 10.1002/hep.28256. Review
320. Wanek T, Halilbasic E, Visentin M, Mairinger S, Römermann K, Stieger B, Kuntner C, Müller M, Langer O, Trauner M. Influence of 24-Nor-Ursodeoxycholic Acid on Hepatic Disposition of [(18)F]Ciprofloxacin, a Positron Emission Tomography Study in Mice. **J Pharm Sci**. 2016 Jan;105(1):106-12. doi: 10.1016/j.xphs.2015.11.014.
321. Halilbasic E, Fuchs C, Traussnigg S, Trauner M. Farnesoid X Receptor Agonists and Other Bile Acid Signaling Strategies for Treatment of Liver Disease. **Dig Dis**. 2016;34(5):580-8. doi: 10.1159/000445268. Review
322. Sombetzki M, Koslowski N, Doss S, Loebermann M, Trauner M, Reisinger EC, Sauer M. Biosensor for Hepatocellular Injury Corresponds to Experimental Scoring of Hepatosplenic Schistosomiasis in Mice. **Biomed Res Int**. 2016;2016:1567254. doi: 10.1155/2016/1567254.
323. Traussnigg S, Dolak W, Trauner M, Kazemi-Shirazi L. Difficult case of Cronkhite-Canada syndrome with small intestinal bacterial overgrowth, Clostridium difficile infection and polymyalgia rheumatica. **BMJ Case Rep**. 2016 Jan 27;2016:bcr2015213465. doi: 10.1136/bcr-2015-213465. Case Report
324. Fuchs CD, Traussnigg SA, Trauner M. Nuclear Receptor Modulation for the Treatment of Nonalcoholic Fatty Liver Disease. **Semin Liver Dis**. 2016 Feb;36(1):69-86. doi: 10.1055/s-0036-1571296. Review
325. Hörl G, Froehlich H, Ferstl U, Ledinski G, Binder J, Cvirn G, Stojakovic T, Trauner M, Koidl C, Tafeit E, Amrein K, Scharnagl H, Jürgens G, Hallström S. Simvastatin Efficiently Lowers Small LDL-IgG Immune Complex Levels: A Therapeutic Quality

- beyond the Lipid-Lowering Effect. *PLoS One*. 2016 Feb 3;11(2):e0148210. doi: 10.1371/journal.pone.0148210.
326. Pinter M, Trauner M, Peck-Radosavljevic M, Sieghart W. Cancer and liver cirrhosis: implications on prognosis and management. *ESMO Open*. 2016 Mar 17;1(2):e000042. doi: 10.1136/esmoopen-2016-000042. Review
327. Reiter FP, Wimmer R, Wottke L, Artmann R, Nagel JM, Carranza MO, Mayr D, Rust C, Fickert P, Trauner M, Gerbes AL, Hohenester S, Denk GU. Role of interleukin-1 and its antagonism of hepatic stellate cell proliferation and liver fibrosis in the Abcb4(-/-) mouse model. *World J Hepatol*. 2016 Mar 18;8(8):401-10. doi: 10.4254/wjh.v8.i8.401.
328. Wagner M, Trauner M. Recent advances in understanding and managing cholestasis. *F1000Res*. 2016 Apr 19;5:F1000 Faculty Rev-705. doi: 10.12688/f1000research.8012.1. eCollection 2016. Review
329. Banales JM, Cardinale V, Carpino G, Marzioni M, Andersen JB, Invernizzi P, Lind GE, Folseraas T, Forbes SJ, Fouassier L, Geier A, Calvisi DF, Mertens JC, Trauner M, Benedetti A, Maroni L, Vaquero J, Macias RI, Raggi C, Perugorria MJ, Gaudio E, Boberg KM, Marin JJ, Alvaro D. Expert consensus document: Cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma (ENS-CCA). *Nat Rev Gastroenterol Hepatol*. 2016 May;13(5):261-80. doi: 10.1038/nrgastro.2016.51.
330. Tang Y, Fickert P, Trauner M, Marcus N, Blomenkamp K, Teckman J. Autophagy induced by exogenous bile acids is therapeutic in a model of alpha-1-AT deficiency liver disease. *Am J Physiol Gastrointest Liver Physiol*. 2016 Jul 1;311(1):G156-65. doi: 10.1152/ajpgi.00143.2015.
331. Dolak W, Beer A, Kristo I, Tribl B, Asari R, Schöniger-Hekele M, Wrba F, Schoppmann SF, Trauner M, Püspök A. A retrospective study on the safety, diagnostic yield, and therapeutic effects of endoscopic unroofing for small gastric subepithelial tumors. *Gastrointest Endosc*. 2016 Dec;84(6):924-929. doi: 10.1016/j.gie.2016.04.019.
332. Mandorfer M, Schwabl P, Steiner S, Scheiner B, Chromy D, Bucsics T, Stättermayer AF, Aichelburg MC, Grabmeier-Pfistershammer K, Trauner M, Reiberger T, Peck-Radosavljevic M. Interferon-free treatment with sofosbuvir/daclatasvir achieves sustained virologic response in 100% of HIV/hepatitis C virus-coinfected patients with advanced liver disease. *AIDS*. 2016 Apr 24;30(7):1039-47. doi: 10.1097/QAD.0000000000001020.
333. Györi GP, Schwarzer R, Püspök A, Schöfl R, Silberhumer GR, Langer FB, Trauner M, Peck-Radosavljevic M, Berlakovich GA, Ferlitsch A. Endoscopic versus surgical management of biliary complications - Outcome analysis after 1188 orthotopic liver transplantations. *Dig Liver Dis*. 2016 Nov;48(11):1323-1329. doi: 10.1016/j.dld.2016.05.016.
334. Mandorfer M, Kozbial K, Schwabl P, Freissmuth C, Schwarzer R, Stern R, Chromy D, Stättermayer AF, Reiberger T, Beinhardt S, Sieghart W, Trauner M, Hofer H, Ferlitsch A, Ferenci P, Peck-Radosavljevic M. Sustained virologic response to interferon-free therapies ameliorates HCV-induced portal hypertension. *J Hepatol*. 2016 Oct;65(4):692-699. doi: 10.1016/j.jhep.2016.05.027.

335. Drolz A, Horvatits T, Roedl K, Rutter K, Staufer K, Kneidinger N, Holzinger U, Zauner C, Schellongowski P, Heinz G, Perkmann T, Kluge S, Trauner M, Fuhrmann V. Coagulation parameters and major bleeding in critically ill patients with cirrhosis. **Hepatology**. 2016 Aug;64(2):556-68. doi: 10.1002/hep.28628.
336. Kozbial K, Moser S, Schwarzer R, Laferl H, Al-Zoairy R, Stauber R, Stättermayer AF, Beinhardt S, Graziadei I, Freissmuth C, Maieron A, Gschwantler M, Strasser M, Peck-Radosavljevic M, Trauner M, Hofer H, Ferenci P. Unexpected high incidence of hepatocellular carcinoma in cirrhotic patients with sustained virologic response following interferon-free direct-acting antiviral treatment. **J Hepatol**. 2016 Oct;65(4):856-858. doi: 10.1016/j.jhep.2016.06.009.
337. Bucsecs T, Schwabl P, Mandorfer M, Bota S, Sieghart W, Ferlitsch A, Trauner M, Reiberger T, Peck-Radosavljevic M. The trigger matters - outcome of hepatorenal syndrome vs. specifically triggered acute kidney injury in cirrhotic patients with ascites. **Liver Int**. 2016 Nov;36(11):1649-1656. doi: 10.1111/liv.13160
338. Scheiner B, Schwabl P, Steiner S, Bucsecs T, Chromy D, Aichelburg MC, Grabmeier-Pfistershammer K, Trauner M, Peck-Radosavljevic M, Reiberger T, Mandorfer M. Interferon-free regimens improve health-related quality of life and fatigue in HIV/HCV-coinfected patients with advanced liver disease: A retrospective study. **Medicine** (Baltimore). 2016 Jul;95(27):e4061. doi: 10.1097/MD.0000000000004061.
339. Zhu C, Fuchs CD, Halilbasic E, Trauner M. Bile acids in regulation of inflammation and immunity: friend or foe? **Clin Exp Rheumatol**. 2016 Jul-Aug;34(4 Suppl 98):25-31. Review
340. Beinhardt S, Al Zoairy R, Ferenci P, Kozbial K, Freissmuth C, Stern R, Stättermayer AF, Stauber R, Strasser M, Zoller H, Watschinger B, Schmidt A, Trauner M, Hofer H, Maieron A. DAA-based antiviral treatment of patients with chronic hepatitis C in the pre- and postkidney transplantation setting. **Transpl Int**. 2016 Sep;29(9):999-1007. doi: 10.1111/tri.12799.
341. Dolak W, Schwaighofer H, Hellmich B, Stadler B, Spaun G, Plieschnegger W, Hebenstreit A, Weber-Eibel J, Siebert F, Emmanuel K, Knoflach P, Gschwantler M, Vogel W, Trauner M, Püspök A; Austrian PDT study group. Photodynamic therapy with polyhematoporphyrin for malignant biliary obstruction: A nationwide retrospective study of 150 consecutive applications. **United European Gastroenterol J**. 2017 Feb;5(1):104-110. doi: 10.1177/2050640616654037.
342. Drolz A, Horvatits T, Roedl K, Rutter K, Staufer K, Haider DG, Zauner C, Heinz G, Schellongowski P, Kluge S, Trauner M, Fuhrmann V. Outcome and features of acute kidney injury complicating hypoxic hepatitis at the medical intensive care unit. **Ann Intensive Care**. 2016 Dec;6(1):61. doi: 10.1186/s13613-016-0162-4.
343. Rutter K, Etschmaier A, Ferlitsch M, Maieron A, Hametner S, Horvatits T, Paternostro R, Salzl P, Reiberger T, Peck-Radosavljevic M, Quehenberger P, Hofer H, Trauner M, Ferenci P, Ferlitsch A. von Willebrand factor antigen (vWF-Ag): A non-invasive predictor of treatment response and serious adverse events in HCV patients with interferon triple therapy. **Dig Liver Dis**. 2016 Oct;48(10):1194-9. doi: 10.1016/j.dld.2016.06.033.
344. Hendriks T, Watzenböck ML, Walenbergh SM, Amir S, Gruber S, Kozma MO, Grabsch HI, Koek GH, Pierik MJ, Staufer K, Trauner M, Kalhan SC, Jonkers D, Hofker MH,



- Binder CJ, Shiri-Sverdlov R. Low levels of IgM antibodies recognizing oxidation-specific epitopes are associated with human non-alcoholic fatty liver disease. *BMC Med*. 2016 Jul 22;14(1):107. doi: 10.1186/s12916-016-0652-0.
345. Arab JP, Karpen SJ, Dawson PA, Arrese M, Trauner M. Bile acids and nonalcoholic fatty liver disease: Molecular insights and therapeutic perspectives. *Hepatology*. 2017 Jan;65(1):350-362. doi: 10.1002/hep.28709. Review
346. Horvatits T, Drolz A, Roedl K, Rutter K, Ferlitsch A, Fauler G, Trauner M, Fuhrmann V. Serum bile acids as marker for acute decompensation and acute-on-chronic liver failure in patients with non-cholestatic cirrhosis. *Liver Int*. 2017 Feb;37(2):224-231. doi: 10.1111/liv.13201.
347. Cornelius C, Schöneweis K, Georgi F, Weber M, Niederberger V, Zieglmayer P, Niespodziana K, Trauner M, Hofer H, Urban S, Valenta R. Immunotherapy With the PreS-based Grass Pollen Allergy Vaccine BM32 Induces Antibody Responses Protecting Against Hepatitis B Infection. *EBioMedicine*. 2016 Sep;11:58-67. doi: 10.1016/j.ebiom.2016.07.023.
348. Nevens F, Andreone P, Mazzella G, Strasser SI, Bowlus C, Invernizzi P, Drenth JP, Pockros PJ, Regula J, Beuers U, Trauner M, Jones DE, Floreani A, Hohenester S, Luketic V, Shiffman M, van Erpecum KJ, Vargas V, Vincent C, Hirschfield GM, Shah H, Hansen B, Lindor KD, Marschall HU, Kowdley KV, Hooshmand-Rad R, Marmon T, Sheeron S, Pencek R, MacConell L, Pruzanski M, Shapiro D; POISE Study Group. A Placebo-Controlled Trial of Obeticholic Acid in Primary Biliary Cholangitis. *N Engl J Med*. 2016 Aug 18;375(7):631-43. doi: 10.1056/NEJMoa1509840.
349. Stättermayer AF, Traussnigg S, Aigner E, Kienbacher C, Huber-Schönauer U, Steindl-Munda P, Stadlmayr A, Wrba F, Trauner M, Datz C, Ferenci P. Low hepatic copper content and PNPLA3 polymorphism in non-alcoholic fatty liver disease in patients without metabolic syndrome. *J Trace Elem Med Biol*. 2017 Jan;39:100-107. doi: 10.1016/j.jtemb.2016.08.006.
350. Munteanu M, Tiniakos D, Anstee Q, Charlotte F, Marchesini G, Bugianesi E, Trauner M, Romero Gomez M, Oliveira C, Day C, Dufour JF, Bellentani S, Ngo Y, Traussnigg S, Perazzo H, Deckmyn O, Bedossa P, Ratziu V, Poynard T; FLIP Consortium and the FibroFrance Group. Diagnostic performance of FibroTest, SteatoTest and ActiTest in patients with NAFLD using the SAF score as histological reference. *Aliment Pharmacol Ther*. 2016 Oct;44(8):877-89. doi: 10.1111/apt.13770.
351. Waldmann E, Gessl I, Sallinger D, Jeschek P, Britto-Arias M, Heinze G, Fasching E, Weiss W, Gschwantler M, Trauner M, Ferlitsch M. Trends in quality of screening colonoscopy in Austria. *Endoscopy*. 2016 Dec;48(12):1102-1109. doi: 10.1055/s-0042-113185.
352. Kruschitz R, Luger M, Kienbacher C, Trauner M, Klammer C, Schindler K, Langer FB, Prager G, Krebs M, Ludvik B. The Effect of Roux-en-Y vs. Omega-Loop Gastric Bypass on Liver, Metabolic Parameters, and Weight Loss. *Obes Surg*. 2016 Sep;26(9):2204-2212. doi: 10.1007/s11695-016-2083-6.
353. Fuchs CD, Paumgartner G, Wahlström A, Schwabl P, Reiberger T, Leditznig N, Stojakovic T, Rohr-Udilova N, Chiba P, Marschall HU, Trauner M. Metabolic preconditioning protects BSEP/ABCB11<sup>-/-</sup> mice against cholestatic liver injury. *J Hepatol*. 2017 Jan;66(1):95-101. doi: 10.1016/j.jhep.2016.08.017.

354. Graziadei I, Zoller H, Fickert P, Schneeberger S, Finkenstedt A, Peck-Radosavljevic M, Müller H, Kohl C, Sperner-Unterweger B, Eschertzhuber S, Hofer H, Öfner D, Tilg H, Vogel W, Trauner M, Berlakovich G. Indications for liver transplantation in adults : Recommendations of the Austrian Society for Gastroenterology and Hepatology (ÖGGH) in cooperation with the Austrian Society for Transplantation, Transfusion and Genetics (ATX). *Wien Klin Wochenschr*. 2016 Oct;128(19-20):679-690. doi: 10.1007/s00508-016-1046-1. Consensus Report
355. Luger M, Kruschitz R, Kienbacher C, Traussnigg S, Langer FB, Schindler K, Würger T, Wrba F, Trauner M, Prager G, Ludvik B. Prevalence of Liver Fibrosis and its Association with Non-invasive Fibrosis and Metabolic Markers in Morbidly Obese Patients with Vitamin D Deficiency. *Obes Surg*. 2016 Oct;26(10):2425-32. doi: 10.1007/s11695-016-2123-2.
356. Fuchs CD, Schwabl P, Reiberger T, Trauner M. Liver Capsule: FXR agonists against liver disease. *Hepatology*. 2016 Nov;64(5):1773. doi: 10.1002/hep.28836. Review
357. Waldmann E, Heinze G, Ferlitsch A, Gessl I, Sallinger D, Jeschek P, Britto-Arias M, Salzl P, Fasching E, Jilma B, Kundi M, Trauner M, Ferlitsch M. Risk factors cannot explain the higher prevalence rates of precancerous colorectal lesions in men. *Br J Cancer*. 2016 Nov 22;115(11):1421-1429. doi: 10.1038/bjc.2016.324.
358. Bastati N, Wibmer A, Tamandl D, Einspieler H, Hodge JC, Poetter-Lang S, Rockenschaub S, Berlakovich GA, Trauner M, Herold C, Ba-Ssalamah A. Assessment of Orthotopic Liver Transplant Graft Survival on Gadoteric Acid-Enhanced Magnetic Resonance Imaging Using Qualitative and Quantitative Parameters. *Invest Radiol*. 2016 Nov;51(11):728-734. doi: 10.1097/RLI.000000000000286.
359. Schwabl P, Mandorfer M, Steiner S, Scheiner B, Chromy D, Herac M, Bucsecs T, Hayden H, Grabmeier-Pfistershammer K, Ferlitsch A, Oberhuber G, Trauner M, Peck-Radosavljevic M, Reiberger T. Interferon-free regimens improve portal hypertension and histological necroinflammation in HIV/HCV patients with advanced liver disease. *Aliment Pharmacol Ther*. 2017 Jan;45(1):139-149. doi: 10.1111/apt.13844.
360. Ba-Ssalamah A, Bastati N, Wibmer A, Fagner R, Hodge JC, Trauner M, Herold CJ, Bashir MR, Van Beers BE. Hepatic gadoteric acid uptake as a measure of diffuse liver disease: Where are we? *J Magn Reson Imaging*. 2017 Mar;45(3):646-659. doi: 10.1002/jmri.25518. Review
361. Eigner W, Bashir K, Primas C, Kazemi-Shirazi L, Wrba F, Trauner M, Vogelsang H. Dynamics of occurrence of refractory coeliac disease and associated complications over 25 years. *Aliment Pharmacol Ther*. 2017 Jan;45(2):364-372. doi: 10.1111/apt.13867.
362. Paternostro R, Wagner D, Reiberger T, Mandorfer M, Schwarzer R, Ferlitsch M, Trauner M, Peck-Radosavljevic M, Ferlitsch A. Low 25-OH-vitamin D levels reflect hepatic dysfunction and are associated with mortality in patients with liver cirrhosis. *Wien Klin Wochenschr*. 2017 Jan;129(1-2):8-15. doi: 10.1007/s00508-016-1127-1.
363. Waldmann E, Gessl I, Sallinger D, Jeschek P, Britto-Arias M, Heinze G, Fasching E, Weiss W, Gschwantler M, Trauner M, Ferlitsch M. Trends in quality of screening colonoscopy in Austria. *Endoscopy*. 2016 Dec;48(12):1109. doi: 10.1055/s-0042-121369.

364. Horvatits T, Drolz A, Rutter K, Roedl K, Fauler G, Müller C, Kluge S, Trauner M, Schenk P, Fuhrmann V. Serum bile acids in patients with hepatopulmonary syndrome. **Z Gastroenterol**. 2017 Apr;55(4):361-367. doi: 10.1055/s-0042-121268.
365. Schwabl P, Hambruch E, Seeland BA, Hayden H, Wagner M, Garnys L, Strobel B, Schubert TL, Riedl F, Mitteregger D, Burnet M, Starlinger P, Oberhuber G, Deuschle U, Rohr-Udilova N, Podesser BK, Peck-Radosavljevic M, Reiberger T, Kremoser C, Trauner M. The FXR agonist PX20606 ameliorates portal hypertension by targeting vascular remodelling and sinusoidal dysfunction. **J Hepatol**. 2017 Apr;66(4):724-733. doi: 10.1016/j.jhep.2016.12.005.
366. Lemberger UJ, Fuchs CD, Karer M, Haas S, Stojakovic T, Schöfer C, Marschall HU, Wrba F, Taketo MM, Egger G, Trauner M, Österreicher CH. Hepatocyte specific expression of an oncogenic variant of  $\beta$ -catenin results in cholestatic liver disease. **Oncotarget**. 2016 Dec 27;7(52):86985-86998. doi: 10.18632/oncotarget.13521.
367. Paternostro R, Reiberger T, Mandorfer M, Schwarzer R, Schwabl P, Bota S, Ferlitsch M, Trauner M, Peck-Radosavljevic M, Ferlitsch A. Plasma renin concentration represents an independent risk factor for mortality and is associated with liver dysfunction in patients with cirrhosis. **J Gastroenterol Hepatol**. 2017 Jan;32(1):184-190. doi: 10.1111/jgh.13439.
368. Halilbasic E, Steinacher D, Trauner M. Nor-Ursodeoxycholic Acid as a Novel Therapeutic Approach for Cholestatic and Metabolic Liver Diseases. **Dig Dis**. 2017;35(3):288-292. doi: 10.1159/000454904. Review
369. Steinacher D, Claudel T, Trauner M. Therapeutic Mechanisms of Bile Acids and Nor-Ursodeoxycholic Acid in Non-Alcoholic Fatty Liver Disease. **Dig Dis**. 2017;35(3):282-287. doi: 10.1159/000454853. Review
370. Steiner S, Bucsics T, Schwabl P, Mandorfer M, Scheiner B, Aichelburg MC, Grabmeier-Pfistershammer K, Ferenci P, Trauner M, Peck-Radosavljevic M, Reiberger T. Progress in eradication of HCV in HIV positive patients with significant liver fibrosis in Vienna. **Wien Klin Wochenschr**. 2017 Aug;129(15-16):517-526. doi: 10.1007/s00508-016-1162-y.
371. Pinter M, Weinmann A, Wörns MA, Hucke F, Bota S, Marquardt JU, Duda DG, Jain RK, Galle PR, Trauner M, Peck-Radosavljevic M, Sieghart W. Use of inhibitors of the renin-angiotensin system is associated with longer survival in patients with hepatocellular carcinoma. **United European Gastroenterol J**. 2017 Nov;5(7):987-996. doi: 10.1177/2050640617695698.
372. Krones E, Eller K, Pollheimer MJ, Racedo S, Kirsch AH, Frauscher B, Wahlström A, Ståhlman M, Trauner M, Grahmmer F, Huber TB, Wagner K, Rosenkranz AR, Marschall HU, Fickert P. NorUrsodeoxycholic acid ameliorates cholemic nephropathy in bile duct ligated mice. **J Hepatol**. 2017 Jul;67(1):110-119. doi: 10.1016/j.jhep.2017.02.019.
373. Unger LW, Herac M, Staufer K, Salat A, Silberhumer G, Hofmann M, Trauner M, Rasoul-Rockenschaub S, Soliman T, Reiberger T, Berlakovich GA. The post-transplant course of patients undergoing liver transplantation for nonalcoholic steatohepatitis versus cryptogenic cirrhosis: a retrospective case-control study. **Eur J Gastroenterol Hepatol**. 2017 Mar;29(3):309-316. doi: 10.1097/MEG.0000000000000794.

374. Fuchs CD, Halilbasic E, Trauner M. Novel treatments targeting metabolic and signaling mechanisms in primary biliary cholangitis. *Clin Liver Dis* (Hoboken). 2017 Mar 1;9(2):43-47. doi: 10.1002/cld.613. Review
375. Weismüller TJ, Trivedi PJ, Bergquist A, Imam M, Lenzen H, Ponsioen CY, Holm K, Gotthardt D, Färkkilä MA, Marschall HU, Thorburn D, Weersma RK, Fevery J, Mueller T, Chazouillères O, Schulze K, Lazaridis KN, Almer S, Pereira SP, Levy C, Mason A, Naess S, Bowlus CL, Floreani A, Halilbasic E, Yimam KK, Milkiewicz P, Beuers U, Huynh DK, Pares A, Manser CN, Dalekos GN, Eksteen B, Invernizzi P, Berg CP, Kirchner G, Sarrazin C, Zimmer V, Fabris L, Braun F, Marzioni M, Juran BD, Said K, Rupp C, Jokelainen K, Benito de Valle M, Saffioti F, Cheung A, Trauner M, Schramm C, Chapman RW, Karlsen TH, Schrupf E, Strassburg CP, Manns MP, Lindor KD, Hirschfield GM, Hansen BE, Boberg KM; International PSC Study Group. Patient Age, Sex, and Inflammatory Bowel Disease Phenotype Associate With Course of Primary Sclerosing Cholangitis. *Gastroenterology*. 2017 Jun;152(8):1975-1984.e8. doi: 10.1053/j.gastro.2017.02.038.
376. Trauner M, Fuchs CD, Halilbasic E, Paumgartner G. New therapeutic concepts in bile acid transport and signaling for management of cholestasis. *Hepatology*. 2017 Apr;65(4):1393-1404. doi: 10.1002/hep.28991. Review
377. Lackner C, Bataller R, Burt A, Miquel R, Schuppan D, Tiniakos D, Trauner M. Fibrosis evaluation by transient elastography in alcoholic liver disease: Is the histological scoring system impacting cutoff values? *Hepatology*. 2017 May;65(5):1758-1761. doi: 10.1002/hep.29075. Editorial
378. Staufer K, Roedl K, Kivaranovic D, Drolz A, Horvatits T, Rasoul-Rockenschaub S, Zauner C, Trauner M, Fuhrmann V. Renal replacement therapy in critically ill liver cirrhotic patients-outcome and clinical implications. *Liver Int*. 2017 Jun;37(6):843-850. doi: 10.1111/liv.13389.
379. Unger LW, Stork T, Bucsics T, Rasoul-Rockenschaub S, Staufer K, Trauner M, Maschke S, Pawloff M, Soliman T, Reiberger T, Berlakovich GA. The role of TIPS in the management of liver transplant candidates. *United European Gastroenterol J*. 2017 Dec;5(8):1100-1107. doi: 10.1177/2050640617704807.
380. Seidel RA, Claudel T, Schleser FA, Ojha NK, Westerhausen M, Nietzsche S, Sponholz C, Cuperus F, Coldewey SM, Heinemann SH, Pohnert G, Trauner M, Bauer M. Impact of higher-order heme degradation products on hepatic function and hemodynamics. *J Hepatol*. 2017 Aug;67(2):272-281. doi: 10.1016/j.jhep.2017.03.037.
381. Bruschi FV, Claudel T, Tardelli M, Caligiuri A, Stulnig TM, Marra F, Trauner M. The PNPLA3 I148M variant modulates the fibrogenic phenotype of human hepatic stellate cells. *Hepatology*. 2017 Jun;65(6):1875-1890. doi: 10.1002/hep.29041.
382. Luger M, Kruschitz R, Kienbacher C, Traussnigg S, Langer FB, Prager G, Schindler K, Kallay E, Hoppichler F, Trauner M, Krebs M, Marculescu R, Ludvik B. Vitamin D<sub>3</sub> Loading Is Superior to Conventional Supplementation After Weight Loss Surgery in Vitamin D-Deficient Morbidly Obese Patients: a Double-Blind Randomized Placebo-Controlled Trial. *Obes Surg*. 2017 May;27(5):1196-1207. doi: 10.1007/s11695-016-2437-0.

383. Horvatits T, Drolz A, Rutter K, Roedl K, Langouche L, Van den Berghe G, Fauler G, Meyer B, Hülsmann M, Heinz G, Trauner M, Fuhrmann V. Circulating bile acids predict outcome in critically ill patients. *Ann Intensive Care*. 2017 Dec;7(1):48. doi: 10.1186/s13613-017-0272-7.
384. Eferl R, Trauner M. Chromosomal instability in HCC: a key function for checkpoint kinase 2. *Gut*. 2018 Feb;67(2):204-205. doi: 10.1136/gutjnl-2017-314101. Editorial
385. Wiest R, Albillos A, Trauner M, Bajaj JS, Jalan R. Targeting the gut-liver axis in liver disease. *J Hepatol*. 2017 Nov;67(5):1084-1103. doi: 10.1016/j.jhep.2017.05.007. Review  
Corrigendum in *J Hepatol*. 2018 Jun;68(6):1336. doi: 10.1016/j.jhep.2018.03.001.
386. Fickert P, Hirschfield GM, Denk G, Marschall HU, Altorjay I, Färkkilä M, Schramm C, Spengler U, Chapman R, Bergquist A, Schrupf E, Nevens F, Trivedi P, Reiter FP, Tornai I, Halilbasic E, Greinwald R, Pröls M, Manns MP, Trauner M; European PSC norUDCA Study Group. norUrsodeoxycholic acid improves cholestasis in primary sclerosing cholangitis. *J Hepatol*. 2017 Sep;67(3):549-558. doi: 10.1016/j.jhep.2017.05.009.
387. Koslowski N, Sombetzki M, Loebermann M, Engelmann R, Grabow N, Österreicher CH, Trauner M, Mueller-Hilke B, Reisinger EC. Single-sex infection with female *Schistosoma mansoni* cercariae mitigates hepatic fibrosis after secondary infection. *PLoS Negl Trop Dis*. 2017 May 19;11(5):e0005595. doi: 10.1371/journal.pntd.0005595.
388. Traussnigg S, Kienbacher C, Gajdošík M, Valkovič L, Halilbasic E, Stift J, Rechling C, Hofer H, Steindl-Munda P, Ferenci P, Wrba F, Trattnig S, Krššák M, Trauner M. Ultra-high-field magnetic resonance spectroscopy in non-alcoholic fatty liver disease: Novel mechanistic and diagnostic insights of energy metabolism in non-alcoholic steatohepatitis and advanced fibrosis. *Liver Int*. 2017 Oct;37(10):1544-1553. doi: 10.1111/liv.13451.
389. Scheiner B, Parada-Rodriguez D, Bucsecs T, Schwabl P, Mandorfer M, Pfisterer N, Riedl F, Sieghart W, Ferlitsch A, Trauner M, Peck-Radosavljevic M, Reiberger T. Non-selective beta-blocker treatment does not impact on kidney function in cirrhotic patients with varices. *Scand J Gastroenterol*. 2017 Sep;52(9):1008-1015. doi: 10.1080/00365521.2017.1329456.
390. Tardelli M, Claudel T, Bruschi FV, Moreno-Viedma V, Trauner M. Adiponectin regulates AQP3 via PPAR $\alpha$  in human hepatic stellate cells. *Biochem Biophys Res Commun*. 2017 Aug 12;490(1):51-54. doi: 10.1016/j.bbrc.2017.06.009.
391. Scheiner B, Lindner G, Reiberger T, Schneeweiss B, Trauner M, Zauner C, Funk GC. Acid-base disorders in liver disease. *J Hepatol*. 2017 Nov;67(5):1062-1073. doi: 10.1016/j.jhep.2017.06.023. Review
392. Rohr-Udilova N, Klinglmüller F, Seif M, Hayden H, Bilban M, Pinter M, Stolze K, Sieghart W, Peck-Radosavljevic M, Trauner M. Oxidative stress mediates an increased formation of vascular endothelial growth factor in human hepatocarcinoma cells exposed to erlotinib. *Oncotarget*. 2017 Jul 6;8(34):57109-57120. doi: 10.18632/oncotarget.19055.

393. Dengler M, Stauer K, Huber H, Stauber R, Bantel H, Weiss KH, Starlinger P, Pock H, Klöters-Plachky P, Gotthardt DN, Rauch P, Lackner C, Stift J, Brostjan C, Gruenberger T, Kumada T, Toyoda H, Tada T, Weiss TS, Trauner M, Mikulits W. Soluble Axl is an accurate biomarker of cirrhosis and hepatocellular carcinoma development: results from a large scale multicenter analysis. *Oncotarget*. 2017 Jul 11;8(28):46234-46248. doi: 10.18632/oncotarget.17598.
394. Chromy D, Schwabl P, Bucsecs T, Scheiner B, Strassl R, Mayer F, Aichelburg MC, Grabmeier-Pfistershammer K, Trauner M, Peck-Radosavljevic M, Reiberger T, Mandorfer M. Non-invasive liver fibrosis assessment and HCV treatment initiation within a systematic screening program in HIV/HCV coinfecting patients. *Wien Klin Wochenschr*. 2018 Feb;130(3-4):105-114. doi: 10.1007/s00508-017-1231-x.
395. Asenbaum U, Ba-Ssalamah A, Mandorfer M, Nolz R, Furtner J, Reiberger T, Ferlitsch A, Kaczirek K, Trauner M, Peck-Radosavljevic M, Wibmer AG. Effects of Portal Hypertension on Gadoteric Acid-Enhanced Liver Magnetic Resonance: Diagnostic and Prognostic Implications. *Invest Radiol*. 2017 Aug;52(8):462-469. doi: 10.1097/RLI.0000000000000366.
396. Pinter M, Haupt L, Hucke F, Bota S, Bucsecs T, Trauner M, Peck-Radosavljevic M, Sieghart W. The impact of thyroid hormones on patients with hepatocellular carcinoma. *PLoS One*. 2017 Aug 3;12(8):e0181878. doi: 10.1371/journal.pone.0181878.
397. Sohail MI, Schmid D, Wlcek K, Spork M, Szakács G, Trauner M, Stockner T, Chiba P. Molecular Mechanism of Taurocholate Transport by the Bile Salt Export Pump, an ABC Transporter Associated with Intrahepatic Cholestasis. *Mol Pharmacol*. 2017 Oct;92(4):401-413. doi: 10.1124/mol.117.108688.
398. Bucsecs T, Schoder M, Goeschl N, Schwabl P, Mandorfer M, Diermayr M, Feldner M, Riedl F, Bauer D, Angermayr B, Cejna M, Ferlitsch A, Sieghart W, Trauner M, Peck-Radosavljevic M, Karner J, Karnel F, Reiberger T. Re-bleeding rates and survival after early transjugular intrahepatic portosystemic shunt (TIPS) in clinical practice. *Dig Liver Dis*. 2017 Dec;49(12):1360-1367. doi: 10.1016/j.dld.2017.08.002.
399. Erice O, Labiano I, Arbelaiz A, Santos-Laso A, Munoz-Garrido P, Jimenez-Agüero R, Olaizola P, Caro-Maldonado A, Martín-Martín N, Carracedo A, Lozano E, Marin JJ, O'Rourke CJ, Andersen JB, Llop J, Gómez-Vallejo V, Padro D, Martin A, Marzioni M, Adorini L, Trauner M, Bujanda L, Perugorria MJ, Banales JM. Differential effects of FXR or TGR5 activation in cholangiocarcinoma progression. *Biochim Biophys Acta Mol Basis Dis*. 2018 Apr;1864(4 Pt B):1335-1344. doi: 10.1016/j.bbadis.2017.08.016.
400. Mueller M, Castro RE, Thorell A, Marschall HU, Auer N, Herac M, Rodrigues CMP, Trauner M. Ursodeoxycholic acid: Effects on hepatic unfolded protein response, apoptosis and oxidative stress in morbidly obese patients. *Liver Int*. 2018 Mar;38(3):523-531. doi: 10.1111/liv.13562.
401. Adeyemi O, Alvarez-Laviada A, Schultz F, Ibrahim E, Trauner M, Williamson C, Glukhov AV, Gorelik J. Ursodeoxycholic acid prevents ventricular conduction slowing and arrhythmia by restoring T-type calcium current in fetuses during cholestasis. *PLoS One*. 2017 Sep 21;12(9):e0183167. doi: 10.1371/journal.pone.0183167.
402. Debray D, Narkewicz MR, Bodewes FAJA, Colombo C, Housset C, de Jonge HR, Jonker JW, Kelly DA, Ling SC, Poynard T, Sogni P, Trauner M, Witters P, Baumann U, Wilschanski M, Verkade HJ. Cystic Fibrosis-related Liver Disease: Research

Challenges and Future Perspectives. *J Pediatr Gastroenterol Nutr.* 2017 Oct;65(4):443-448. doi: 10.1097/MPG.0000000000001676.

403. Fuchs CD, Claudel T, Scharnagl H, Stojakovic T, Trauner M. FXR controls CHOP expression in steatohepatitis. *FEBS Lett.* 2017 Oct;591(20):3360-3368. doi: 10.1002/1873-3468.12845.
404. Reiberger T, Püspök A, Schoder M, Baumann-Durchschein F, Bucsics T, Datz C, Dolak W, Ferlitsch A, Finkenstedt A, Graziadei I, Hametner S, Karnel F, Krones E, Maieron A, Mandorfer M, Peck-Radosavljevic M, Rainer F, Schwabl P, Stadlbauer V, Stauber R, Tilg H, Trauner M. Zoller H, Schöfl R, Fickert P. Austrian consensus guidelines on the management and treatment of portal hypertension (Billroth III). *Wien Klin Wochenschr.* 2017 Nov;129(Suppl 3):135-158. doi: 10.1007/s00508-017-1262-3. Consensus Report
405. Gessl I, Waldmann E, Britto-Arias M, Penz D, Pablik E, Trauner M. Ferlitsch M. Surveillance colonoscopy in Austria: Are we following the guidelines? *Endoscopy.* 2018 Feb;50(2):119-127. doi: 10.1055/s-0043-119637.
406. Stauer K, Dengler M, Huber H, Marculescu R, Stauber R, Lackner C, Dienes HP, Kivaranovic D, Schachner C, Zeitlinger M, Wulkersdorfer B, Rauch P, Prager G, Trauner M. Mikulits W. The non-invasive serum biomarker soluble Axl accurately detects advanced liver fibrosis and cirrhosis. *Cell Death Dis.* 2017 Oct 26;8(10):e3135. doi: 10.1038/cddis.2017.554.
407. Deutsche Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS) (federführend); Deutsche Gesellschaft für Innere Medizin (DGIM); Deutsche M. Crohn/Colitis ulcerosa Vereinigung (DCCV); Deutsche Leberhilfe e.V.; Deutsche Gesellschaft für Ultraschall in der Medizin (DEGUM); Deutsche Gesellschaft für Endoskopie und Bildgebende Verfahren (DGE-BV); Deutsche Gesellschaft für Kinder- und Jugendmedizin (DGKJ); Gesellschaft für Pädiatrische Gastroenterologie (GPGE); Deutsche Gesellschaft für Rheumatologie (DGRh); Deutsche Röntgengesellschaft (DRG); Deutsche Transplantationsgesellschaft (DTG); Deutsche Gesellschaft für Pathologie (DGP) und Bundesverband Deutscher Pathologen (BDP); Österreichische Gesellschaft für Gastroenterologie (ÖGG); Schweizer Gastroenterologische Gesellschaft (SGG); Authors; Collaborators. [Practice guideline autoimmune liver diseases - AWMF-Reg. No. 021-27]. *Z Gastroenterol.* 2017 Nov;55(11):1135-1226. doi: 10.1055/s-0043-120199. Consensus Report (all authors listed in acknowledgement)
408. Schwarzer R, Kivaranovic D, Mandorfer M, Paternostro R, Wolrab D, Heinisch B, Reiberger T, Ferlitsch M, Gerner C, Trauner M. Peck-Radosavljevic M, Ferlitsch A. Randomised clinical study: the effects of oral taurine 6g/day vs placebo on portal hypertension. *Aliment Pharmacol Ther.* 2018 Jan;47(1):86-94. doi: 10.1111/apt.14377.
409. Bruschi FV, Tardelli M, Claudel T, Trauner M. PNPLA3 expression and its impact on the liver: current perspectives. *Hepat Med.* 2017 Nov 6;9:55-66. doi: 10.2147/HMER.S125718. Review
410. Tardelli M, Bruschi FV, Claudel T, Moreno-Viedma V, Halilbasic E, Marra F, Herac M, Stulnig TM, Trauner M. AQP3 is regulated by PPAR $\gamma$  and JNK in hepatic stellate cells carrying PNPLA3 I148M. *Sci Rep.* 2017 Nov 7;7(1):14661. doi: 10.1038/s41598-017-14557-9.

411. Kozbial K, Moser S, Al-Zoairy R, Schwarzer R, Datz C, Stauber R, Laferl H, Strasser M, Beinhardt S, Stättermayer AF, Gschwantler M, Zoller H, Maieron A, Graziadei I, Trauner M, Steindl-Munda P, Hofer H, Ferenci P. Follow-up of sustained virological responders with hepatitis C and advanced liver disease after interferon/ribavirin-free treatment. *Liver Int.* 2018 Jun;38(6):1028-1035. doi: 10.1111/liv.13629.
412. Unger LW, Berlakovich GA, Trauner M, Reiberger T. Management of portal hypertension before and after liver transplantation. *Liver Transpl.* 2018 Jan;24(1):112-121. doi: 10.1002/lt.24830. Review
413. Bucsics T, Schoder M, Diermayr M, Feldner-Busztin M, Goeschl N, Bauer D, Schwabl P, Mandorfer M, Angermayr B, Cejna M, Ferlitsch A, Sieghart W, Trauner M, Peck-Radosavljevic M, Karner J, Karnel F, Reiberger T. Transjugular intrahepatic portosystemic shunts (TIPS) for the prevention of variceal re-bleeding - A two decades experience. *PLoS One.* 2018 Jan 9;13(1):e0189414. doi: 10.1371/journal.pone.0189414.
414. Bucsics T, Hoffman S, Grünberger J, Schoder M, Matzek W, Stadlmann A, Mandorfer M, Schwabl P, Ferlitsch A, Peck-Radosavljevic M, Trauner M, Karner J, Karnel F, Reiberger T. ePTFE-TIPS vs repetitive LVP plus albumin for the treatment of refractory ascites in patients with cirrhosis. *Liver Int.* 2018 Jun;38(6):1036-1044. doi: 10.1111/liv.13615.
415. Rohr-Udilova N, Bauer E, Timelthaler G, Eferl R, Stolze K, Pinter M, Seif M, Hayden H, Reiberger T, Schulte-Hermann R, Peck-Radosavljevic M, Stoiber D, Trauner M. Impact of glutathione peroxidase 4 on cell proliferation, angiogenesis and cytokine production in hepatocellular carcinoma. *Oncotarget.* 2018 Jan 22;9(11):10054-10068. doi: 10.18632/oncotarget.24300.
416. Arab JP, Arrese M, Trauner M. Recent Insights into the Pathogenesis of Nonalcoholic Fatty Liver Disease. *Annu Rev Pathol.* 2018 Jan 24;13:321-350. doi: 10.1146/annurev-pathol-020117-043617. Review
417. Mandorfer M, Schwabl P, Paternostro R, Pomej K, Bauer D, Thaler J, Ay C, Quehenberger P, Fritzer-Szekeres M, Peck-Radosavljevic M, Trauner M, Reiberger T, Ferlitsch A; Vienna Hepatic Hemodynamic Lab. Von Willebrand factor indicates bacterial translocation, inflammation, and procoagulant imbalance and predicts complications independently of portal hypertension severity. *Aliment Pharmacol Ther.* 2018 Apr;47(7):980-988. doi: 10.1111/apt.14522.
418. Lemberger UJ, Fuchs CD, Schöfer C, Bileck A, Gerner C, Stojakovic T, Taketo MM, Trauner M, Egger G, Österreicher CH. Hepatocyte specific expression of an oncogenic variant of  $\beta$ -catenin results in lethal metabolic dysfunction in mice. *Oncotarget.* 2018 Jan 30;9(13):11243-11257. doi: 10.18632/oncotarget.24346.
419. Beinhardt S, Al-Zoairy R, Kozbial K, Stättermayer AF, Maieron A, Stauber R, Strasser M, Zoller H, Graziadei I, Rasoul-Rockenschaub S, Trauner M, Ferenci P, Hofer H. Long-term follow-up of ribavirin-free DAA-based treatment in HCV recurrence after orthotopic liver transplantation. *Liver Int.* 2018 Jul;38(7):1188-1197. doi: 10.1111/liv.13652.
420. Pfisterer N, Dexheimer C, Fuchs EM, Bucsics T, Schwabl P, Mandorfer M, Gessl I, Sandrieser L, Baumann L, Riedl F, Scheiner B, Pachofszky T, Dolak W, Schrutka-Kölbl



- C, Ferlitsch A, Schöniger-Hekele M, Peck-Radosavljevic M, Trauner M, Madl C, Reiberger T. Betablockers do not increase efficacy of band ligation in primary prophylaxis but they improve survival in secondary prophylaxis of variceal bleeding. ***Aliment Pharmacol Ther.*** 2018 Apr;47(7):966-979. doi: 10.1111/apt.14485.
421. Paternostro R, Heinisch BB, Reiberger T, Mandorfer M, Schwarzer R, Seeland B, Trauner M, Peck-Radosavljevic M, Ferlitsch A. Erectile dysfunction in cirrhosis is impacted by liver dysfunction, portal hypertension, diabetes and arterial hypertension. ***Liver Int.*** 2018 Aug;38(8):1427-1436. doi: 10.1111/liv.13704.
422. Schwarzer R, Kivaranovic D, Paternostro R, Mandorfer M, Reiberger T, Trauner M, Peck-Radosavljevic M, Ferlitsch A. Carvedilol for reducing portal pressure in primary prophylaxis of variceal bleeding: a dose-response study. ***Aliment Pharmacol Ther.*** 2018 Apr;47(8):1162-1169. doi: 10.1111/apt.14576.
423. Mandorfer M, Bucsecs T, Hutya V, Schmid-Scherzer K, Schaefer B, Zoller H, Ferlitsch A, Peck-Radosavljevic M, Trauner M, Ferenci P, Kneussl M, Reiberger T. Liver disease in adults with  $\alpha$ 1-antitrypsin deficiency. ***United European Gastroenterol J.*** 2018 Jun;6(5):710-718. doi: 10.1177/2050640618764057.
424. Eilenberg M, Langer FB, Beer A, Trauner M, Prager G, Stauffer K. Significant Liver-Related Morbidity After Bariatric Surgery and Its Reversal-a Case Series. ***Obes Surg.*** 2018 Mar;28(3):812-819. doi: 10.1007/s11695-017-2925-x.
425. Fuchs CD, Paumgartner G, Mlitz V, Kunczer V, Halilbasic E, Leditznig N, Wahlström A, Stählmann M, Thüringer A, Kashofer K, Stojakovic T, Marschall HU, Trauner M. Colesevelam attenuates cholestatic liver and bile duct injury in *Mdr2*<sup>-/-</sup> mice by modulating composition, signalling and excretion of faecal bile acids. ***Gut.*** 2018 Sep;67(9):1683-1691. doi: 10.1136/gutjnl-2017-314553.
426. Rohr-Udilova N, Klinglmüller F, Schulte-Hermann R, Stift J, Herac M, Salzmann M, Finotello F, Timelthaler G, Oberhuber G, Pinter M, Reiberger T, Jensen-Jarolim E, Eferl R, Trauner M. Deviations of the immune cell landscape between healthy liver and hepatocellular carcinoma. ***Sci Rep.*** 2018 Apr 18;8(1):6220. doi: 10.1038/s41598-018-24437-5.
427. Drolz A, Horvatits T, Roedl K, Rutter K, Brunner R, Zauner C, Schellongowski P, Heinz G, Funk GC, Trauner M, Schneeweiss B, Fuhrmann V. Acid-base status and its clinical implications in critically ill patients with cirrhosis, acute-on-chronic liver failure and without liver disease. ***Ann Intensive Care.*** 2018 Apr 19;8(1):48. doi: 10.1186/s13613-018-0391-9.
428. Slijepcevic D, Roscam Abbing RLP, Fuchs CD, Haazen LCM, Beuers U, Trauner M, Oude Elferink RPJ, van de Graaf SFJ. Na<sup>+</sup>-taurocholate cotransporting polypeptide inhibition has hepatoprotective effects in cholestasis in mice. ***Hepatology.*** 2018 Sep;68(3):1057-1069. doi: 10.1002/hep.29888.
429. Pollheimer MJ, Racedo S, Mikels-Vigdal A, Marshall D, Bowlus C, Lackner C, Madl T, Karlsen TH, Hov JR, Lyman SK, Adamkewicz J, Smith V, Moreau E, Zollner G, Eide TJ, Stojakovic T, Scharnagl H, Gruber HJ, Stauber RE, Trauner M, Fickert P. Lysyl oxidase-like protein 2 (LOXL2) modulates barrier function in cholangiocytes in cholestasis. ***J Hepatol.*** 2018 Aug;69(2):368-377. doi: 10.1016/j.jhep.2018.04.009.

430. Zenouzi R, Liwinski T, Yamamura J, Weiler-Normann C, Sebode M, Keller S, Lohse AW, Schramm C; International PSC Study Group (IPSCSG). Follow-up magnetic resonance imaging/3D-magnetic resonance cholangiopancreatography in patients with primary sclerosing cholangitis: challenging for experts to interpret. *Aliment Pharmacol Ther.* 2018 Jul;48(2):169-178. doi: 10.1111/apt.14797. Banner-Co-Authorship listed in Pubmed
431. Stauffer K, Halilbasic E, Hillebrand P, Harm S, Schwarz S, Jaksch P, Kivaranovic D, Klepetko W, Trauner M, Kazemi-Shirazi L. Impact of nutritional status on pulmonary function after lung transplantation for cystic fibrosis. *United European Gastroenterol J.* 2018 Aug;6(7):1049-1055. doi: 10.1177/2050640618778381.
432. Kamogawa-Schifter Y, Yamaoka Y, Uchida T, Beer A, Tribl B, Schöniger-Hekele M, Trauner M, Dolak W. Prevalence of Helicobacter pylori and its CagA subtypes in gastric cancer and duodenal ulcer at an Austrian tertiary referral center over 25 years. *PLoS One.* 2018 May 29;13(5):e0197695. doi: 10.1371/journal.pone.0197695.
433. Gautherot J, Claudel T, Cuperus F, Fuchs CD, Falguières T, Trauner M. Thyroid hormone receptor  $\beta$ 1 stimulates ABCB4 to increase biliary phosphatidylcholine excretion in mice. *J Lipid Res.* 2018 Sep;59(9):1610-1619. doi: 10.1194/jlr.M084145.
434. Jha P, McDevitt MT, Halilbasic E, Williams EG, Quiros PM, Gariani K, Sleiman MB, Gupta R, Ulbrich A, Jochem A, Coon JJ, Trauner M, Pagliarini DJ, Auwerx J. Genetic Regulation of Plasma Lipid Species and Their Association with Metabolic Phenotypes. *Cell Syst.* 2018 Jun 27;6(6):709-721.e6. doi: 10.1016/j.cels.2018.05.009.
435. Tardelli M, Claudel T, Bruschi FV, Trauner M. Nuclear Receptor Regulation of Aquaglyceroporins in Metabolic Organs. *Int J Mol Sci.* 2018 Jun 15;19(6):1777. doi: 10.3390/ijms19061777. Review
436. Scheiner B, Stamment PR, Pokorny S, Bucsecs T, Schwabl P, Brichta A, Thaler J, Lampichler K, Ba-Ssalamah A, Ay C, Ferlitsch A, Trauner M, Mandorfer M, Reiberger T. Anticoagulation in non-malignant portal vein thrombosis is safe and improves hepatic function. *Wien Klin Wochenschr.* 2018 Jul;130(13-14):446-455. doi: 10.1007/s00508-018-1351-y.
437. Schwabl P, Brusilovskaya K, Supper P, Bauer D, Königshofer P, Riedl F, Hayden H, Fuchs CD, Stift J, Oberhuber G, Aschauer S, Bonderman D, Gnad T, Pfeifer A, Uschner FE, Trebicka J, Rohr-Udilova N, Podesser BK, Peck-Radosavljevic M, Trauner M, Reiberger T. The soluble guanylate cyclase stimulator riociguat reduces fibrogenesis and portal pressure in cirrhotic rats. *Sci Rep.* 2018 Jun 19;8(1):9372. doi: 10.1038/s41598-018-27656-y.
438. Stauffer K, Kivaranovic D, Rasoul-Rockenschaub S, Soliman T, Trauner M, Berlakovich G. Waitlist mortality and post-transplant survival in patients with cholestatic liver disease - Impact of changes in allocation policy. *HPB (Oxford).* 2018 Oct;20(10):916-924. doi: 10.1016/j.hpb.2018.03.013.
439. Scheiner B, Kirstein M, Popp S, Hucke F, Bota S, Rohr-Udilova N, Reiberger T, Müller C, Trauner M, Peck-Radosavljevic M, Vogel A, Sieghart W, Pinter M. Association of Platelet Count and Mean Platelet Volume with Overall Survival in Patients with Cirrhosis and Unresectable Hepatocellular Carcinoma. *Liver Cancer.* 2019 May;8(3):203-217. doi: 10.1159/000489833.

440. Mandorfer M, Scheiner B, Stättermayer AF, Schwabl P, Paternostro R, Bauer D, Schaefer B, Zoller H, Peck-Radosavljevic M, Trauner M, Reiberger T, Ferenci P, Ferlitsch A. Impact of patatin-like phospholipase domain containing 3 rs738409 G/G genotype on hepatic decompensation and mortality in patients with portal hypertension. ***Aliment Pharmacol Ther.*** 2018 Aug;48(4):451-459. doi: 10.1111/apt.14856.
441. Koh EH, Chernis N, Saha PK, Xiao L, Bader DA, Zhu B, Rajapakshe K, Hamilton MP, Liu X, Perera D, Chen X, York B, Trauner M, Coarfa C, Bajaj M, Moore DD, Deng T, McGuire SE, Hartig SM. miR-30a Remodels Subcutaneous Adipose Tissue Inflammation to Improve Insulin Sensitivity in Obesity. ***Diabetes.*** 2018 Dec;67(12):2541-2553. doi: 10.2337/db17-1378.
442. Haider L, Mandorfer M, Güngören Z, Reiberger T, Bastati N, Hodge JC, Chromy D, Trauner M, Herold C, Peck-Radosavljevic M, Ba-Ssalamah A. Noninvasive Monitoring of Liver Disease Regression after Hepatitis C Eradication Using Gadoteric Acid-Enhanced MRI. ***Contrast Media Mol Imaging.*** 2018 Jul 12;2018:8489709. doi: 10.1155/2018/8489709.
443. Poetter-Lang S, Stauffer K, Baltzer P, Tamandl D, Muin D, Bastati N, Halilbasic E, Hodge JC, Trauner M, Kazemi-Shirazi L, Ba-Ssalamah A. The Efficacy of MRI in the diagnostic workup of cystic fibrosis-associated liver disease: A clinical observational cohort study. ***Eur Radiol.*** 2019 Feb;29(2):1048-1058. doi: 10.1007/s00330-018-5650-5.
444. Tang Y, Blumenkamp KS, Fickert P, Trauner M, Teckman JH. NorUDCA promotes degradation of  $\alpha$ 1-antitrypsin mutant Z protein by inducing autophagy through AMPK/ULK1 pathway. ***PLoS One.*** 2018 Aug 1;13(8):e0200897. doi: 10.1371/journal.pone.0200897.
445. Strnad P, Buch S, Hamesch K, Fischer J, Rosendahl J, Schmelz R, Brueckner S, Brosch M, Heimes CV, Woditsch V, Scholten D, Nischalke HD, Janciauskiene S, Mandorfer M, Trauner M, Way MJ, McQuillin A, Reichert MC, Krawczyk M, Casper M, Lammert F, Braun F, von Schönfels W, Hinz S, Burmeister G, Hellerbrand C, Teufel A, Feldman A, Schattenberg JM, Bantel H, Pathil A, Demir M, Kluwe J, Boettler T, Ridinger M, Wodarz N, Soyka M, Rietschel M, Kiefer F, Weber T, Marhenke S, Vogel A, Hinrichsen H, Canbay A, Schlattjan M, Sosnowsky K, Sarrazin C, von Felden J, Geier A, Deltenre P, Sipos B, Schafmayer C, Nothnagel M, Aigner E, Datz C, Stickel F, Morgan MY, Hampe J, Berg T, Trautwein C. Heterozygous carriage of the alpha1-antitrypsin Pi\*Z variant increases the risk to develop liver cirrhosis. ***Gut.*** 2019 Jun;68(6):1099-1107. doi: 10.1136/gutjnl-2018-316228.
446. Königshofer P, Brusilovskaya K, Schwabl P, Podesser BK, Trauner M, Reiberger T. Invasive Hemodynamic Characterization of the Portal-hypertensive Syndrome in Cirrhotic Rats. ***J Vis Exp.*** 2018 Aug 1;(138):57261. doi: 10.3791/57261.
447. Gessl I, Waldmann E, Penz D, Majcher B, Dokladanska A, Hinterberger A, Szymanska A, Ferlitsch A, Trauner M, Ferlitsch M. Evaluation of adenomas per colonoscopy and adenomas per positive participant as new quality parameters in screening colonoscopy. ***Gastrointest Endosc.*** 2019 Mar;89(3):496-502. doi: 10.1016/j.gie.2018.08.013.
448. Bucsics T, Grasl B, Ferlitsch A, Schwabl P, Mandorfer M, Zinober K, Stern R, Chromy D, Scheiner B, Sieghart W, Peck-Radosavljevic M, Trauner M, Reiberger T. Point Shear Wave Elastography for Non-invasive Assessment of Liver Fibrosis in Patients

with Viral Hepatitis. *Ultrasound Med Biol*. 2018 Dec;44(12):2578-2586. doi: 10.1016/j.ultrasmedbio.2018.07.031.

449. Scheiner B, Steininger L, Semmler G, Unger LW, Schwabl P, Bucsics T, Paternostro R, Ferlitsch A, Trauner M, Reiberger T, Mandorfer M. Controlled attenuation parameter does not predict hepatic decompensation in patients with advanced chronic liver disease. *Liver Int*. 2019 Jan;39(1):127-135. doi: 10.1111/liv.13943.
450. Peter J, Fournier C, Durdevic M, Knoblich L, Keip B, Dejaco C, Trauner M, Moser G. A Microbial Signature of Psychological Distress in Irritable Bowel Syndrome. *Psychosom Med*. 2018 Oct;80(8):698-709. doi: 10.1097/PSY.0000000000000630.
451. Habib A, Chokr D, Wan J, Hegde P, Mabire M, Siebert M, Ribeiro-Parenti L, Le Gall M, Lettéron P, Pilard N, Mansouri A, Brouillet A, Tardelli M, Weiss E, Le Faouder P, Guillou H, Cravatt BF, Moreau R, Trauner M, Lotersztajn S. Inhibition of monoacylglycerol lipase, an anti-inflammatory and antifibrogenic strategy in the liver. *Gut*. 2019 Mar;68(3):522-532. doi: 10.1136/gutjnl-2018-316137.
452. Pfisterer N, Riedl F, Pachofszky T, Gschwantler M, König K, Schuster B, Mandorfer M, Gessl I, Illiasch C, Fuchs EM, Unger L, Dolak W, Maieron A, Kramer L, Madl C, Trauner M, Reiberger T. Outcomes after placement of a SX-ELLA oesophageal stent for refractory variceal bleeding-A national multicentre study. *Liver Int*. 2019 Feb;39(2):290-298. doi: 10.1111/liv.13971.
453. Paternostro R, Heinisch BB, Reiberger T, Mandorfer M, Bardach C, Lampichler K, Seeland B, Schwarzer R, Trauner M, Peck-Radosavljevic M, Ferlitsch A. Dysbalanced sex hormone status is an independent predictor of decompensation and mortality in patients with liver cirrhosis. *Hepatol Res*. 2019 Feb;49(2):201-211. doi: 10.1111/hepr.13253.
454. Nejabat M, Leisser A, Karanikas G, Wadsak W, Mitterhauser M, Mayerhöfer M, Kienbacher C, Trauner M, Hacker M, Haug AR. [<sup>11</sup>C]acetate PET as a tool for diagnosis of liver steatosis. *Abdom Radiol (NY)*. 2018 Nov;43(11):2963-2969. doi: 10.1007/s00261-018-1558-4.
455. Waldmann E, Penz D, Majcher B, Zagata J, Šinkovec H, Heinze G, Dokladanska A, Szymanska A, Trauner M, Ferlitsch A, Ferlitsch M. Impact of high-volume, intermediate-volume and low-volume bowel preparation on colonoscopy quality and patient satisfaction: An observational study. *United European Gastroenterol J*. 2019 Feb;7(1):114-124. doi: 10.1177/2050640618809842.
456. Drolz A, Horvatits T, Rutter K, Landahl F, Roedl K, Meersseman P, Wilmer A, Kluwe J, Lohse AW, Kluge S, Trauner M, Fuhrmann V. Lactate Improves Prediction of Short-Term Mortality in Critically Ill Patients With Cirrhosis: A Multinational Study. *Hepatology*. 2019 Jan;69(1):258-269. doi: 10.1002/hep.30151.
457. Eder M, Strassl R, Beinhardt S, Stättermayer AF, Kozbial K, Lagler H, Holzmann H, Trauner M, Hofer H. High seroprevalence of anti-Hepatitis E antibodies in Austrian patients with autoimmune hepatitis. *Liver Int*. 2019 Apr;39(4):640-645. doi: 10.1111/liv.14005.
458. Blokker BA, Maijo M, Echeandia M, Galduroz M, Patterson AM, Ten A, Philo M, Schungel R, Gutierrez-de Juan V, Halilbasic E, Fuchs C, Le Gall G, Milkiewicz M, Milkiewicz P, Banales JM, Rushbrook SM, Mato JM, Trauner M, Müller M, Martínez-

Chantar ML, Varela-Rey M, Beraza N. Fine-Tuning of Sirtuin 1 Expression Is Essential to Protect the Liver From Cholestatic Liver Disease. *Hepatology*. 2019 Feb;69(2):699-716. doi: 10.1002/hep.30275.

459. Gessl I, Waldmann E, Penz D, Majcher B, Dokladanska A, Hinterberger A, Szymanska A, Trauner M, Ferlitsch M. Resection rates and safety profile of cold vs. hot snare polypectomy in polyps sized 5-10 mm and 11-20 mm. *Dig Liver Dis*. 2019 Apr;51(4):536-541. doi: 10.1016/j.dld.2019.01.007.
460. Stift J, Semmler G, Walzel C, Mandorfer M, Schwarzer R, Schwabl P, Paternostro R, Scheiner B, Wöran K, Pinter M, Stättermayer AF, Trauner M, Peck-Radosavljevic M, Ferlitsch A, Reiberger T. Transjugular aspiration liver biopsy performed by hepatologists trained in HVPG measurements is safe and provides important diagnostic information. *Dig Liver Dis*. 2019 Aug;51(8):1144-1151. doi: 10.1016/j.dld.2019.01.020.
461. Younossi ZM, Stepanova M, Anstee QM, Lawitz EJ, Wai-Sun Wong V, Romero-Gomez M, Kersey K, Li G, Subramanian GM, Myers RP, Djedjos CS, Okanou T, Trauner M, Goodman Z, Harrison SA. Reduced Patient-Reported Outcome Scores Associate With Level of Fibrosis in Patients With Nonalcoholic Steatohepatitis. *Clin Gastroenterol Hepatol*. 2019 Nov;17(12):2552-2560.e10. doi: 10.1016/j.cgh.2019.02.024.
462. Winhofer Y, Wolf P, Fellingner P, Tura A, Hillebrand P, Staufer K, Trauner M, Jaksch P, Muraközy G, Kautzky-Willer A, Pacini G, Krebs M, Luger A, Kazemi-Shirazi L. Markedly delayed insulin secretion and a high rate of undetected overt diabetes characterize glucose metabolism in adult patients with cystic fibrosis after lung transplantation. *Endocr Pract*. 2019 Mar;25(3):254-262. doi: 10.4158/EP-2018-0461.
463. Chromy D, Mandorfer M, Bucsics T, Schwabl P, Scheiner B, Schmidbauer C, Aichelburg MC, Ferenci P, Trauner M, Peck-Radosavljevic M, Reiberger T. High efficacy of interferon-free therapy for acute hepatitis C in HIV-positive patients. *United European Gastroenterol J*. 2019 May;7(4):507-516. doi: 10.1177/2050640619835394.
464. Trauner M, Gulamhusein A, Hameed B, Caldwell S, Shiffman ML, Landis C, Eksteen B, Agarwal K, Muir A, Rushbrook S, Lu X, Xu J, Chuang JC, Billin AN, Li G, Chung C, Subramanian GM, Myers RP, Bowlus CL, Kowdley KV. The Nonsteroidal Farnesoid X Receptor Agonist Cilofexor (GS-9674) Improves Markers of Cholestasis and Liver Injury in Patients With Primary Sclerosing Cholangitis. *Hepatology*. 2019 Sep;70(3):788-801. doi: 10.1002/hep.30509.
465. Ferenci P, Pfeiffenberger J, Stättermayer AF, Stauber RE, Willheim C, Weiss KH, Munda-Steindl P, Trauner M, Schilsky M, Zoller H. HSD17B13 truncated variant is associated with a mild hepatic phenotype in Wilson's Disease. *JHEP Rep*. 2019 Mar 19;1(1):2-8. doi: 10.1016/j.jhepr.2019.02.007.
466. Scheiner B, Ulbrich G, Mandorfer M, Reiberger T, Müller C, Waneck F, Trauner M, Kölblinger C, Ferlitsch A, Sieghart W, Peck-Radosavljevic M, Pinter M. Short- and long-term effects of transarterial chemoembolization on portal hypertension in patients with hepatocellular carcinoma. *United European Gastroenterol J*. 2019 Jul;7(6):850-858. doi: 10.1177/2050640619840199.
467. Trauner M, Nevens F, Shiffman ML, Drenth JPH, Bowlus CL, Vargas V, Andreone P, Hirschfield GM, Pencek R, Malecha ES, MacConell L, Shapiro D. Long-term efficacy and safety of obeticholic acid for patients with primary biliary cholangitis: 3-year results

of an international open-label extension study. *Lancet Gastroenterol Hepatol*. 2019 Jun;4(6):445-453. doi: 10.1016/S2468-1253(19)30094-9.

468. Simbrunner B, Röthenbacher A, Haslacher H, Bauer D, Chromy D, Bucsics T, Schwabl P, Paternostro R, Scheiner B, Trauner M, Mandorfer M, Schwarzingler I, Reiberger T. Ascitic fluid polymorphic nuclear cell count impacts on outcome of cirrhotic patients with ascites. *United European Gastroenterol J*. 2019 Jun;7(5):651-661. doi: 10.1177/2050640619843000.
469. Scheiner B, Kirstein MM, Hucke F, Finkelmeier F, Schulze K, von Felden J, Koch S, Schwabl P, Hinrichs JB, Waneck F, Waidmann O, Reiberger T, Müller C, Sieghart W, Trauner M, Weinmann A, Wege H, Trojan J, Peck-Radosavljevic M, Vogel A, Pinter M. Programmed cell death protein-1 (PD-1)-targeted immunotherapy in advanced hepatocellular carcinoma: efficacy and safety data from an international multicentre real-world cohort. *Aliment Pharmacol Ther*. 2019 May;49(10):1323-1333. doi: 10.1111/apt.15245.
470. Chromy D, Mandorfer M, Bucsics T, Schwabl P, Bauer D, Scheiner B, Schmidbauer C, Lang GF, Szekeres T, Ferenci P, Trauner M, Reiberger T. Prevalence and Predictors of Hepatic Steatosis in Patients with HIV/HCV Coinfection and the Impact of HCV Eradication. *AIDS Patient Care STDS*. 2019 May;33(5):197-206. doi: 10.1089/apc.2018.0333.
471. Tardelli M, Bruschi FV, Claudel T, Fuchs CD, Auer N, Kunczer V, Stojakovic T, Scharnagl H, Habib A, Grabner GF, Zimmermann R, Lotersztajn S, Trauner M. Lack of monoacylglycerol lipase prevents hepatic steatosis by favoring lipid storage in adipose tissue and intestinal malabsorption. *J Lipid Res*. 2019 Jul;60(7):1284-1292. doi: 10.1194/jlr.M093369.
472. Orola MJ, Tizian C, Zhu C, Andersen L, Gülich AF, Alteneder M, Stojakovic T, Wiedermann U, Trauner M, Ellmeier W, Sakaguchi S. The zinc-finger transcription factor MAZR regulates iNKT cell subset differentiation. *Cell Mol Life Sci*. 2019 Nov;76(21):4391-4404. doi: 10.1007/s00018-019-03119-z.
473. Lynch KD, Chapman RW, Keshav S, Montano-Loza AJ, Mason AL, Kremer AE, Vetter M, de Krijger M, Ponsioen CY, Trivedi P, Hirschfield G, Schramm C, Liu CH, Bowlus CL, Estes DJ, Pratt D, Hedin C, Bergquist A, de Vries AC, van der Woude CJ, Yu L, Assis DN, Boyer J, Ytting H, Hallibasic E, Trauner M, Marschall HU, Daretti LM, Marzioni M, Yimam KK, Perin N, Floreani A, Beretta-Piccoli BT, Rogers JK; International Primary Sclerosing Cholangitis Study Group (IPSCSG), Levy C. Effects of Vedolizumab in Patients With Primary Sclerosing Cholangitis and Inflammatory Bowel Diseases. *Clin Gastroenterol Hepatol*. 2020 Jan;18(1):179-187.e6. doi: 10.1016/j.cgh.2019.05.013.
474. Hamesch K, Mandorfer M, Pereira VM, Moeller LS, Pons M, Dolman GE, Reichert MC, Schneider CV, Woditsch V, Voss J, Lindhauer C, Fromme M, Spivak I, Guldiken N, Zhou B, Arslanow A, Schaefer B, Zoller H, Aigner E, Reiberger T, Wetzel M, Siegmund B, Simões C, Gaspar R, Maia L, Costa D, Bento-Miranda M, van Helden J, Yagmur E, Bzdok D, Stolk J, Gleiber W, Knipel V, Windisch W, Mahadeva R, Bals R, Koczulla R, Barrecheguren M, Miravittles M, Janciauskiene S, Stickel F, Lammert F, Liberal R, Genesca J, Griffiths WJ, Trauner M, Krag A, Trautwein C, Strnad P; European Alpha1-Liver Study Group. Liver Fibrosis and Metabolic Alterations in Adults With alpha-1-antitrypsin Deficiency Caused by the Pi\*ZZ Mutation. *Gastroenterology*. 2019 Sep;157(3):705-719.e18. doi: 10.1053/j.gastro.2019.05.013.

475. Meischl T, Rasoul-Rockenschaub S, Györi G, Sieghart W, Reiberger T, Trauner M, Soliman T, Berlakovich G, Pinter M. C-reactive protein is an independent predictor for hepatocellular carcinoma recurrence after liver transplantation. *PLoS One*. 2019 May 29;14(5):e0216677. doi: 10.1371/journal.pone.0216677.
476. Semmler G, Simbrunner B, Scheiner B, Schwabl P, Paternostro R, Bucsics T, Stättermayer AF, Bauer D, Pinter M, Ferenci P, Trauner M, Mandorfer M, Reiberger T. Impact of farnesoid X receptor single nucleotide polymorphisms on hepatic decompensation and mortality in cirrhotic patients with portal hypertension. *J Gastroenterol Hepatol*. 2019 Dec;34(12):2164-2172. doi: 10.1111/jgh.14700.
477. Semmler G, Stift J, Scheiner B, Wöran K, Schwabl P, Paternostro R, Bucsics T, Stättermayer AF, Pinter M, Ferlitsch A, Trauner M, Reiberger T, Mandorfer M. Performance of Controlled Attenuation Parameter in Patients with Advanced Chronic Liver Disease and Portal Hypertension. *Dig Dis Sci*. 2019 Dec;64(12):3642-3651. doi: 10.1007/s10620-019-05702-7.
478. Al-Dury S, Wahlström A, Panzitt K, Thorell A, Ståhlman M, Trauner M, Fickert P, Bäckhed F, Fändriks L, Wagner M, Marschall HU. Obeticholic acid may increase the risk of gallstone formation in susceptible patients. *J Hepatol*. 2019 Nov;71(5):986-991. doi: 10.1016/j.jhep.2019.06.011.
479. Stauffer K, Halilbasic E, Spindelboeck W, Eilenberg M, Prager G, Stadlbauer V, Posch A, Munda P, Marculescu R, Obermayer-Pietsch B, Stift J, Lackner C, Trauner M, Stauber RE. Evaluation and comparison of six noninvasive tests for prediction of significant or advanced fibrosis in nonalcoholic fatty liver disease. *United European Gastroenterol J*. 2019 Oct;7(8):1113-1123. doi: 10.1177/2050640619865133.
480. Bruschi FV, Claudel T, Tardelli M, Starlinger P, Marra F, Trauner M. PNPLA3 I148M Variant Impairs Liver X Receptor Signaling and Cholesterol Homeostasis in Human Hepatic Stellate Cells. *Hepatol Commun*. 2019 Jul 15;3(9):1191-1204. doi: 10.1002/hep4.1395.
481. Traussnigg S, Schattenberg JM, Demir M, Wiegand J, Geier A, Teuber G, Hofmann WP, Kremer AE, Spreda F, Kluwe J, Petersen J, Boettler T, Rainer F, Halilbasic E, Greinwald R, Pröls M, Manns MP, Fickert P, Trauner M; Austrian/German NAFLD-norUDCA study group. Norursodeoxycholic acid versus placebo in the treatment of non-alcoholic fatty liver disease: a double-blind, randomised, placebo-controlled, phase 2 dose-finding trial. *Lancet Gastroenterol Hepatol*. 2019 Oct;4(10):781-793. doi: 10.1016/S2468-1253(19)30184-0.
482. Unger LW, Forstner B, Schneglberger S, Muckenhuber M, Eigenbauer E, Bauer D, Scheiner B, Mandorfer M, Trauner M, Reiberger T. Guideline-conform statin use reduces overall mortality in patients with compensated liver disease. *Sci Rep*. 2019 Aug 12;9(1):11674. doi: 10.1038/s41598-019-47943-6.
483. Anstee QM, Lawitz EJ, Alkhoury N, Wong VW, Romero-Gomez M, Okanoue T, Trauner M, Kersey K, Li G, Han L, Jia C, Wang L, Chen G, Subramanian GM, Myers RP, Djedjos CS, Kohli A, Bzowej N, Younes Z, Sarin S, Shiffman ML, Harrison SA, Afdhal NH, Goodman Z, Younossi ZM. Noninvasive Tests Accurately Identify Advanced Fibrosis due to NASH: Baseline Data From the STELLAR Trials. *Hepatology*. 2019 Nov;70(5):1521-1530. doi: 10.1002/hep.30842.

484. Reiter FP, Ye L, Bösch F, Wimmer R, Artmann R, Ziesch A, Kanitz V, Mayr D, Steib CJ, Trauner M, Regel I, Gerbes AL, Mayerle J, Hohenester S, de Toni EN, Denk G. Antifibrotic effects of hypocalcemic vitamin D analogs in murine and human hepatic stellate cells and in the CCl<sub>4</sub> mouse model. *Lab Invest*. 2019 Dec;99(12):1906-1917. doi: 10.1038/s41374-019-0310-1.
485. Unger LW, Forstner B, Schneglberger S, Muckenhuber M, Eigenbauer E, Scheiner B, Mandorfer M, Trauner M, Reiberger T. Patterns and prevalence of dyslipidemia in patients with different etiologies of chronic liver disease. *Wien Klin Wochenschr*. 2019 Sep;131(17-18):395-403. doi: 10.1007/s00508-019-01544-5.
486. Schwabl P, Köppel S, Königshofer P, Bucsics T, Trauner M, Reiberger T, Liebmann B. Detection of Various Microplastics in Human Stool: A Prospective Case Series. *Ann Intern Med*. 2019 Oct 1;171(7):453-457. doi: 10.7326/M19-0618.
487. Penz D, Ferlitsch A, Waldmann E, Irina G, Daniel P, Asaturi A, Hinterberger A, Majcher B, Szymanska A, Trauner M, Ferlitsch M. Impact of adenoma detection rate on detection of advanced adenomas and endoscopic adverse events in a study of over 200,000 screening colonoscopies. *Gastrointest Endosc*. 2020 Jan;91(1):135-141. doi: 10.1016/j.gie.2019.08.038.
488. Paternostro R, Lampichler K, Bardach C, Asenbaum U, Landler C, Bauer D, Mandorfer M, Schwarzer R, Trauner M, Reiberger T, Ferlitsch A. The value of different CT-based methods for diagnosing low muscle mass and predicting mortality in patients with cirrhosis. *Liver Int*. 2019 Dec;39(12):2374-2385. doi: 10.1111/liv.14217.
489. Scheiner B, Semmler G, Maurer F, Schwabl P, Bucsics TA, Paternostro R, Bauer D, Simbrunner B, Trauner M, Mandorfer M, Reiberger T. Prevalence of and risk factors for anaemia in patients with advanced chronic liver disease. *Liver Int*. 2020 Jan;40(1):194-204. doi: 10.1111/liv.14229.
490. Terziroli Beretta-Piccoli B, Mieli-Vergani G, Vergani D, Vierling JM, Adams D, Alpini G, Banales JM, Beuers U, Björnsson E, Bowlus C, Carbone M, Chazouillères O, Dalekos G, De Gottardi A, Harada K, Hirschfield G, Invernizzi P, Jones D, Krawitt E, Lanzavecchia A, Lian ZX, Ma X, Manns M, Mavilio D, Quigley EM, Sallusto F, Shimoda S, Strazzabosco M, Swain M, Tanaka A, Trauner M, Tsuneyama K, Zigmond E, Gershwin ME. The challenges of primary biliary cholangitis: What is new and what needs to be done. *J Autoimmun*. 2019 Dec;105:102328. doi: 10.1016/j.jaut.2019.102328. Review
491. Mandorfer M, Kozbial K, Schwabl P, Chromy D, Semmler G, Stättermayer AF, Pinter M, Hernández-Gea V, Fritzer-Szekeres M, Steindl-Munda P, Trauner M, Peck-Radosavljevic M, García-Pagán JC, Ferenci P, Reiberger T. Changes in Hepatic Venous Pressure Gradient Predict Hepatic Decompensation in Patients Who Achieved Sustained Virologic Response to Interferon-Free Therapy. *Hepatology*. 2020 Mar;71(3):1023-1036. doi: 10.1002/hep.30885.
492. Simbrunner B, Mandorfer M, Trauner M, Reiberger T. Gut-liver axis signaling in portal hypertension. *World J Gastroenterol*. 2019 Oct 21;25(39):5897-5917. doi: 10.3748/wjg.v25.i39.5897. Review
493. Semmler G, Scheiner B, Schwabl P, Bucsics T, Paternostro R, Chromy D, Stättermayer AF, Trauner M, Mandorfer M, Ferlitsch A, Reiberger T. The impact of hepatic steatosis



on portal hypertension. **PLoS One**. 2019 Nov 6;14(11):e0224506. doi: 10.1371/journal.pone.0224506.

494. Morstein J, Trads JB, Hinnah K, Willems S, Barber DM, Trauner M, Merk D, Trauner D. Optical control of the nuclear bile acid receptor FXR with a photohormone. **Chem Sci**. 2019 Nov 19;11(2):429-434. doi: 10.1039/c9sc02911g.
495. Lercher A, Bhattacharya A, Popa AM, Caldera M, Schlapansky MF, Baazim H, Agerer B, Gürtl B, Kosack L, Májek P, Brunner JS, Vitko D, Pinter T, Genger JW, Orlova A, Pikor N, Reil D, Ozsvár-Kozma M, Kalinke U, Ludewig B, Moriggl R, Bennett KL, Menche J, Cheng PN, Schabbauer G, Trauner M, Klavins K, Bergthaler A. Type I Interferon Signaling Disrupts the Hepatic Urea Cycle and Alters Systemic Metabolism to Suppress T Cell Function. **Immunity**. 2019 Dec 17;51(6):1074-1087.e9. doi: 10.1016/j.immuni.2019.10.014.
496. Gäbler G, Coenen M, Fohringer K, Trauner M, Stamm TA. Towards a nationwide implementation of a standardized nutrition and dietetics terminology in clinical practice: a pre-implementation focus group study including a pretest and using the consolidated framework for implementation research. **BMC Health Serv Res**. 2019 Nov 29;19(1):920. doi: 10.1186/s12913-019-4600-5.
497. Horvatits T, Drolz A, Trauner M, Fuhrmann V. Liver Injury and Failure in Critical Illness. **Hepatology**. 2019 Dec;70(6):2204-2215. doi: 10.1002/hep.30824. Review
498. Scheiner B, Stättermayer AF, Schwabl P, Bucsecs T, Paternostro R, Bauer D, Simbrunner B, Schmidt R, Marculescu R, Ferlitsch A, Peck-Radosavljevic M, Pinter M, Trauner M, Reiberger T, Ferenci P, Mandorfer M. Impact of HSD17B13 rs72613567 genotype on hepatic decompensation and mortality in patients with portal hypertension. **Liver Int**. 2020 Feb;40(2):393-404. doi: 10.1111/liv.14304.
499. Younossi ZM, Ratziu V, Loomba R, Rinella M, Anstee QM, Goodman Z, Bedossa P, Geier A, Beckebaum S, Newsome PN, Sheridan D, Sheikh MY, Trotter J, Knapple W, Lawitz E, Abdelmalek MF, Kowdley KV, Montano-Loza AJ, Boursier J, Mathurin P, Bugianesi E, Mazzella G, Oliveira A, Cortez-Pinto H, Graupera I, Orr D, Gluud LL, Dufour JF, Shapiro D, Campagna J, Zaru L, MacConell L, Shringarpure R, Harrison S, Sanyal AJ; REGENERATE Study Investigators. Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial. **Lancet**. 2019 Dec 14;394(10215):2184-2196. doi: 10.1016/S0140-6736(19)33041-7. Banner-Co-Authorship listed in Pubmed
500. Trauner M, Gindin Y, Jiang Z, Chung C, Subramanian GM, Myers RP, Gulamhusein A, Kowdley KV, Levy C, Goodman Z, Manns MP, Muir AJ, Bowlus CL. Methylation signatures in peripheral blood are associated with marked age acceleration and disease progression in patients with primary sclerosing cholangitis. **JHEP Rep**. 2019 Dec 5;2(1):100060. doi: 10.1016/j.jhepr.2019.11.004.
501. Schwarzer R, Reiberger T, Mandorfer M, Kivaranovic D, Hametner S, Hametner S, Paternostro R, Scheiner B, Schneeweiss-Friedl J, Trauner M, Schoefl R, Maieron A. The von Willebrand Factor antigen to platelet ratio (VITRO) score predicts hepatic decompensation and mortality in cirrhosis. **J Gastroenterol**. 2020 May;55(5):533-542. doi: 10.1007/s00535-019-01656-9.
502. Unger LW, Forstner B, Muckenhuber M, Scheuba K, Eigenbauer E, Scheiner B, Pfisterer N, Paternostro R, Trauner M, Mandorfer M, Reiberger T. Hepatic Steatosis in

- Lean Patients: Risk Factors and Impact on Mortality. *Dig Dis Sci*. 2020 Sep;65(9):2712-2718. doi: 10.1007/s10620-019-06000-y.
503. Tardelli M, Bruschi FV, Fuchs CD, Claudel T, Auer N, Kunczer V, Baumgartner M, A H O Ronda O, Verkade HJ, Stojakovic T, Scharnagl H, Habib A, Zimmermann R, Lotersztajn S, Trauner M. Monoacylglycerol Lipase Inhibition Protects From Liver Injury in Mouse Models of Sclerosing Cholangitis. *Hepatology*. 2020 May;71(5):1750-1765. doi: 10.1002/hep.30929.
504. Simbrunner B, Beer A, Wöran K, Schmitz F, Primas C, Wewalka M, Pinter M, Dolak W, Scheiner B, Puespoek A, Trauner M, Oberhuber G, Mandorfer M, Reiberger T. Portal hypertensive gastropathy is associated with iron deficiency anemia. *Wien Klin Wochenschr*. 2020 Jan;132(1-2):1-11. doi: 10.1007/s00508-019-01593-w.
505. Semmler G, Wöran K, Scheiner B, Unger LW, Paternostro R, Stift J, Schwabl P, Bucsics T, Bauer D, Simbrunner B, Stättermayer AF, Pinter M, Trauner M, Reiberger T, Mandorfer M. Novel reliability criteria for controlled attenuation parameter assessments for non-invasive evaluation of hepatic steatosis. *United European Gastroenterol J*. 2020 Apr;8(3):321-331. doi: 10.1177/2050640619900820.
506. Paternostro R, Pfeiffenberger J, Ferenci P, Stättermayer AF, Stauber RE, Wrba F, Longerich T, Lackner K, Trauner M, Ferlitsch A, Reiberger T, Weiss KH. Non-invasive diagnosis of cirrhosis and long-term disease monitoring by transient elastography in patients with Wilson disease. *Liver Int*. 2020 Apr;40(4):894-904. doi: 10.1111/liv.14368.
507. Paternostro R, Kapzan L, Mandorfer M, Schwarzer R, Benedikt S, Viveiros A, Bauer D, Ferlitsch M, Zoller H, Trauner M, Ferlitsch A. Anemia and iron deficiency in compensated and decompensated cirrhosis: Prevalence and impact on clinical outcomes. *J Gastroenterol Hepatol*. 2020 2020 Sep;35(9):1619-1627. . doi: 10.1111/jgh.14988.
508. Sladky VC, Knapp K, Soratroi C, Heppke J, Eichin F, Rocamora-Reverte L, Szabo TG, Bongiovanni L, Westendorp B, Moreno E, van Liere EA, Bakker B, Spierings DCJ, Wardenaar R, Pereyra D, Starlinger P, Schultze S, Trauner M, Stojakovic T, Scharnagl H, Fava LL, Fojer F, de Bruin A, Villunger A. E2F-Family Members Engage the PIDDosome to Limit Hepatocyte Ploidy in Liver Development and Regeneration. *Dev Cell*. 2020 Feb 10;52(3):335-349.e7. doi: 10.1016/j.devcel.2019.12.016.
509. Panzitt K, Jungwirth E, Krones E, Lee JM, Pollheimer M, Thallinger GG, Kolb-Lenz D, Xiao R, Thorell A, Trauner M, Fickert P, Marschall HU, Moore DD, Wagner M. FXR-dependent Rubicon induction impairs autophagy in models of human cholestasis. *J Hepatol*. 2020 Jun;72(6):1122-1131. doi: 10.1016/j.jhep.2020.01.014.
510. Smajis S, Gajdošik M, Pflieger L, Traussnigg S, Kienbacher C, Halilbasic E, Ranzenberger-Haider T, Stangl A, Beiglböck H, Wolf P, Lamp T, Hofer A, Gastaldelli A, Barbieri C, Luger A, Trattinig S, Kautzky-Willer A, Krššák M, Trauner M, Krebs M. Metabolic effects of a prolonged, very-high-dose dietary fructose challenge in healthy subjects. *Am J Clin Nutr*. 2020 Feb 1;111(2):369-377. doi: 10.1093/ajcn/nqz271.
511. Bruschi FV, Tardelli M, Herac M, Claudel T, Trauner M. Metabolic regulation of hepatic PNPLA3 expression and severity of liver fibrosis in patients with NASH. *Liver Int*. 2020 May;40(5):1098-1110. doi: 10.1111/liv.14402.

512. Sydor S, Best J, Messerschmidt I, Manka P, Vilchez-Vargas R, Brodesser S, Lucas C, Wegehaupt A, Wenning C, Aßmuth S, Hohenester S, Link A, Faber KN, Moshage H, Cubero FJ, Friedman SL, Gerken G, Trauner M, Canbay A, Bechmann LP. Altered Microbiota Diversity and Bile Acid Signaling in Cirrhotic and Noncirrhotic NASH-HCC. *Clin Transl Gastroenterol.* 2020 Mar;11(3):e00131. doi: 10.14309/ctg.000000000000131.
513. Schmidbauer C, Chromy D, Schmidbauer V, Bauer D, Apata M, Nguyen D, Mandorfer M, Simbrunner B, Rieger A, Mayer F, Schmidt R, Holzmann H, Trauner M, Gschwantler M, Reiberger T. Epidemiological trends in HCV transmission and prevalence in the Viennese HIV+ population. *Liver Int.* 2020 Apr;40(4):787-796. doi: 10.1111/liv.14399.
514. Scheiner B, Northup PG, Gruber AB, Semmler G, Leitner G, Quehenberger P, Thaler J, Ay C, Trauner M, Reiberger T, Lisman T, Mandorfer M. The impact of ABO blood type on the prevalence of portal vein thrombosis in patients with advanced chronic liver disease. *Liver Int.* 2020 Jun;40(6):1415-1426. doi: 10.1111/liv.14404.
515. Harrison SA, Wong VW, Okanoue T, Bzowej N, Vuppalanchi R, Younes Z, Kohli A, Sarin S, Caldwell SH, Alkhoury N, Shiffman ML, Camargo M, Li G, Kersey K, Jia C, Zhu Y, Djedjos CS, Subramanian GM, Myers RP, Gunn N, Sheikh A, Anstee QM, Romero-Gomez M, Trauner M, Goodman Z, Lawitz EJ, Younossi Z; STELLAR-3 and STELLAR-4 Investigators. Selonsertib for patients with bridging fibrosis or compensated cirrhosis due to NASH: Results from randomized phase III STELLAR trials. *J Hepatol.* 2020 Jul;73(1):26-39. doi: 10.1016/j.jhep.2020.02.027.
516. Halilbasic E, Fuerst E, Heiden D, Japtok L, Diesner SC, Trauner M, Kulu A, Jaksch P, Hoetzenecker K, Kleuser B, Kazemi-Shirazi L, Untersmayr E. Plasma Levels of the Bioactive Sphingolipid Metabolite S1P in Adult Cystic Fibrosis Patients: Potential Target for Immunonutrition? *Nutrients.* 2020 Mar 14;12(3):765. doi: 10.3390/nu12030765.
517. Fuchs CD, Krivanec S, Steinacher D, Mlitz V, Wahlström A, Stahlman M, Claudel T, Scharnagl H, Stojakovic T, Marschall HU, Trauner M. Absence of Bsep/Abcb11 attenuates MCD diet-induced hepatic steatosis but aggravates inflammation in mice. *Liver Int.* 2020 Jun;40(6):1366-1377. doi: 10.1111/liv.14423.
518. Tardelli M, Bruschi FV, Trauner M. The role of metabolic lipases in the pathogenesis and management of liver disease. *Hepatology.* 2020 Sep;72(3):1117-1126. doi: 10.1002/hep.31250.
519. Hainberger D, Stolz V, Zhu C, Schuster M, Müller L, Hamminger P, Rica R, Waltenberger D, Alteneder M, Krausgruber T, Hladik A, Knapp S, Bock C, Trauner M, Farrar MA, Ellmeier W. NCOR1 Orchestrates Transcriptional Landscapes and Effector Functions of CD4<sup>+</sup>T Cells. *Front Immunol.* 2020 Apr 3;11:579. doi: 10.3389/fimmu.2020.00579.
520. Trauner M, Chung C, Myers RP, Kowdley KV. Reply to HEP-20-0140 Letter: Could Butyrate Be Incorporated With Farnesoid X Receptor Agonist Cilofexor to Enhance Primary Sclerosing Cholangitis Treatment? *Hepatology.* 2020 Oct;72(4):1497-1498. doi: 10.1002/hep.31269. Letter
521. Györi GP, Pereyra D, Rumpf B, Hackl H, Köditz C, Ortmayr G, Reiberger T, Trauner M, Berlakovich GA, Starlinger P. The von Willebrand Factor Facilitates Model for End-

Stage Liver Disease-Independent Risk Stratification on the Waiting List for Liver Transplantation. *Hepatology*. 2020 Aug;72(2):584-594. doi: 10.1002/hep.31047.

522. Wagner C, Hois V, Pajed L, Pusch LM, Wolinski H, Trauner M, Zimmermann R, Taschler U, Lass A. Lysosomal acid lipase is the major acid retinyl ester hydrolase in cultured human hepatic stellate cells but not essential for retinyl ester degradation. *Biochim Biophys Acta Mol Cell Biol Lipids*. 2020 Aug;1865(8):158730. doi: 10.1016/j.bbali.2020.158730.
523. Schneider CV, Hamesch K, Gross A, Mandorfer M, Moeller LS, Pereira V, Pons M, Kuca P, Reichert MC, Benini F, Burbaum B, Voss J, Gutberlet M, Woditsch V, Lindhauer C, Fromme M, Kümpers J, Bewersdorf L, Schaefer B, Eslam M, Bals R, Janciauskiene S, Carvão J, Neureiter D, Zhou B, Wöran K, Bantel H, Geier A, Dirrachs T, Stickel F, Teumer A, Verbeek J, Nevens F, Govaere O, Krawczyk M, Roskams T, Haybaeck J, Lurje G, Chorostowska-Wynimko J, Genesca J, Reiberger T, Lammert F, Krag A, George J, Anstee QM, Trauner M, Datz C, Gaisa NT, Denk H, Trautwein C, Aigner E, Strnad P; European Alpha-1 Liver Study Group. Liver Phenotypes of European Adults Heterozygous or Homozygous for Pi\*Z Variant of AAT (Pi\*MZ vs Pi\*ZZ genotype) and Noncarriers. *Gastroenterology*. 2020 Aug;159(2):534-548.e11. doi: 10.1053/j.gastro.2020.04.058.
524. Stättermayer AF, Halilbasic E, Wrba F, Ferenci P, Trauner M. Variants in ABCB4 (MDR3) across the spectrum of cholestatic liver diseases in adults. *J Hepatol*. 2020 Sep;73(3):651-663. doi: 10.1016/j.jhep.2020.04.036. Review
525. Lax SF, Skok K, Zechner P, Kessler HH, Kaufmann N, Koelblinger C, Vander K, Bargfrieder U, Trauner M. Pulmonary Arterial Thrombosis in COVID-19 With Fatal Outcome : Results From a Prospective, Single-Center, Clinicopathologic Case Series. *Ann Intern Med*. 2020 Sep 1;173(5):350-361. doi: 10.7326/M20-2566.
526. Simbrunner B, Marculescu R, Scheiner B, Schwabl P, Bucsecs T, Stadlmann A, Bauer DJM, Paternostro R, Eigenbauer E, Pinter M, Stättermayer AF, Trauner M, Mandorfer M, Reiberger T. Non-invasive detection of portal hypertension by enhanced liver fibrosis score in patients with different aetiologies of advanced chronic liver disease. *Liver Int*. 2020 Jul;40(7):1713-1724. doi: 10.1111/liv.14498.
527. Burisch J, Eigner W, Schreiber S, Aletaha D, Weninger W, Trauner M, Reinisch W, Narula N. Risk for development of inflammatory bowel disease under inhibition of interleukin 17: A systematic review and meta-analysis. *PLoS One*. 2020 May 27;15(5):e0233781. doi: 10.1371/journal.pone.0233781.
528. Trauner M. Effective medical treatments for PSC needed ASAP - is AESOP the answer? *J Hepatol*. 2020 Jul;73(1):12-14. doi: 10.1016/j.jhep.2020.05.009. Editorial
529. Nardo AD, Grün NG, Zeyda M, Dumanic M, Oberhuber G, Rivelles E, Helbich TH, Markgraf DF, Roden M, Claudel T, Trauner M, Stulnig TM. Impact of osteopontin on the development of non-alcoholic liver disease and related hepatocellular carcinoma. *Liver Int*. 2020 Jul;40(7):1620-1633. doi: 10.1111/liv.14464.
530. Gajdošík M, Chmelík M, Halilbasic E, Pflieger L, Klepochová R, Trauner M, Trattinig S, Krššák M. In Vivo <sup>1</sup>H MR Spectroscopy of Biliary Components of Human Gallbladder at 7T. *J Magn Reson Imaging*. 2021 Jan;53(1):98-107. doi: 10.1002/jmri.27207.

531. Reiberger T, Schwabl P, Trauner M, Peck-Radosavljevic M, Mandorfer M. Measurement of the Hepatic Venous Pressure Gradient and Transjugular Liver Biopsy. **J Vis Exp**. 2020 Jun 18;(160). doi: 10.3791/58819.
532. Semmler G, Binter T, Kozbial K, Schwabl P, Hametner-Schreil S, Zanetto A, Gavasso S, Chromy D, Bauer DJM, Simbrunner B, Scheiner B, Bucsics T, Stättermayer AF, Pinter M, Steindl-Munda P, Schöfl R, Russo FP, Simioni P, Trauner M, Ferenci P, Reiberger T, Mandorfer M. Non-invasive risk stratification after HCV-eradication in patients with advanced chronic liver disease. **Hepatology**. 2021 Apr;73(4):1275-1289. doi: 10.1002/hep.31462
533. Meischl T, Rasoul-Rockenschaub S, Györi G, Scheiner B, Trauner M, Soliman T, Berlakovich G, Pinter M. Alpha-fetoprotein-adjusted-to-HCC-size criteria are associated with favourable survival after liver transplantation for hepatocellular carcinoma. **United European Gastroenterol J**. 2021 Mar;9(2):209-219. doi: 10.1177/2050640620948665.
534. Gindin Y, Chung C, Jiang Z, Zhou JZ, Xu J, Billin A, Myers RP, Goodman Z, Landi A, Houghton M, Green RM, Levy C, Kowdley KV, Bowlus CL, Muir AJ, Trauner M. A Fibrosis-Independent Hepatic Transcriptomic Signature Identifies Novel Drivers of Disease Progression in Primary Sclerosing Cholangitis. **Hepatology**. 2021 Mar;73(3):1105-1116. doi: 10.1002/hep.31488.
535. Skok K, Stelzl E, Trauner M, Kessler HH, Lax SF. Post-mortem viral dynamics and tropism in COVID-19 patients in correlation with organ damage. **Virchows Arch**. 2021 Feb;478(2):343-353. doi: 10.1007/s00428-020-02903-8.
536. Beer L, Bastati N, Ba-Ssalamah A, Pötter-Lang S, Lampichler K, Bican Y, Lauber D, Hodge J, Binter T, Pomej K, Simbrunner B, Semmler G, Trauner M, Mandorfer M, Reiberger T. MRI-defined sarcopenia predicts mortality in patients with chronic liver disease. **Liver Int**. 2020 Nov;40(11):2797-2807. doi: 10.1111/liv.14648.
537. Lax SF, Skok K, Trauner M; Pulmonary arterial thrombosis as an important complication of COVID-19 pulmonary disease: letter to the editor. **Virchows Arch**. 2020 Sep;477(3):467-468. doi: 10.1007/s00428-020-02896-4. Letter
538. Trauner M. EASL Recognition Award Recipient 2020: Prof. James L. Boyer. **J Hepatol**. 2020 Sep;73(3):487-489. doi: 10.1016/j.jhep.2020.03.001. Editorial
539. Brusilovskaya K, Königshofer P, Lampach D, Szodl A, Supper P, Bauer D, Beer A, Stift J, Timelthaler G, Oberhuber G, Podesser BK, Seif M, Zinober K, Rohr-Udilova N, Trauner M, Reiberger T, Schwabl P. Soluble guanylyl cyclase stimulation and phosphodiesterase-5 inhibition improve portal hypertension and reduce liver fibrosis in bile duct-ligated rats. **United European Gastroenterol J**. 2020 Dec;8(10):1174-1185. doi: 10.1177/2050640620944140.
540. Lax SF, Skok K, Zechner PM, Trauner M. Pulmonary Arterial Thrombosis in COVID-19 With Fatal Outcome. **Ann Intern Med**. 2021 Jan;174(1):139-140. doi: 10.7326/L20-1276.
541. Schwabl P, Hambruch E, Budas GR, Supper P, Burnet M, Liles JT, Birkel M, Brusilovskaya K, Königshofer P, Peck-Radosavljevic M, Watkins WJ, Trauner M, Breckenridge DG, Kremoser C, Reiberger T. The Non-Steroidal FXR Agonist Cilofexor

Improves Portal Hypertension and Reduces Hepatic Fibrosis in a Rat NASH Model. **Biomedicines**. 2021 Jan 9;9(1):60. doi: 10.3390/biomedicines9010060.

542. Steininger L, Chromy D, Bauer D, Simbrunner B, Binter T, Schwabl P, Schmidbauer C, Trauner M, Gschwantler M, Mandorfer M, Reiberger T. Direct patient-physician communication via a hepatitis C hotline facilitates treatment initiation in patients with poor adherence. **Wien Klin Wochenschr**. 2020 Dec 22. doi: 10.1007/s00508-020-01790-y.
543. Younossi ZM, Anstee QM, Wai-Sun Wong V, Trauner M, Lawitz EJ, Harrison SA, Camargo M, Kersey K, Subramanian GM, Myers RP, Stepanova M. The Association of Histologic and Noninvasive Tests With Adverse Clinical and Patient-Reported Outcomes in Patients With Advanced Fibrosis Due to Nonalcoholic Steatohepatitis. **Gastroenterology**. 2020 Dec 8:S0016-5085(20)35529-3. doi: 10.1053/j.gastro.2020.12.003.
544. Paternostro R, Bardach C, Hofer BS, Scheiner B, Schwabl P, Asenbaum U, Ba-Ssalamah A, Scharitzer M, Bucscis T, Simbrunner B, Bauer D, Trauner M, Mandorfer M, Reiberger T, Lampichler K. Prognostic impact of sarcopenia in cirrhotic patients stratified by different severity of portal hypertension. **Liver Int**. 2020 Dec 8. doi: 10.1111/liv.14758.
545. Simbrunner B, Semmler G, Stadlmann A, Scheiner B, Schwabl P, Paternostro R, Bucscis T, Bauer D, Eigenbauer E, Pinter M, Stättermayer AF, Quehenberger P, Marculescu R, Trauner M, Mandorfer M, Reiberger T. Vitamin A levels reflect disease severity and portal hypertension in patients with cirrhosis. **Hepatol Int**. 2020 Dec;14(6):1093-1103. doi: 10.1007/s12072-020-10112-3.
546. Skok K, Vander K, Setaffy L, Kessler HH, Aberle S, Bargfrieder U, Trauner M, Lax SF. COVID-19 autopsies: Procedure, technical aspects and cause of fatal course. Experiences from a single-center. **Pathol Res Pract**. 2021 Jan;217:153305. doi: 10.1016/j.prp.2020.153305.
547. Wöran K, Semmler G, Jachs M, Simbrunner B, Maria Bauer DJ, Binter T, Pomej K, Stättermayer AF, Schwabl P, Bucscis T, Paternostro R, Lampichler K, Pinter M, Trauner M, Mandorfer M, Stift J, Reiberger T, Scheiner B. Clinical Course of Porto-Sinusoidal Vascular Disease Is Distinct From Idiopathic Noncirrhotic Portal Hypertension. **Clin Gastroenterol Hepatol**. 2020 Dec 3:S1542-3565(20)31629-3. doi: 10.1016/j.cgh.2020.11.039.
548. Pfisterer N, Schmidbauer C, Riedl F, Maieron A, Stadlbauer V, Hennlich B, Schwarzer R, Puespoek A, Bucscis T, Effenberger M, Bota S, Gschwantler M, Peck-Radosavljevic M, Mandorfer M, Madl C, Trauner M, Reiberger T. Perceptions on the management of varices and on the use of albumin in patients with cirrhosis among GI specialists in Austria. **Wien Klin Wochenschr**. 2020 Dec 3. doi: 10.1007/s00508-020-01769-9.
549. Bruschi FV, Tardelli M, Einwallner E, Claudel T, Trauner M. PNPLA3 I148M Up-Regulates Hedgehog and Yap Signaling in Human Hepatic Stellate Cells. **Int J Mol Sci**. 2020 Nov 18;21(22):8711. doi: 10.3390/ijms21228711.
550. Jachs M, Hartl L, Schaufler D, Desbalmes C, Simbrunner B, Eigenbauer E, Bauer DJM, Paternostro R, Schwabl P, Scheiner B, Bucscis T, Stättermayer AF, Pinter M, Trauner M, Mandorfer M, Reiberger T. Amelioration of systemic inflammation in advanced

chronic liver disease upon beta-blocker therapy translates into improved clinical outcomes. *Gut*. 2020 Nov 16;gutjnl-2020-322712. doi: 10.1136/gutjnl-2020-322712.

551. Sarrazin C, Zimmermann T, Berg T, Hinrichsen H, Mauss S, Wedemeyer H, Zeuzem S; Deutsche Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS); Deutsche Gesellschaft für Pathologie e.V. (DGP) und Bundesverband Deutscher Pathologen (BDP); Deutsche Leberstiftung; Gesellschaft für Virologie e.V. (GfV); Gesellschaft für Pädiatrische Gastroenterologie und Ernährung (GPGE); Österreichische Gesellschaft für Gastroenterologie und Hepatologie (ÖGGH); Schweizerische Gesellschaft für Gastroenterologie (SGG); Deutsche Transplantationsgesellschaft e.V. (DTG); Deutsche Leberhilfe e.V.; Deutsche Gesellschaft für Infektiologie e.V. (DGI); Deutsche Gesellschaft für Suchtmedizin e.V. (DGS); Deutsche AIDS-Gesellschaft e.V. (DAIG); Deutsche Arbeitsgemeinschaft niedergelassener Ärzte für die Versorgung HIV-Infizierter (DAGNÄ); Robert Koch-Institut (RKI); Collaborators: Prophylaxe, Diagnostik und Therapie der Hepatitis-C-Virus(HCV)-Infektion. *Z Gastroenterol*. 2020 Nov;58(11):1110-1131. doi: 10.1055/a-1226-0241.
552. Nardo AD, Schneeweiss-Gleixner M, Bakail M, Dixon ED, Lax SF, Trauner M. Pathophysiological mechanisms of liver injury in COVID-19. *Liver Int*. 2021 Jan;41(1):20-32. doi: 10.1111/liv.14730.
553. Kerschbaumer A, Smolen JS, Nash P, Doerner T, Dougados M, Fleischmann R, Geissler K, McInnes IB, Takeuchi T, Trauner M, Winthrop K, de Wit M, Boehncke WH, Falzon L, van der Heijde D. Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: a systematic literature research. *RMD Open*. 2020 Nov;6(3):e001374. doi: 10.1136/rmdopen-2020-001374.
554. Younossi ZM, Wong VW, Anstee QM, Romero-Gomez M, Trauner MH, Harrison SA, Lawitz EJ, Okanoue T, Camargo M, Kersey K, Myers RP, Goodman Z, Stepanova M. Fatigue and Pruritus in Patients with Advanced Fibrosis Due to Nonalcoholic Steatohepatitis: The Impact on Patient-Reported Outcomes. *Hepatol Commun*. 2020 Aug 28;4(11):1637-1650. doi: 10.1002/hep4.1581.
555. Nash P, Kerschbaumer A, Dörner T, Dougados M, Fleischmann RM, Geissler K, McInnes I, Pope JE, van der Heijde D, Stoffer-Marx M, Takeuchi T, Trauner M, Winthrop KL, de Wit M, Aletaha D, Baraliakos X, Boehncke WH, Emery P, Isaacs JD, Kremer J, Lee EB, Maksymowych WP, Voshaar M, Tam LS, Tanaka Y, van den Bosch F, Westhovens R, Xavier R, Smolen JS. Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: a consensus statement. *Ann Rheum Dis*. 2021 Jan;80(1):71-87. doi: 10.1136/annrheumdis-2020-218398.
556. Costa D, Simbrunner B, Jachs M, Hartl L, Bauer D, Paternostro R, Schwabl P, Scheiner B, Stättermayer AF, Pinter M, Trauner M, Mandorfer M, Reiberger T. Systemic inflammation increases across distinct stages of advanced chronic liver disease and correlates with decompensation and mortality. *J Hepatol*. 2020 Oct 16:S0168-8278(20)33684-9. doi: 10.1016/j.jhep.2020.10.004.
557. Pomej K, Scheiner B, Park D, Bauer D, Balcar L, Meischl T, Mandorfer M, Reiberger T, Müller C, Trauner M, Pinter M. Vascular Complications in Patients with Hepatocellular Carcinoma Treated with Sorafenib. *Cancers* (Basel). 2020 Oct 13;12(10):2961. doi: 10.3390/cancers12102961.

558. Paternostro R, Traussnigg S, Staufer K, Mandorfer M, Halilbasic E, Lagler H, Stift J, Wrba F, Munda P, Trauner M. Prevalence of anti-Hepatitis E antibodies and impact on disease severity in non-alcoholic fatty liver disease. *Hepatol Res*. 2021 Jan;51(1):69-79. doi: 10.1111/hepr.13581
559. Simbrunner B, Stadlmann A, Schwabl P, Paternostro R, Bauer DJM, Bucsecs T, Scheiner B, Lampichler K, Wöran K, Beer A, Eigenbauer E, Pinter M, Stättermayer AF, Marculescu R, Szekeres T, Trauner M, Mandorfer M, Reiberger T. Placental growth factor levels neither reflect severity of portal hypertension nor portal-hypertensive gastropathy in patients with advanced chronic liver disease. *Dig Liver Dis*. 2020 Oct 5:S1590-8658(20)30471-0. doi: 10.1016/j.dld.2020.09.006.
560. Waldmann E, Penz D, Šinkovec H, Heinze G, Rinner C, Jiricka L, Majcher B, Hinterberger A, Trauner M, Ferlitsch M. Interval cancer after colonoscopy in the Austrian National Screening Programme: influence of physician and patient factors. *Gut*. 2020 Oct 6:gutjnl-2019-319427. doi: 10.1136/gutjnl-2019-319427.
561. Bauer D, Farthofer A, Chromy D, Simbrunner B, Steininger L, Schmidbauer C, Binter T, Trauner M, Mandorfer M, Schmidt R, Mayer F, Holzmann H, Strassl R, Reiberger T. Recent outbreaks of severe hepatitis A virus infections in Vienna. *Eur J Clin Microbiol Infect Dis*. 2021 Feb;40(2):335-344. doi: 10.1007/s10096-020-04028-x.
562. Traussnigg S, Halilbasic E, Hofer H, Munda P, Stojakovic T, Fauler G, Kashofer K, Krssak M, Wolzt M, Trauner M. Open-label phase II study evaluating safety and efficacy of the non-steroidal farnesoid X receptor agonist PX-104 in non-alcoholic fatty liver disease. *Wien Klin Wochenschr*. 2020 Sep 15. doi: 10.1007/s00508-020-01735-5.
563. Stift J, Semmler G, Wöran K, Simbrunner B, Scheiner B, Schwabl P, Paternostro R, Pinter M, Stättermayer AF, Meischl T, Beer A, Trauner M, Mandorfer M, Reiberger T. Comparison of the diagnostic quality of aspiration and core-biopsy needles for transjugular liver biopsy. *Dig Liver Dis*. 2020 Dec;52(12):1473-1479. doi: 10.1016/j.dld.2020.08.028.
564. Stättermayer AF, Ferenci P, Trauner M. Reply to: "Challenges in understanding the consequences of variants in ABCB4 gene". *J Hepatol*. 2021 Jan;74(1):244-245. doi: 10.1016/j.jhep.2020.09.004. Letter
565. Beer L, Bastati N, Ba-Ssalamah A, Pötter-Lang S, Lampichler K, Bican Y, Lauber D, Hodge J, Binter T, Pomej K, Simbrunner B, Semmler G, Trauner M, Mandorfer M, Reiberger T. MRI-defined sarcopenia predicts mortality in patients with chronic liver disease. *Liver Int*. 2020 Nov;40(11):2797-2807. doi: 10.1111/liv.14648.
566. Lax SF, Skok K, Zechner PM, Setaffy L, Kessler HH, Kaufmann N, Vander K, Cokić N, Maierhofer U, Bargfrieder U, Trauner M. Systemic consequences and clinical aspects of SARS-CoV-2 infection. *Pathologe*. 2021 Feb 11:1-8. doi: 10.1007/s00292-021-00913-0. Review.
567. Taylor-Weiner A, Pokkalla H, Han L, Jia C, Huss R, Chung C, Elliott H, Glass B, Pethia K, Carrasco-Zevallos O, Shukla C, Khettry U, Najarian R, Taliano R, Subramanian GM, Myers RP, Wapinski I, Khosla A, Resnick M, Montalto MC, Anstee QM, Wong VW, Trauner M, Lawitz EJ, Harrison SA, Okanoue T, Romero-Gomez M, Goodman Z, Loomba R, Beck AH, Younossi ZM. A Machine Learning Approach Enables



Quantitative Measurement of Liver Histology and Disease Monitoring in NASH. *Hepatology*. 2021 Feb 11. doi: 10.1002/hep.31750.

568. Hamminger P, Marchetti L, Preglej T, Platzer R, Zhu C, Kamnev A, Rica R, Stolz V, Sandner L, Alteneider M, Kaba E, Waltenberger D, Huppa JB, Trauner M, Bock C, Lyck R, Bauer J, Dupré L, Seiser C, Boucheron N, Engelhardt B, Ellmeier W. Histone deacetylase 1 controls CD4+ T cell trafficking in autoinflammatory diseases. *J Autoimmun*. 2021 May;119:102610. doi: 10.1016/j.jaut.2021.102610.
569. Fromme M, Schneider CV, Pereira V, Hamesch K, Pons M, Reichert MC, Benini F, Ellis P, H Thorhauge K, Mandorfer M, Burbaum B, Woditsch V, Chorostowska-Wynimko J, Verbeek J, Nevens F, Genesca J, Miravittles M, Nuñez A, Schaefer B, Zoller H, Janciauskiene S, Abreu N, Jasmins L, Gaspar R, Gomes C, Schneider KM, Trauner M, Krag A, Goptu B, Thorburn D, Marshall A, Hurst JR, Lomas DA, Lammert F, Gaisa NT, Clark V, Griffiths W, Trautwein C, Turner AM, McElvaney NG, Strnad P. Hepatobiliary phenotypes of adults with alpha-1 antitrypsin deficiency. *Gut*. 2021 Feb 25;gutjnl-2020-323729. doi: 10.1136/gutjnl-2020-323729.
570. Geier A, Tiniakos D, Denk H, Trauner M. From the origin of NASH to the future of metabolic fatty liver disease. *Gut*. 2021 Feb 25;gutjnl-2020-323202. doi: 10.1136/gutjnl-2020-323202.
571. Tardelli M, Bruschi FV, Fuchs CD, Claudel T, Auer N, Kunczer V, Ronda OAHO, Verkade HJ, Stojakovic T, Scharnagl H, Trauner M. Absence of Adiponutrin (PNPLA3) and Monoacylglycerol Lipase Synergistically Increases Weight Gain and Aggravates Steatohepatitis in Mice. *Int J Mol Sci*. 2021 Feb 20;22(4):2126. doi: 10.3390/ijms22042126.
572. Mayer KA, Smole U, Zhu C, Derdak S, Minervina AA, Salnikova M, Witzeneder N, Christamentl A, Boucheron N, Waidhofer-Söllner P, Trauner M, Hoermann G, Schmetterer KG, Mamedov IZ, Bilban M, Ellmeier W, Pickl WF, Gualdoni GA, Zlabinger GJ. The energy sensor AMPK orchestrates metabolic and translational adaptation in expanding T helper cells. *FASEB J*. 2021 Apr;35(4):e21217. doi: 10.1096/fj.202001763RR.
573. Starlinger P, Ahn JC, Mullan A, Gyoeri GP, Pereyra D, Alva-Ruiz R, Hackl H, Reiberger T, Trauner M, Santol J, Simbrunner B, Mandorfer M, Berlakovich G, Kamath PS, Heimbach J. The Addition of C-Reactive Protein and von Willebrand Factor to MELD-Na Improves Prediction of Waitlist Mortality. *Hepatology*. 2021 Mar 31. doi: 10.1002/hep.31838.
574. Reich M, Spomer L, Klindt C, Fuchs K, Stindt J, Deutschmann K, Höhne J, Liaskou E, Hov JR, Karlsen TH, Beuers U, Verheij J, Ferreira-Gonzalez S, Hirschfield G, Forbes SJ, Schramm C, Esposito I, Nierhoff D, Fickert P, Fuchs CD, Trauner M, García-Beccaria M, Gabernet G, Nahnsen S, Mallm JP, Vogel M, Schoonjans K, Lautwein T, Köhrer K, Häussinger D, Luedde T, Heikenwalder M, Keitel V. Downregulation of TGR5 (GPBAR1) in biliary epithelial cells contributes to the pathogenesis of sclerosing cholangitis. *J Hepatol*. 2021 Apr 16:S0168-8278(21)00244-0. doi: 10.1016/j.jhep.2021.03.029.
575. Waldmann EA, Kammerlander AA, Gessl I, Penz D, Majcher B, Hinterberger A, Bretthauer M, Trauner MH, Ferlitsch M. Association of Adenoma Detection Rate and Adenoma Characteristics with Colorectal Cancer Mortality after screening

colonoscopy. *Clin Gastroenterol Hepatol*. 2021 Apr 17;S1542-3565(21)00457-2. doi: 10.1016/j.cgh.2021.04.023.

576. Dixon ED, Nardo AD, Claudel T, Trauner M. The Role of Lipid Sensing Nuclear Receptors (PPARs and LXR) and Metabolic Lipases in Obesity, Diabetes and NAFLD. *Genes (Basel)*. 2021 Apr 26;12(5):645. doi: 10.3390/genes12050645. Review.
577. Semmler G, Binter T, Kozbial K, Schwabl P, Chromy D, Bauer D, Simbrunner B, Müllner-Bucsics T, Scheiner B, Stättermayer A, Pinter M, Steindl-Munda P, Trauner M, Ferenci P, Reiberger T, Mandorfer M. Influence of Genetic Variants on Disease Regression and Outcomes in HCV-Related Advanced Chronic Liver Disease after SVR. *J Pers Med*. 2021 Apr 7;11(4):281. doi: 10.3390/jpm11040281.

### Book Chapters

1. Trauner M, Fickert P, Stauber RE. Cholestasis in systemic infection. In: Boyer JL, Gilat T, Kotrlík J, Marecek Z, Paumgartner G, Spicak J, eds. *Diseases of the Liver and the Bile Ducts - New Aspects and Clinical Implications*. Dordrecht: Kluwer Academic Publishers, 1999; 84-96.
2. Boyer JL, Lee JM, Trauner M, Soroka CJ, Gartung C, Karpen SJ. Cellular and molecular response of hepatic bile salt transporters to cholestatic liver injury. In: Paumgartner G, Stiehl A, Gerok W, Keppler D, Leuschner U, eds. *Bile Acids and Cholestasis*. Dordrecht: Kluwer Academic Publishers, 1999; 145-150.
3. Lee JM, Trauner M, Soroka CJ, Stieger B, Meier PJ, Boyer JL. Molecular expression of the sister of P-glycoprotein in chronic bile duct obstruction in the rat. In: Paumgartner G, Stiehl A, Gerok W, Keppler D, Leuschner U, eds. *Bile Acids and Cholestasis*. Dordrecht: Kluwer Academic Publishers, 1999; 123-128.
4. Trauner M, Obermayer-Pietsch B, Fickert P, Stauber RE. Alcohol and the endocrine system. In: Kurz M, O'Malley S, Saria A, Zernig G, eds. *Handbook of Alcoholism*. Boca Raton: CRC Press, 2000; 231-238.
5. Stauber RE, Trauner M, Fickert P. Liver. In: Kurz M, O'Malley S, Saria A, Zernig G, eds. *Handbook of Alcoholism*. Boca Raton: CRC Press, 2000; 183-194.
6. Stauber RE, Trauner M, Fickert P. Gastrointestinal system and pancreas. In: Kurz M, O'Malley S, Saria A, Zernig G, eds. *Handbook of Alcoholism*. Boca Raton: CRC Press, 2000; 195-202.
7. Trauner M, Fickert P, Zollner G, Schreiber F, Stauber RE. Antibiotika-induzierte Cholestase. In: Janata O, Reisinger E, eds. *Infektiologie. Aktuelle Aspekte. Jahrbuch 2000*. Wien: Österreichische Verlagsgesellschaft 2000; 145-152.
8. Trauner M, Fickert P, Zollner G, Stauber RE, Zatloukal K, Denk H, Krejs GJ. Cellular and molecular mechanisms of cholestasis. In: Boyer JL, Blum HE, Maier KP, Sauerbruch T, Stalder GA, eds. *Liver Cirrhosis and Its Development*. Dordrecht: Kluwer Academic Publishers, 2000; 40-67.
9. Stauber RE, Trauner M, Fickert P. Alkoholinduzierte Lebererkrankungen. In: Kurz M, O'Malley S, Saria A, Zernig G, eds. *Handbuch des Alkoholismus*. Innsbruck: Verlag der Universitätsklinik f. Psychiatrie Innsbruck, 2000; 215-227.

10. Stauber RE, **Trauner M**, Fickert P. Alkoholinduzierte Erkrankungen des Pankreas und des Gastrointestinaltrakts. In: Kurz M, O'Malley S, Saria A, Zernig G, eds. Handbuch des Alkoholismus. Innsbruck: Verlag der Universitätsklinik f. Psychiatrie Innsbruck, 2000; 229-237.
11. **Trauner M**, Obermayer-Pietsch B, Fickert P, Stauber RE. Alkohol und Endokrines System. In: Kurz M, O'Malley S, Saria A, Zernig G, eds. Handbuch des Alkoholismus. Innsbruck: Verlag der Universitätsklinik f. Psychiatrie Innsbruck, 2000; 275-282.
12. **Trauner M**, Fickert P, Zollner G, Stauber RE, Krejs GJ. Molecular basis of bile formation and cholestasis. In: Grigorescu M, Pascu O, Paumgartner G, eds. Hepatobiliary Diseases: Cholestasis and Gallstones. Dordrecht: Kluwer Academic Publishers, 2000; 3-20.
13. **Trauner M**, Fickert P, Zollner G, Zatloukal K, Denk H. Acquired alterations of hepatobiliary transport systems in human cholestatic liver diseases: potential targets of pharmacotherapy. In: Keppler D, Leuschner U, Paumgartner G, Stiehl A, eds. Bile Acids: From Genomics to Disease and Therapy. Dordrecht: Kluwer Academic Publishers, 2003; 163-177.
14. Denk H, Dienes H.P., **Trauner M**. Leber und intrahepatische Gallenwege (Molekulare Defekte der Gallensekretion als Ursache der Cholestase). In: Böcker W, Denk H, Heitz PW, eds. Pathologie. Urban & Fischer, 2004; 755-798.
15. **Trauner M**, Fickert P, Zollner G. Acquired alterations in transporter expression and function in cholestasis. In: Trauner M, Jansen PLM, eds. Molecular Pathogenesis of Cholestasis. Georgetown, New York: Landes Bioscience & Kluwer Academic Plenum Publishers, 2004; 266-288.
16. Marschall HU, Wagner M, Zollner G, Fickert P, Gumhold J, Silbert D, Diczfalusy U, Benthin L, Grundström R, Gustafsson U, Sahlin S, Einarsson C, **Trauner M**. Comprehensive study of the effects of rifampicin and ursodeoxycholic acid on genes and proteins involved in regulation, transport and detoxification of biliary compounds in gallstone patients. In: Keppler D, Leuschner U, Paumgartner G, Stiehl A, eds. Bile Acid Biology and its Therapeutic Implications. Dordrecht: Kluwer Academic Publishers, 2005; 219-225.
17. **Trauner M**, Fickert P, Halilbasic E, Wagner M, Zollner G. Adaptive hepatobiliary transporter regulation by ursodeoxycholic acid. In: Keppler D, Leuschner U, Paumgartner G, Stiehl A, eds. Bile Acid Biology and its Therapeutic Implications. Dordrecht: Kluwer Academic Publishers, 2005; 132-137
18. **Trauner M**, Fickert P, Halilbasic E, Wagner M, Zollner G. Molecular mechanisms of cholestasis. In: Blumberg RS, Gangl A, Manns MP, Tilg H, Zeitz M, eds. Gut-Liver Interactions: Basic and Clinical Concepts. Dordrecht: Kluwer Academic Publishers, 2005; 195-206.
19. Fickert P, **Trauner M**. Postoperative Jaundice. In: Benhamou JP, Blei A, Dufour JF, Friedman S, Gines P, Reichen J, Rodes J, Rizzetto M, Valla DC, Zoulim F, eds. Oxford Textbook of Hepatology: From Basic Science to Clinical Practice (3<sup>rd</sup> edition), Wiley, 2007; 1945-1952.
20. Wagner M, **Trauner M**. Physiology of bile formation. In: Benhamou JP, Blei A, Dufour JF, Friedman S, Gines P, Reichen J, Rodes J, Rizzetto M, Valla DC, Zoulim F, eds.

Oxford Textbook of Hepatology: From Basic Science to Clinical Practice (3<sup>rd</sup> edition), Wiley, 2007: 290-304.

21. **Trauner M**, Moustafa, T, Fickert P, Halilbasic E, Guelly C, Fuchsbichler A, Denk H, Zatloukal K, Wagner M, Zollner G. Side chain-shortened bile acids for the treatment of cholestasis: lessons from *nor*-ursodeoxycholic acid. In: Beuers U, Keppler D, Leuschner U, Stiehl A, Trauner M, eds. Bile Acids: Biological Actions and Clinical Relevance. Dordrecht: Kluwer Academic Publishers, 2007: 75-80.
22. Stauber RE, Fickert P, **Trauner M**. Hepatobiliäre Funktionsstörungen, Leberversagen. In: Buchardi H, Larsen R, Kuhlen R, Jauch KW, Schölmerich J, eds. Die Intensivmedizin (10<sup>th</sup> edition). Springer, 2007: 557-568.
23. Wagner M, Zollner G, **Trauner M**. Beyond PXR and CAR, Regulation of Xenobiotic Metabolism by Other Nuclear Receptors. In: Xie W., ed. Nuclear Receptors in Drug Metabolism. John Wiley & Sons, 2008, 275-300.
24. Denk H, Dienes HP, Jochum W, Schirmacher P, **Trauner M**. Leber und intrahepatische Gallenwege. In: Pathologie. Böcker, Denk, Heitz Moch (Hrsg), 4. Auflage, Urban und Fischer Verlag (ISBN 978-3-437-42382-6), 755-798, 2008
25. **Trauner M**. Cholangitis, cholecystitis, primary sclerosing cholangitis. In: Lang F, ed. Encyclopedic Reference of Molecular Mechanisms of Disease. Springer, 2009 (ISBN 978-3540671367).
26. Halilbasic E, Fickert P, Fiorotto R, Marschall HU, Moustafa T, Fuchsbichler A, Gumhold J, Silbert D, Langner C, Maitra U, Denk H, Strazzabosco M, **Trauner M**. Side-chain-modification as critical determinant of the therapeutic properties of 24-*nor*ursodeoxycholic acid in Mdr2 (Abcb4) knockout mice. In: Beuers U, Keppler D, Leuschner U, Stiehl A, Trauner M, eds. Bile Acids Biology and Therapeutic Actions. Dordrecht: Kluwer Academic Publishers, 2009: 157-162.
27. **Trauner M**, Moustafa, T, Fickert P, Halilbasic E, Guelly C, Fuchsbichler A, Denk H, Zatloukal K, Wagner M, Zollner G. Side chain-shortened bile acids for the treatment of cholestasis: lessons from *nor*-ursodeoxycholic acid. In: Beuers U, Keppler D, Leuschner U, Stiehl A, Trauner M, eds. Bile Acids Biology and Therapeutic Actions. Dordrecht: Kluwer Academic Publishers, 2009: 151-156.
28. Claudel T, **Trauner M**. Bile acids and their receptors. In: Dufour J, Clavien P, eds. Signaling Pathways in Liver Diseases. Springer Scientific Publishers, 2009: 317-332. (ISBN: 978-3-642-00149-9).
29. **Trauner M**. New pathophysiological mechanisms in cholestatic liver diseases – role in therapy. In: Arroyo V, Abraldes JG, Gines P, Sanchez-Tapias JM, Forns X, Bataller R, Rodes J, eds. Treatment of Liver Diseases. Ars Medica, 2009: 281 – 289 (ISBN 978-84-9751-481-1).
30. **Trauner M**, Fickert P, Baghdasaryan A, Claudel T, Halilbasic E, Moustafa T, Wagner M, Zollner G. Immunology and Liver Disease: New Insights into Autoimmune Cholangitis through Animal Models, In: M.E. Gershwin, A.W. Lohse, M.P. Manns, D. Vergani, Immunology and Liver Disease. Karger, 2009: 99-104 (ISBN 978-3-8055-9446-2)
31. Fickert P, **Trauner M**. Ikterus. In: Brunkhorst R, Schölmerich J (Hrsg). Differenzialdiagnostik und Differentialtherapie. Entscheidungen in der Inneren Medizin. Elsevier. 1. Auflage 2010: 126-127, (ISBN: 978-3-437-42501-1)

32. **Trauner M.** Cholestasis: Molecular Basis. In: Satdarshan P.S. Monga. Molecular Pathology of Liver Diseases. Springer Scientific Publishers, 2010: 475-484 (ISBN 978-1-4419-7106-7)
33. Stauber RE, Fickert P, **Trauner M.** Hepatobiliäre Funktionsstörungen und Leberversagen. In: Burchardi, Larsen, Marx, Muhl, Schölmerich (Hrsg). Die Intensivmedizin. 11. Auflage. Springer Verlag, 2011: 567-578 (ISBN 978-3-642-16928-1),
34. Schirmacher P, Dienes HP, Jochum W, **Trauner M.**, Lackner C. Leber und intrahepatische Gallenwege. In: Pathologie. 5. Auflage, Böcker, Denk, Heitz, Höfler, Kreipe, Moch (Hrsg), Urban und Fischer Verlag, 2012: 623-665 (ISBN 978-3-437-4234-0),
35. **Trauner M.**, Halilbasic E, Baghdasaryan A, Moustafa T, Krones E, Fickert P, Hofer H, Penner E. Primary Sclerosing Cholangitis: New Approaches to Diagnosis, Surveillance and Treatment. In: H. Tilg, R.S. Blumberg, S. Endres, A. Kaser, M.P. Manns, eds. Innate Immunity in Gastrointestinal Disorders: Basic and Therapeutic Concepts, Karger 2012: 39-47 (ISBN 978-3-318-02210-0)
36. **Trauner M.** Mechanisms of intrahepatic cholestasis. In: Therapy in Liver Disease 2013. Ginès P, Forns X, Fernández J, Crespo G, Rodés J, Arroyo V, eds. Elsevier Espana, S.L., 2013: 327-338 (ISBN 978-84-7592-758-9)
37. **Trauner M.**, Halilbasic E, Kazemi-Shirazi L, Kienbacher C, Stauffer K, Traussnigg S, Hofer H. Therapeutic Role of Bile Acids and Nuclear Receptor Agonists in Fibrosing Cholangiopathies. In: R.W. Chapman, D.H. Adams, U. Beuers, C.P. Day, M.P. Manns, eds. Liver Diseases in 2013: Advances in Pathogenesis and Treatment, Karger, 2013:631-636 (ISBN 978-3-318-02665-8)
38. Halilbasic E, Baghdasaryan A, **Trauner M.** Nuclear Receptors as Drug Targets in Cholestatic Liver Diseases. In: Cholestatic Liver Diseases. Clinics in Liver Disease. Levy C (Editor), Gitlin N (Consulting Editor) Elsevier Inc, 2013: 161-189 (ISSN 1089-3261)
39. Halilbasic E, Fuchs C, Traussnigg S, **Trauner M.** Farnesoid X Receptor Agonists and other Bile Acid Signaling Strategies for Treatment of Liver Disease. In: J. Schölmerich, M.J. Bruno, E.M. El-Omar, P. Ginès, D.K. Podolsky, eds. Therapeutic Strategies in Diseases of the Digestive Tract – 2015 and Beyond, Karger, 2015:163-172 (ISBN 978-3-318-05876-5)
40. Halilbasic E, Fuchs C, Hofer H, Paumgartner G, **Trauner M.** Therapy of Primary Sclerosing Cholangitis – Today and Tomorrow. In: P. Ginès, U. Beuers, H. Cortez-Pinto, A.W. Lohse, A. Parés, eds. Autoimmune Diseases of the Liver, Karger, 2015:149-163 (ISBN 978-3-318-05563-4)
41. Halilbasic E, **Trauner M.** Primary biliary cirrhosis and primary sclerosing cholangitis: A pathophysiological and therapeutic role for bile acids and other nuclear receptor agonists. Therapy in Liver Diseases 2015. In: Ginès P, Forns X, Fernández J, Crespo G, Solà E, Rodés J, Arroyo V, eds. Elsevier Espana, S.L, 2015:163-172 (ISBN 978-84-759-2788-6)
42. B. Seeland, C. Zauner, **M. Trauner.** Ikterus auf der Intensivstation. In: Gastroenterologie für Intensivmediziner. Canbay A, Gerken G. (Hrsg). Thieme Verlag 2017: 77-83, (ISBN: 978-3-13-221041-7)

43. Fickert P, **Trauner M**. Ikterus. In: Differenzialdiagnostik und Differentialtherapie in der Inneren Medizin, Klug entscheiden – gut behandeln. Brunkhorst R, Schölmerich J (Hrsg), 2. Auflage, Elsevier, 2018: 128-129 (ISBN 978-3-437-42502-8)
44. Schirmacher P, **Trauner M**, Lackner C, Weber A, Evert M, Baba HA). Leber und intrahepatische Gallenwege. In: Pathologie. Höfler, Kreipe, Moch (Hrsg). 6. Auflage, Urban und Fischer Verlag, 2019: 631-673 (ISBN 978-3-437-42390-1)
45. Kazemi-Shirazi L., **Trauner M**. Ikterus. In: Riemann J.F., Fischbach W, Galle P.R., Mössner J (Hrsg). Referenz Gastroenterologie. Thieme Verlag, 2019: 160-164 (ISBN 978-3-13-240500-4).
46. Claudel T, **Trauner M**. Bile Acids as Signaling Molecules. The Liver – Biology and Pathobiology, 6<sup>th</sup> Edition. Arias I, Alter, H.J., Boyer J.L., Shafritz D.A., Thorgeirsson S.S., Wolkoff A.W. (eds), Wiley Blackwell, 2020:299-312 (ISBN 978 111 943 6829)
47. Fuchs C, Halilbasic E, **Trauner M**. Pathophysiologic Basis for Alternative Therapies for Cholestasis. The Liver – Biology and Pathobiology, 6<sup>th</sup> Edition. Arias I, Alter, H.J., Boyer J.L., Shafritz D.A., Thorgeirsson S.S., Wolkoff A.W. (eds), Wiley Blackwell, 2020:364-377 (ISBN 978 111 943 6829)

#### Books as Editor

1. **Trauner M**, Jansen PLM, eds. Molecular Pathogenesis of Cholestasis (25 Kapitel, 366 Seiten). Georgetown, New York: Landes Bioscience & Kluwer Academic Plenum Publishers, 2004 (ISBN 0-306-48240-1).
2. Beuers U, Keppler D, Leuschner U, Stiehl A, **Trauner M**, eds. Bile Acids: Biological Actions and Clinical Relevance. Dordrecht: Kluwer Academic Publishers, 2007 (ISBN 978-1-4020-6251-3)
3. Beuers U, Keppler D, Leuschner U, Stiehl A, **Trauner M**, eds. Bile Acid Biology and Therapeutic Actions. Dordrecht: Kluwer Academic Publishers, 2009 (ISBN 978-1-4020-9643-3).
4. Häussinger D, Beuers U, Keitel V, **Trauner M**, eds. XXII International Bile Acid Meeting – Hepatic and Extrahepatic Targets of Bile Acid Signaling. Karger Publishers, 2013
5. Häussinger D, Beuers U, Keitel V, **Trauner M**, eds. XXIII International Bile Acid Meeting – Bile Acids as Signal Integrators and Metabolic Modulators. Karger Publishers, 2015 (ISBN 978-3-318-05436-1)
6. Tilg H, Kaser A, Manns MP, Szabo G, **Trauner M**. Gut-Liver Interactions: From IBD to NASH. Karger Publishers, 2016. (ISBN 978-3-318-05879-6)
7. Häussinger D, Beuers U, Keitel V, **Trauner M**, eds. XXIV Internationale Bile Acid Meeting: Bile Acids in Health and Disease. Karger Publishers, 2017 (ISBN 978-3-318-05923-6)
8. **Trauner M**. Ernährung und Verdauung. Medizinisches Curriculum Wien, Block 13, 2017 (ISBN 978-3-7089-1607-1)